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1) SALT BALANCE AND MECHANISMS OF NATRIURESIS
The sodium ion occupies a unique and central role in animal function.
Sodium salts, in particular sodium chloride, comprise more than 90% of the
total osmoles in the extracellular fluid space (ECF). Active extrusion from the
intracellular space renders sodium principally an extracellular ion, whereas
water moves readily between the compartments along osmotic gradients.
Plasma osmolality is closely regulated within narrow limits and it thus follows
that the volume of the ECF is determined by its total osmolar content.
Normal tissue function requires that blood is delivered under optimal
perfusion pressures and flow rates. A principle determinant of these is the
ECF and particularly the plasma volume, and it would seem logical that
animals have developed powerful and complex mechanisms to maintain ECF
volume within narrow limits.
Sodium homeostasis results from a balance between dietary intake and
excretion. The body contains some 4000 mmols of sodium and nearly all of the
exchangeable sodium resides in the extracellular compartment. There is limited
ability to store sodium within the body so that extremely tight control of
excretion must exist during periods of salt scarcity. Salt thirst is well recog¬
nised in animals and Denton (1982) has reviewed evidence for a similar phenom¬
enon in man. As for sodium excretion, faecal losses of sodium are poorly
controlled, but acclimatisation to severe environmental conditions does involve
reduction of salt loss in sweat (Conn, 1949). However, the kidney remains the
principle determinant of salt excretion and sodium balance and any discussion
on homeostatic control of sodium and ECF volume must focus on the primacy
of this organ.
In large areas of the planet, sodium is scarce and it is present in only
trace amounts in most plants. Accordingly, during evolutionary development for
a wide variety of animals, in various ecological niches, there would be great
survival value in the possession of effective mechanisms for the acquisition of
salt and of its retention in the body. Anthropological evidence suggests that
the development of hominoids over 30 million years from the late Oligocene
period has been determined by pressures operating to influence salt retaining
mechanisms. Up to the late Pliocene time, diet was predominantly if not
exclusively vegetarian. Early man (1.7 million years) was a hunter of large
animals. However it is likely that meat made up a small and intermittent fract¬
ion of the diet. Clark (1970) emphasises that vegetarian foods form 60-80% of
the diet of hunter-gatherers in warm and temparate climates today, the prop¬
ortion decreasing as one approaches the poles. Some contemporary feral societ¬
ies remain almost entirely vegetarian today. New Guinea Highlanders have a
diet of which sweet potatoes form the basis. Analysis of urine excretion
suggests a daily ingestion of only 1-3 mmol of sodium per day with a K+/Na+
ratio of up to 400 (Oomen et al., 1961). Similarly, the Chimbu tribe of New
Guinea and Yanomamo Indians of Tropical Venezuala and Brazil have pred¬
ominantly vegetarian diets with very low salt intakes (MacFarlane et al., 1964;
Oliver et al., 1975). The low sodium status is no physiological handicap, but is
reflected in very high aldosterone levels.
Thus man has developed in salt-poor circumstances and has enjoyed
successful existence due to the development of avid salt-retaining responses.
Tropical regions are extremely poor in salt, most sodium being present in
animals. Denton (1982) has drawn attention to this and put forward the pro¬
vocative contention that endocannibalism, seemingly widely practiced until
recently, and setting aside the religious symbolism, was in fact evolutionarily
advantageous in allowing recirculation of a scarce mineral.
Over the last 100 years or so, dietary content has changed dramatically
in many parts of the world. From being highly sought after, prized and expens¬
ive, salt has, in the developed world, become cheap and abundant. Sodium in¬
take has markedly increased so that 'normal' intake in the USA, Europe and
Australia is now 50-400 mmols per day and in some areas such as northern
Honshu in Japan, the figure is upwards of 500 mmol/day. Interest is now focus¬
ed on the manner by which the kidneys are able to excrete such supraphysio-
logical amounts of salt. This is not just an academic question. The incidence of
hypertension is exceedingly high in Japan and other countries where salt intake
is high whereas it is almost unknown in those communities with very low
sodium intakes. It has been hypothesised that some individuals have a genetic¬
ally determined inability to excrete salt adequately and that renal salt retent¬
ion is a causative factor in the development of high blood pressure (de
Wardener and MacGregor, 1982). There is interest in differential sensitivity of
different populations to high salt intake. It is well known that Negro populat¬
ions in the USA are more prone to hypertension and that they suffer greater
morbidity and mortality from its effects than American Caucasians (Akinkugbe,
1985). Desor et al. (1975) have shown that black children have greater prefer¬
ence for the salt taste. In addition, Negroes have reduced capacity to excrete
an intravenously administered salt load, in comparison with whites (Luft et al.,
1977). Whites reached the USA after migration from Europe and 20-40,000
generations in temperate regions. They lost skin pigment as an evolutionary
adaptation and it may be that changes in sodium control also occured. In the
cooler climate, there would have been reduced sodium losses from skin and
amelioration of pressure on sodium homeostasis. Blacks arrived in the USA only
200-400 years ago. Thus their history is in the tropics with recent considerable
salt stress. They may have less capacity to excrete salt and greater hedonic
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preference.
Strauss et al. (1958) conducted classical balance studies in man which
have been confirmed repeatedly in animals and man. If an individual is in
balance on a 10 mmol sodium diet and this is increased to 150 mmol, sodium
excretion will increase until, after 3-5 days or so, output again matches in¬
take. However, there will be a period of initial sodium retention and the new
steady state will be reached with a small increase in weight, exchangeable
sodium, plasma and ECF volumes and venous pressure. The reverse set of
events occurs when salt intake is again reduced. Thus the body functions in a
homeostatic manner, in that marked changes in input are detected and the
body's response is to correct for any changes, keeping total body sodium within
narrow limits. As in all homeostatic mechanisms, salt balance is achieved by a
feedback loop principle with an afferent or sensing mechanism, feeding inform¬
ation to a central processor, which then determines the effector response.
Implicit is such a system, is a 'set point' around which balance occurs and
towards which control mechanisms operate. This concept has received relativ¬
ely little attention, but Hollenberg (1980) has addressed the question. He
defines 'set point' as that amount of sodium chloride in the body when the
individual is in balance on zero salt intake (or at least allowing for small
obligatory losses in urine, faeces, skin). Thus an individual on a 10 mmol
sodium diet will promptly excrete an extra salt load, even as little as 30 mmol.
But if a diuretic is first given resulting in loss of some 100 mmols, then gain¬
ing 30 mmol will not result in a natriuresis. Only when the deficit of 100 mmol
is replaced and the body returned above zero set point will a natriuresis occur
after salt addition. The studies with primitive feral communities ingesting less
than 5 mmol/day show individuals to be perfectly healthy. According to the
above theory, they are not to be considered in salt deficit or negative sodium
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balance. However it does indicate that any metabolic stress such as diarrhoeal
illness may rapidly move individuals in such populations into severe sodium
deficit.
As stated above, the kidney has the important function of regulating salt
excretion commensurate with requirements. In addition, the kidney must regul¬
ate other ions, acid-base and water balance, and excrete waste products of
metabolism. The kidney is able to perform such diverse functions by means of
morphological and functional nephron heterogeneity and by operating against a
background of enormous turnover. Over one fifth of the cardiac output is to
the kidneys and each day 25,000 mmol of sodium are filtered of which around
99% are reabsorbed. It will be apparent that only small alterations in renal
control can result in very large changes in sodium excretion.
The last two decades have seen remarkable advances in our knowledge
of renal function. Fields such as glomerular and tubular dynamics, electrophys-
iology, hormone and drug receptor interactions, tubule transport functions, and
molecular biochemistry and enzymology have been extended and enlarged by
refinement of traditional methodology and as a consequence of new in vivo and
vitro techniques.
Much research seeks to dissect out particular stimulus and response
characteristics, free from extraneous and interacting influences. A challenge,
particularly for in vitro studies, is to identify those phenomena which are
physiologically relevant. Precaution is also required in interpreting results in
whole animal or human studies where responses are evoked by stimuli unlikely
to occur in nature.
Afferent Mechanisms
As already stated, maintenance of ECF volume is an important homeo-
static function, requiring information on the fullness of the circulation or
"effective circulating volume", before responses can be initiated. As befitting
such an important function, there is evidence that volume detectors reside on
venous and arterial sides of the systemic circulation and in the kidney itself.
Neural receptors, comprising branching ends of small medullated fibres
running in the vagus nerve, have been identified in the atria and central com¬
pliance veins, and shown to alter discharge with mechanical stretch or changes
in transmural pressure. Various manoeuvres resulting in changes in venous
return and central venous pressure, such as adoption of the supine position,
weightlessness, negative-pressure breathing and head-out water immersion, are
associated with an acute natriuretic response. Many workers have demonstrat¬
ed increased sodium output following left atrial distension produced by balloon
inflation in dogs. Interpretation of latter findings has been rendered more com¬
plex by the discovery of atrial natriuretic peptide which will be discussed
later. However, at least one study has demonstrated that the natriuresis of
atrial stretch was completely abolished by cervical vagotomy. It should be
pointed out however, that not all groups concur with an important role for
intrathoracic volume receptors in sodium homeostasis. A number of studies
have demonstrated either trivial, or no changes in sodium excretion, following
cardiac denervation or cervical vagotomy, in response to volume expansion
(reviewed by Reineck et al., 1985; Seifter et al., 1986).
That volume receptors exist on the arterial side of the circulation was
first inferred by Epstein et al (1953). They demonstrated that closure of post¬
traumatic atrio-ventricular fistulae in Korean War Veterans resulted in a
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natriuresis, concomitant with an increase in diastolic pressure and decrease in
right atrial and central venous pressures. The site of the arterial receptor is
unknown, but the carotid sinus baroreceptor has been proposed as a likely site.
Traction stimulation of the baroreceptor in anaesthetised rats resulted in a
large natriuresis (Keeler, 1974) and two groups have shown that bilateral
carotid ligation is antinatriuretic (Zambraski et al., 1976; Di Bona, 1977). The
reflex response was shown to be dependant on intact renal innervation and
bilateral carotid ligation was shown to increase renal sympathetic nerve activ¬
ity.
Afferent fibres from volume receptors are believed to travel along the
IX and X cranial nerves to hypothalamic and medullary centres. From here
integrated physiological responses are initiated including antidiuretic hormone
release and modulation of sympathetic nerve discharge to the periphery. In
addition, it seems likely that intracranial receptors exist with a role in salt
balance: injection of hypertonic saline into the third or fourth ventricle direct¬
ly increases sodium output (Passo et al., 1975). A role for the brain in deter¬
mining the balance between natriuretic and antinatriuretic mechanisms has
been given further credence by the demonstration of receptor sites for atrial
natriuretic peptide and angiotensin II. In addition, the hypothalamus is believed
to produce the putative natriuretic hormone, Na+/K+-ATPase inhibitor (vide
infra).
That the kidney itself is capable of sensing changes in intravascular
volume or pressure has been demonstrated using the isolated perfused whole
kidney preparation. Increased perfusion pressure promotes a natriuretic
response by virtue of a baroreceptor mechanism at the juxtaglomerular
apparatus. The efferent response involves modulation of the activity of the
hormonal renin-angiotensin system which will be discussed later.
Efferent Mechanisms
As indicated, the afferent sensing component of body sodium control is
organised at a number of sites to allow an integrated response. Similarly, it is
evident that efferent mechanisms are multiple and originate both within and
outside the kidney, although the kidney is the final common pathway for
control. Salt excretion is determined by a complex interaction of neuronal,
hormonal and physical factors and many mechanisms have been defined and
demonstrated to alter salt excretion. What is not clear always, is the relative
importance of each, and its physiological interaction with others under normal
conditions.
Renal Nerves
The postganglionic innervation of the kidneys is composed mainly of
adrenergic vasomotor fibres. Histochemical staining for catacholamines reveals
an extensive adrenergic innervation of all arterial components, particularly
concentrated at the afferent arterioles in the region of the juxtaglomerular
apparatus (McKenna and Angelakos, 1968). More recently, Miiller and Barajas
(1972) using electronmicroscopy and histochemical techniques, have demonstrat¬
ed adrenergic innervation of proximal and distal tubules in monkey and rat.
The result of changes in volume status of the body is modulation of efferent
sympathetic outflow to the periphery including the kidneys. Thus Prosnitz and
Di Bona (1978) have demonstrated in the dog that an increase of 15 mmHg in
left atrial pressure reduced renal nerve activity by 40% and increased sodium
excretion by 80%. Bilateral cervical vagotomy abolished both the decrease in
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renal nerve activity and the natriuresis. Along these lines, Thames et al. (1982)
have reported a significant inverse relationship between pulmonary artery
wedge pressure and renal nerve activity.
The phenomenon of denervation-natriuresis has been long recognised as
has the acute reduction in sodium output produced by renal nerve stimulation.
However, almost all early studies were performed on anaesthetised animals and
Smith (1951), repeating studies on conscious dogs, was unable to demonstrate
any effect of denervation on salt output. The prevailing view is that the renal
nerves exert little tonic influence under normal circumstances and that denerv-
ation-natriuresis is an artifact of anaesthesia-induced renal vasoconstriction
(reviewed by Gottschalk et al., 1985). Some studies however, have suggested
that renal nerves have a physiological role under certain circumstances. Thus
Schneider et al. (1978) demonstrated that renally denervated dogs are unable
to appropriately conserve sodium when maintained on a low salt diet. Patients
with idiopathic autonomic insufficiency syndrome are assumed to have partial
or complete renal denervation. Bartter et al. (1959) found that such patients
were also unable to decrease urinary sodium excretion appropriately when
placed on a salt restricted diet.
The renal nerves can potentially modulate sodium excretion by more than
one mechanism. Direct nerve stimulation can produce large decrements in
glomerular titration rate (GFR) and renal blood flow (RBF) with stimulation of
renin release being contributory. More recent studies however, with low level
electrical nerve stimulation have shown reduced sodium excretion in the
absence of haemodynamic changes. That this is due to a direct effect at the
proximal tubule has been confirmed by micropuncture studies (reviewed by
Raymond and Stein, 1987). Although renal nerve stimulation results in activat¬
ion of both the renin-angiotensin and prostaglandin systems, both of which may
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affect sodium balance, Zambraski and Di Bona (1976; 1982) showed that block¬
ade of both systems, with saralasin and indomethacin, did not attenuate the
effect of renal nerve stimulation. There is little dispute that renal vasocon¬
striction is mediated by an effect at a-adrenergic receptors on the vasculat¬
ure. However, the receptor subtype subserving the tubular effect is not clear
and in vivo micropuncture and in vitro microperfusion of proximal tubules have
been utilised to address this question. Although some reports suggest that the
H.-receptor is of importance, most studies indicate that the a-receptor mediates
the increased sodium reabsorption induced by renal nerve stimulation (reviewed
by Kim et al., 1980).
Glomerular filtration rate and glomerular-tubular balance
With control of sodium excretion taking place against a background of
enormous turnover it might be expected that small alterations in GFR would
elicit significant alterations in sodium excretion. In fact, modulation of tubular
reabsorption ensures relative constancy of fractional sodium excretion. This
coupling between filtration and tubular reabsoption is termed glomerular-
tubular balance and has been confirmed in whole animal studies, in the isolated
perfused kidney preparation and by micropuncture (reviewed by Reineck et al.,
1985).
To appreciate this phenomenon requires understanding of processes con¬
trolling sodium reabsorption in the nephron. Most studies have focused on the
part played by the proximal tubule though other segments of the nephron
contribute to sodium homeostasis.
Reabsorption of fluid from the proximal tubule is isosmotic and ultimat¬
ely depends upon the active transport of sodium across the basolateral
membrane of the proximal tubular cells, mediated by the enzyme Na+/K+-ATP
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ase. Sodium enters the cells from the lumen down electrochemical gradients
and its passive transfer across the apical membrane is linked to ion and solute
transport in electrogenic or neutral processes. 50-70% of sodium transport
occurs in the proximal tubule underlying its importance and capacity for
control. Uptake of fluid into the peritubular capillary is dependant on the
passive Starling forces governing transport across all capillaries. Fluid flux can
be expressed by the arithmetical formula:
flux = Kf (AP -ATT)
where A P is the hydrostatic pressure gradient across the capillary, ATT is the
oncotic pressure gradient and Kj. an ultrafiltration coefficient. At the peritub¬
ular capillary, forces favour reabsorption, and it is evident that the rate of
uptake is dependant on the peritubular capillary oncotic pressure and hydro¬
static pressure, and the plasma flow rate which determines the rate of delivery
of oncotically active particles. The peritubular oncotic pressure is believed to
be of particular importance, and by means of micropuncture, Brenner et al.
(1969a) have clearly demonstrated a direct relationship between proximal
reabsorption and the peritubular oncotic pressure. Under circumstances in
which GFR alters without change in renal haemodynamics, peritubular capillary
oncotic pressure will vary with the filtration fraction, that is, the fraction of
plasma water extracted by the process of glomerular filtration. The result will
be the maintenance of glomerular-tubular balance. The passive Starling forces
are not incompatible with the active nature of sodium reabsorption across the
proximal tubule. The explanation lies in the so called "pump-leak" model of
reabsorption. Alterations in the physical forces will influence the rate of up¬
take of reabsorbate from the interstitial space surrounding the tubule. If the
balance of forces does not favour uptake, and interstitial pressure increases,
fluid will leak back into the lumen across the tight junctions (Reineck et al.,
1985). The mutual interdependence of active and passive processes was demon¬
strated by Green et al. (1974) who showed that in the absence of active
sodium transport, peritubular oncotic pressure failed to exert an influence on
proximal reabsorption.
One of the first studies to demonstrate disruption of glomerular-tubular
balance was the work of de Wardener and colleagues (1961). They demonstrat¬
ed in the dog that volume expansion with saline produced an acute natriuresis
even when GFR and RBF were artificially reduced by aortic clamping. It has
been shown by micropuncture that saline loading causes a reduction in proximal
fractional sodium reabsorption (Dirks et al., 1965).
Ichikawa and Brenner (1979) have further studied this phenomenon,
drawn attention to the importance of the change in plasma protein concentrat¬
ion during intravenous salt loading, and stressed peritubular forces. Thus Stein
et al. (1973) have revealed greater increases in sodium excretion in saline-
expanded rats than in those with equivalent plasma expansion produced by
hyperoncotic albumin infusions. Intravenous saline loading, producing measur¬
able changes in plasma oncotic pressure, is unlikely to be a physiological
manoeuvre. However, under physiological conditions, physical forces are still
likely to be important. Alterations in renal haemodynamics produce disruption
of glomerular-tubular balance through changes in the filtration fraction. At
any given plasma protein concentration, the magnitude of the oncotic force
across the peritubular capillary is in large part determined by the filtration
fraction. This parameter is in turn influenced by efferent arteriolar tone,
which modulates both peritubular capillary oncotic and hydrostatic pressures.
Manoeuvres which increase renal blood flow (pharmacological vasodilators,
increased salt diet, hormones) usually reduce the filtration fraction, the effect
of which is to discourage reabsorption and increase sodium excretion. The
physical forces at the proximal tubule are thought to mediate, at least in part,
the phenomenon of pressure natriuresis (Koch et al., 1968).
Neuronal and hormonal influences can modulate the effects of physical
factors. Thus the renal nerves and angiotensin II have direct effects at the
proximal tubule, but in addition they effect changes in renal haemodynamics
and influence the filtration-fraction.
Sodium transport across more distal segments of the nephron has not
been studied in as great detail as that across the proximal tubule, principally
because deep segments are not amenable to micropuncture. The role of other
segments of the nephron in the response to salt loading and volume expansion
is therefore not entirely clear. Most parts of the nephron can be shown to
exhibit volume or load dependancy of reabsorption, a process that will tend to
maintain glomerular-tubular balance. Thus sodium excretion in the urine is nor¬
mally less than the delivery to the distal nephron produced by reduction of
proximal reabsorption. Stein et al (1976) have provided some evidence that the
thin ascending limb of the loop of Henle in juxtamedullary nephrons particip¬
ates in the natriuretic response to volume expansion. The mechanism involves
an increase in medullary blood flow allowing dissipation of the hypertonic
interstitium, which normally encourages passive reabsorption of sodium from
the ascending limb (Reineck et al., 1985). In addition, as will be presented
later, the distal tubule appears to be the site of action of a number of
hormones involved in salt homeostasis.
Renin-angiotensin-aldosterone axis
Tigerstedt and Bergman partially purified a pressor substance from
freshly excised rabbit kidney in 1898. They named the agent renin and since
that time a voluminous literature has accumulated on this antinatriuretic hor-
monal axis. It forms a complex, interacting system, a principle function of
which is the maintenance of glomerular filtration rate and sodium balance
under conditions of sodium depletion and reduction in renal perfusion pressure.
Renin is secreted in the kidney from juxtaglomerular cells, differentiated myo¬
epithelial cells located at the distal end of the afferent arteriole. This region
is in apposition to specialised cells of the distal tubule comprising the macula
densa. A great number of inputs have been reported to influence renin secret¬
ion but three stimuli in particular are accepted as physiologically important
(reviewed by Davis and Freeman, 1976).
1. A reduction in renal perfusion pressure stimulates renin secretion mediated
by an intrarenal barareceptor believed to reside at the juxtaglomerular
cells.
2. Sympathetic nerve stimulation and circulatory catecholamines increase
renin release via ^-adrenergic receptors on the juxtaglomerular cells.
3. The macula densa is somehow able to sense the composition of distal tubul¬
ar fluid. Thus, a reduction in sodium and/or chloride load or concentration
stimulates renin secretion.
In addition, angiotensin II produces feedback inhibition of renin release
(Vander and Geelhoed, 1965), and the prostaglandins are also able to modulate
renin release (vide infra).
Renin, a proteolytic enzyme, acts on a circulating a^ globulin, angioten-
sinogen, to create a decapeptide angiotensin I. The latter has little or no act¬
ivity until metabolised by a converting enzyme to the octapeptide angiotensin
II. Hydrolysis of angiotensin II yields the heptapeptide angiotensin III which has
similar activity, but a shorter biological half-life (Koushanpour and Kriz, 1986).
It was widely believed that the principle function of angiotensin II was in
stimulation of aldosterone release from the adrenal cortex (Laragh and Sealey,
1973). However, it is now apparent that angiotensin II itself exerts multiple
effects both systemically and in the kidney, and can profoundly affect sodium
balance.
Angiotensin II is a potent vasoconstrictor and systemic effects are char¬
acterised by changes in peripheral vascular resistance and effective ECF
volume, with maintenance of blood pressure. In addition to circulating levels,
angiotensin II is produced in the kidney in high concentration where it modul¬
ates intrarenal haemodynamics. The renal constrictor action of angiotensin II is
confined primarily to the efferent arterioles (Edwards, 1983), the effect of
which is to maintain glomerular filtration under circumstances in which renal
perfusion may be embarrassed. In addition, the reduction of filtration fraction
will, as discussed, by reducing peritubular capillary hydrostatic pressure and
increasing capillary oncotic pressure, favour reabsorption of sodium at the
proximal tubule (Mujais et al., 1986). Angiotensin II receptors have been identi¬
fied on proximal tubular cells, and microperfusion studies have demonstrated a
direct action in promoting sodium reabsorption at the proximal tubule (Schuster
et al., 1984a). The local formation of angiotensin n may contribute to the
tubuloglomerular feedback mechanism which relates the composition of fluid at
the macula densa to control of GFR (Zanchetti, 1985). There has recently been
interest in the action of the renin-angiotensin system in the CNS with the
recognition that all components are present within the brain, and there is
evidence that this system is independant of the circulating system. Admini¬
stration of angiotensin II into the cerebral ventricles produces a pressor
response in a number of animal models. Part of the response may be through
facilitation of sympathetic outflow, and there is evidence that angiotensin
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enhances sympathetic nerve activity both centrally and peripherally (Zanchetti,
1985). Thus through multiple mechanisms, angiotensin II maintains glomerular
filtration to ensure that processing of products of metabolism can continue, at
the same time encouraging retention of sodium within the body to protect ECF
volume and blood pressure.
The importance of aldosterone in maintaining sodium balance is evident
from the salt wasting and death that occurs in the deficiency state, Addison's
disease. Administered aldosterone promotes salt retention and a significant in¬
verse correlation exists between the level of sodium intake and the secretion
of the hormone. By micropuncture and isolated tubular perfusion preparations,
the site of action of aldosterone has been localised to the cortical collecting
tubule where it appears to affect Na+/K+- ATPase (Reineck et al., 1985).
Several observations however, indicate that aldosterone is not the primary
regulator of urinary sodium excretion and that other factors assume greater
importance under certain conditions. In the study of de Wardener et al. (1961)
referred to earlier, the natriuretic response to saline loading occured not only
with a reduced GFR, but also in the presence of exogenously administered
mineralocorticoid excess. In Addison's disease, normal salt balance can be
achieved with a fixed replacement dose of mineralocorticoid, in spite of widely
varying dietary salt intake (Rosenbaum et al., 1955). Finally, the chronic
administration of mineralocorticoid causes only a transient period of sodium
retention after which a natriuresis ensues and balance is restored; the widely
studied phenomenon "mineralocorticoid escape" (August et al., 1958).
Prostaglandins
The prostaglandins form a family of compounds produced in many tissues
in the body including the kidney, where they function as local hormones or
autacoids (reviewed by Lote and Haylor, 1986; Nadler and Brenner, 1987). The
rate limiting step in synthesis is the release of arachidonic acid from mem¬
brane bound phospholipids, a process in the kidney stimulated by the vasoactive
hormones angiotensin II, noradrenaline, vasopressin and bradykinin. Cyclooxy-
genase converts arachidonic acid into unstable prostaglandin endoperoxides
which are then enzymatically converted to active prostaglandins. The product¬
ion of various prostaglandins is compartmentalised within the nephron, and the
principle sites of synthesis are the cortical arterioles where prostaglandin
(prostacyclin) predominates, and glomerular mesangial and epithelial cells, cort¬
ical and medullary collecting ducts, and medullary interstitial cells where prost¬
aglandin E£ predominates. The prostaglandins have diverse actions within the
kidney, effects having been demonstrated on RBF, GFR, renin release and
tubular salt and water handling. Many studies have attempted to define physio¬
logical roles for renal prostaglandins, but there is a great deal of controversy
with discrepant results. The anatomical and functional complexity of the
kidney has made evaluation of specific prostaglandin function difficult. In
addition, it is likely that prostaglandins act as local regulators of hormonal and
other stimuli, so that observed actions of these autacoids will be largely deter¬
mined by the prevailing influence of other circulating and intrarenal factors.
Four main approaches have been utilised to define a role for prosta¬
glandins in sodium homeostasis; infusion of arachidonic acid or prostaglandins
systemically or intrarenally; assessment of endogenous prostaglandin activity
under salt depletion and loading manoeuvres; studies into the effect of cyclo-
oxygenase inhibition with non-steroidal anti-inflammatory drugs; and in vitro
studies on isolated tubular preparations.
The infusion of arachidonic acid and the major renal prostaglandins
PGE2 and PG^ consistently increases RBF and GFR and results in a natriur-
n
esis (Ballerman et al., 1986). It is unclear from such studies whether vasodilat¬
ion completely accounts for the natriuresis or whether a tubular effect can be
invoked. The physiological relevance of the doses used is questionable, and it
is unlikely that prostaglandins presented in this way will act at the sites at
which prostaglandins are endogenously synthesised and utilised.
Manoeuvres to alter sodium status have produced conflicting results. Salt
loading has been reported to increase, produce no change, or decrease renal
venous and urinary prostaglandin excretion in man and animals (Nielsen et al.,
1979; Rathaus et al., 1981; Dunn, 1983). Part of the explanation may be that
analysis of prostaglandin content of venous blood or urine provides an overall
assessment of excretion, but does not allow for metabolism and compartmental-
isation of synthesis, and, in the urine, prostaglandin excretion depends on flow
rate.
Studies with cyclo-oxygenase inhibition have produced some consensus
concerning the function of renal prostaglandins. In salt replete, unstressed
animals and man, inhibition of prostaglandin synthesis produces few ill effects
on renal haemodynamics and salt output. Prostaglandins appear to exert an
important effect during those conditions in which intrarenal vasoconstrictor
factors, angiotensin II and noradrenaline, are increased, such as salt depletion,
hypotension, anaesthesia, and surgery. Prostaglandins counteract vasoconstrict¬
ion of afferent and efferent arterioles to maintain RBF, and under such
circumstances cyclo-oxygenase inhibition can result in marked reduction in
RBF, GFR and salt excretion (Nadler and Brenner, 1987).
In vitro microperfusion and micropuncture studies have been used to
address the question as to whether prostaglandins have direct tubular effects.
Although there remains some dispute, it appears that PGE2 especially, modul¬
ates salt transport at the medullary thick ascending loop of Henle and at the
cortical and medullary collecting ducts. The importance of such effects is not
clear (Lote and Haylor, 1986).
Non-steroidal anti-inflammatory drugs reduce plasma renin activity in the
baseline state, suggesting that prostaglandins have a physiological role in renin
secretion. By the use of various models, an effect of the prostaglandins can be
demonstrated on the action of all three of the principle stimuli to renin
secretion discussed earlier. However, while the influence of prostaglandins on
renin release is established, they are not essential intermediaries, rather they
appear to function as modulators of the renin secretory response to other
stimuli (Zanchetti, 1985; Lote and Haylor, 1986).
Whether prostaglandins play a role in the natriuretic response to ECF
volume loading is not clear. Two groups at least have demonstrated that the
natriuresis following saline loading can be blunted by cyclo-oxygenase inhibit¬
ors (Higashihara et al., 1979; Wilson et al., 1982), and Carmines et al. (1985)
have demonstrated that cyclo-oxygenase inhibition impairs pressure natriuresis.
However, such conclusions have not always been confirmed (Kirschenbaum and
Stein, 1977).
In summary, the exact role of prostaglandins in volume control has not
yet been determined. What seems clear is that the secretion of prostaglandins
is tightly coupled to the activity of vasoactive hormones and they function to
modulate their renal effects.
Atrial Natriuretic Peptide
As early as 1956 Kisch described the presence of osmophilic granules in
guinea pig atrial cardiocytes. This was followed up by Jamieson and Palade
(1964), and in 1976, Marie et al. demonstrated that the degree of granularity
varied with the water and salt intake of rats. However, the discovery by de
Bold and colleagues (1981) that injection of atrial extracts produced a marked
natriuresis in rats, signalled intense interest and a profusion of research into a
new putative natriuretic hormone. Since 1981, a group of active related
peptides has been isolated, purified, peptide sequences determined, and
synthesised (Buckalew et al., 1987; Ballerman, 1987). The polypeptide precursor
molecule has been identified by cDNA sequencing as a single 151 amino-acid
molecule in man, termed pre-pro-atrial natriuretic peptide, though the principle
storage form, pro-ANP, consists of 126-amino acids. A 28-amino acid residue
has been isolated from human atrial tissue, and the recent development of sen¬
sitive radioimmunoassay confirms that this moiety, named a-hANP, is the
normal circulating form in man, with normal plasma levels in the region of
10-70 pg/ml (Needleman and Greenwald, 1986; Buckalew et al., 1987). Dietz
(1984) demonstrated in the rat heart-lung preparation that atrial distension
produced a marked rise in ANP release. ANP release and increased plasma ANP
levels have been demonstrated in various experimental manoeuvres in animals
and man, including intravenous volume expansion (Yamaji et al., 1985), headout
water immersion (Ogihara et al., 1985), and chronic elevation of dietary salt
intake (Shenker et al., 1985), and increased central venous and hence atrial
pressure may be the physiological stimulus for hormone release. Very high
levels have been identified in pathological conditions associated with circulat¬
ory overload, congestive cardiac failure (Shenker et al., 1985) and chronic
renal failure (Espiner et al, 1985), and in tachyarrhythmias (Tikkanen et al.,
1985). Infusion of angiotensin II, vasopressin and pheynylephrine also increase
ANP release (Manning et al., 1985). Such stimulation has been shown for
vasopressin and a adrenergic agonists in vitro (Sonnenberg and Veress, 1984)
suggesting that the response is not purely due to pressor effects.
Experimental models, which have included infusion into whole animals
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and man, and isolated tissue and cellular preparations, have shown ANP to
have a number of important actions in the body. It seems clear that ANP
mediates its effects through the intracellular second messenger, cGMP (Hamet
et al., 1986). Specific high affinity receptors have been identified in vascular,
adrenal and renal tissue and in the brain (Ballerman, 1987). ANP relaxes pre-
constricted blood vessels in vitro (Kleinert et al., 1984) and reduces blood
pressure in vivo (Weidmann et al., 1986). Suppression of plasma renin activity,
basal and angiotensin II stimulated aldosterone release, and vasopressin release,
are known hormonal effects (Samson, 1985; Anderson et al, 1986). There is
debate about the mechanism of its effects in the kidney. Increased glomerular
filtration rate and glomerulotubular imbalance (Huang et al., 1985), redistribut¬
ion of renal blood flow to deeper salt-losing nephrons (Cole and Needleman,
1985) and direct tubular effects have all been postulated to account for its
marked natriuretic response. In the kidney, ANP receptors and cGMP product¬
ion have been demonstrated in the glomeruli and papillae, and isolated tubular
and cell studies suggest that sodium reabsorption is inhibited in the cortical
and medullary collecting duct (Sonnenberg et al., 1982; Zeidel et al, 1987). The
proximal tubule is devoid of ANP receptors and cGMP activity in response to
ANP (Genest, 1986), and evidence for a proximal site of action from lithium
and free water clearance techniques probably reflects an indirect effect such
as inhibition of angiotensin II formation (Buckalew et al, 1987).
Most of the reported studies have utilised ANP at a dose that represents
a truly pharmacological stimulus, and it is not yet possible to accord to ANP
its correct physiological status. Specific inhibitors available for use in man will
clarify the picture when available and in this context, Naruse et al., (1985)
have demonstrated reduced urinary sodium excretion after inoculation of spec¬
ific ANP-antiserum into rats. Some groups have attempted to infuse ANP at
such small doses that blood levels produced are at least comparable to the
elevated levels found in the pathological conditions mentioned. Such studies in
man have demonstrated a smaller but significant natriuresis, with renin and
aldosterone suppression, but without change in blood pressure (Cuneo et al.,
1986; Anderson et al., 1987), and natriuresis without alteration of glomerular
filtration rate was shown in low dose studies in animals (Yukimura et al., 1984)
The discovery of ANP holds the promise of a novel mechanism for body
sodium homeostasis. The mutual regulatory interaction of vasopressin, angioten¬
sin II and the catecholamines with ANP, provides the basis for integrating
afferent mechanisms that respond to central blood volume, with variation in
systemic blood pressure and the capacity to excrete salt.
The Kallikrein-kinin system
In addition to its significance in the systemic circulation, all components
of the kallikrein-kinin system are present within the kidney. Much research has
attempted to define a role for the system in the kidney but as yet it remains
of potential but unproven significance. Renal kallikrein, a serine protease, is
synthesised in the distal tubule, and acts on filtered low molecular weight
kininogen to produce lysylbradykinin (kallidin) which is biologically active. In
man, bradykinin is probably formed enzymatically in the urine. The kinins are
broken down by kininases present in proximal and distal tubules (Scicli and
Carretero, 1986).
The activity of the renal kallikrein-kinin system is usually inferred from
measuring urinary kallikrein excretion. However, the relationship to kinin
release is unclear and Vinci et al. (1977) were unable to demonstrate a correl¬
ation between the two components in urine.
Intra-arterial renal injection of kinins results in vasodilatation and
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natriuresis (Carretero and Scicli, 1980) and from such studies a physiological
role has been ascribed to the system. However, the presence of kininases in
high concentration at the proximal tubule results in complete breakdown of
kinins administered in this way, with minute amounts appearing at the distal
tubule, the site of endogenous production (Nasjletti et al., 1975). In addition, it
is unclear whether renal kallikrein releases kinins into the renal circulation to
exert vasoactive effects. It is not yet clear whether kinins directly affect
tubular sodium handling, but those studies suggestive of an effect, point to a
distal site, particularly the collecting duct (Jackson et al., 1985).
The kinin-kallikrein system appears to have a reciprocal stimulatory
relationship with the prostaglandins. Thus kinins stimulate phospholipase A2,
releasing arachidonic acid, the precursor for a range of prostaglandins.
Conversely, phospholipase A2 can activate membrane bound renal kallikrein,
and prostaglandins increase urinary kallikrein excretion (Scicli and Carretero,
1986). Studies with cyclooxygenase inhibition suggest that the prostaglandins
may mediate, at least in part, the renal effects of infused kinins (Cinotti,
1983), and prostaglandins are involved in the antagonism of vasopressin by
kinins (Schuster et al., 1984b).
The kallikrein-kinin system interacts with the renin-angiotensin-aldoster¬
one axis at a number of points. Urinary kallikrein activates pro-renin in vitro
(Sealey et al., 1978), and in vivo, bradykinin infusion stimulates renin release
(Flamenbaum et al., 1979). Aldosterone is a potent stimulus to renal kallikrein
synthesis (Marin-Grez, 1982). In addition, Kininase II is identical to angiotensin
converting enzyme. Kinins are elevated by angiotensin converting enzyme
inhibitors and may contribute to drug effects. A low sodium diet produces a
rise in kallikrein excretion (Margolius et al., 1974). Such a finding and the
known hormonal interactions have led some observers to postulate that the
prostaglandins and kinins act synergistically to counteract the antinatriuretic,
renal vasoconstrictor action of the renin-angiotensin-aldosterone axis under
conditions of salt depletion.
Whether the kallikrein-kinin system contributes to natriuresis under
conditions of sodium excess in unclear. As discussed, the system appears to be
principally activated in salt depletion. Intravenous salt loading has been
reported to increase urinary kallikrein excretion (Mills et al., 1976). However,
many stimuli that increase urine flow rate including diuretics, water loading
and saline loading, increase kallikrein excretion in a way that may be artefact-
ual and represent a "wash-out" phenomenon (Marin-Grez, 1982). In spite of
this, the administration of antibodies against kinins to saline-expanded rats has
been reported to result in a decrease in sodium excretion (Marin-Grez, 1974),
so the situation is not yet resolved.
Other hormonal influences on sodium excretion
In addition to the above factors, experimental evidence has been
presented for a distinct natriuretic hormone involved in renal salt-handling.
Cross circulation experiments in animals have indicated the existence of a
transferrable hormonal factor in three separate models: mineralocorticoid
escape, progressive nephron loss and body fluid volume expansion. The nature
of the factor(s) has not yet been elucidated. There is however, evidence that
it derives from the hypothalamus, is a normal constituent of plasma, and
inhibits sodium transport at the nephron. As distinct from established hormones
producing effects at the kidney, its cellular mode of action involves inhibition
of Na+/K+-ATPase (reviewed by Sonnenberg, 1986). In addition to a possible
physiological role, it has been implicated in the pathogenesis of essential
hypertension, in which a compensatory increase in activity serves to augment
sodium excretion by the kidney (de Wardener and MacGregor, 1982).
Heller (1987) has reviewed the evidence for a number of other substanc¬
es which may regulate intrarenal haemodynamies, under physiological and patho¬
physiological conditions. The potential renal importance of these mediators,
which include serotonin, neuropeptide Y, adenosine and histamine,is becoming
an area of active interest.
2) DOPAMINE AS AN ENDOGENOUS RENAL HORMONE
In this section evidence for the renal synthesis of dopamine will be re¬
viewed. The distinct actions of the amine at the kidney and on other renally
associated hormones will be discussed with an attempt to place dopamine into
the framework of the mechanisms of natriuresis already referred to.
Dopamine is the natural precursor for noradrenaline and adrenaline and
the metabolic pathway for catecholamine synthesis is depicted in Figure 1. The
relevant enzymes are present in adrenergic neurones and the adrenal medulla,
in which the formation of L-dopa from L-tyrosine, under the action of tyrosine
hydroxylase, is the rate limiting step.
An independent physiological role for dopamine became accepted when
evidence accrued that it acted as a neurotransmitter in its own right in the
central nervous system. Dopamine is the principle catecholamine within the
basal ganglia, and three principle dopaminergic systems have been identified -
the nigrostriatal, mesolimbic and tubero-infundibular pathways. Further details
concerning dopamine in the central nervous systems are beyond scope of this
review.
That dopamine might have a distinct role in the periphery, and particul¬
arly at the kidney, separate from that purely as a precursor, was suggested by
two separate lines of evidence. First was the demonstration that it is present
in high concentration in renal tissue and urine, relative to noradrenaline and
adrenaline. Secondly, infused dopamine was shown to possess a unique profile
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FIG. 1. The biosynthetic pathway for the
catecholamines
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Renal synthesis and urinary excretion of dopamine
Free dopamine is found in large amounts in the urine of man, and is the
major excreted catecholamine (Sourkes and Drujan, 1957). Reported values for
free catecholamines in man are: adrenaline 0-82 nmol/24h, noradrenaline
118-414 nmol/24h and dopamine 653-2285 nmol/24hr (Crout, 1968). A similar
pattern pertains to the rat, but not to the dog, where noradrenaline predomin¬
ates (Ball et al., 1982).
There has been some debate concerning the source of urine dopamine
and it was previously believed to derive from circulating plasma dopamine.
With the development of sensitive radioenzymatic methods for catecholamine
estimation, various groups have reported plasma free dopamine levels, values
ranging between 40 and 330 pg/ml (reviewed by Van Loon and Sole, 1980). Ball
et al. (1978a) measured dopamine in plasma and urine from six subjects and
demonstrated a mean urinary clearance of 1996 ml/min. Although dopamine can
undergo renal tubular transport (Rennick, 1968), it was evident that even with
filtration and secretion, plasma dopamine could not quantitatively account for
normal levels of free dopamine in urine. The obvious conclusion was that the
kidney must actively synthesise dopamine.
To account for the levels of dopamine in urine, three hypothesis have
been forwarded :-
1. Deconjugation in the kidney of circulating plasma dopamine conjugates.
2. Renal dopaminergic nerves.
3. Renal decarboxylation of circulating plasma L-dopa.
Dopamine conjugates, principally the sulphate and glucuronide, form the
major portion (> 95%) of total plasma dopamine, with values in the nanogram
range. In addition, levels in urine are ten times those of the free amine
(Kuchel et al., 1979). The conjugated forms are traditionally believed to
represent inactive, metabolic end-products of the free amine (Anton, 1987).
Kuchel's group have however, suggested that dopamine sulphate can be con¬
verted to noradrenaline (Buu and Kuchel, 1979), or deconjugated to free dopa¬
mine in the kidney (Unger et al., 1978), thereby effecting a transport or stor¬
age function for the free amine. There is however, little confirmatory evid¬
ence. Bradley et al. (1985) infused dopamine-4-sulphate into the renal artery of
the dog. The preparation was inactive in terms of renal haemodynamic effects,
and no conversion to free catecholamines in urine could be demonstrated.
Similarly, in the isolated, perfused rat kidney preparation, the addition of
dopamine-4-sulphate to the perfusate did not result in an increase in urine free
dopamine (Adam and Adams, 1985). The most compelling evidence against dopa¬
mine conjugates contributing to free urine dopamine comes from the work with
the dopa decarboxylase inhibitor, carbidopa. In studies in man (Williams et al.,
1986) and in the isolated perfused rat kidney (Baines and Drangova, 1984;
Adam and Adams, 1985), carbidopa can be shown to markedly suppress or
abolish urine dopamine excretion, strongly suggesting that the action of dopa
decarboxylase is a prerequisite for free dopamine synthesis and release into
the urine.
The first evidence for the existence of functional dopaminergic nerves in
the kidney came in 1973. Electrode stimulation of the mid-brain in the
anaesthetised dog produced a renal vasodilator response which could be block¬
ed by the dopamine antagonist, haloperidol (Bell and Lang, 1973). Dinerstein et
al. (1979) followed up this work by demonstrating, using histofluorescence
techniques in the canine kidney, a population of neuronal elements at the
glomerular vascular pole which contained predominantly dopamine. Further
evidence came from a study by Chapman et al. (1979). In rats, renal vasodilat-
ion was produced after renal nerve stimulation in the presence of a-adrenergic
blockade. That vasodilation was due to a dopaminergic response, was suggested
by blockade of the effect with sulpiride. However, Bradley et al. (1986a) were
unable to demonstrate any effect of dopamine receptor blockade on the renal
response to renal nerve stimulation, and have drawn attention to the fact that
numerous studies have failed to confirm the anatomical basis and functional
role for dopaminergic nerves in the kidney. There is no doubt that manoeuvres
which activate the renal nerves, either renal nerve stimulation (Bradley and
Hjemdahl, 1984), or bilateral carotid occlusion (Bradley et al., 1987), lead to
the release of both noradrenaline and dopamine. It is unclear from such observ¬
ations whether dopamine is present within noradrenergic neurones, the two
amines being released concurrently on renal nerve stimulation, or whether
dopamine is being released from a specific and distinct population of neurones.
It is as yet uncertain to what degree dopamine released from neuronal tissue,
either noradrenergic or dopaminergic, contributes to free dopamine levels in
urine. In animals, chronic denervation produces either no change (Stephenson et
al., 1982; Baines and Drangova, 1984; Adam and Adams, 1985) or only a modest
reduction in urine dopamine (Morgunov and Baines, 1981; Baines, 1982).
Christensen et al. (1976) studied tetraplegic patients with physiologically
complete cervical spinal cord transection above the sympathetic outflow.
Urinary excretion of dopamine was not significantly different from normal
values whereas urinary noradrenaline and adrenaline were markedly reduced as
would be expected. In another study in man (Williams et al., 1986), carbidopa
reduced urinary dopamine excretion without affecting urinary noradrenaline.
The authors suggested that intraneuronal blockade of dopa decarboxylase would
have been expected to lower noradrenaline as well as dopamine, and postulated
that dopamine in urine is produced by extraneuronal decarboxylation of L-dopa.
The isolated perfused rat kidney actively synthesises dopamine in the
absence of renal innervation, and the addition of L-dopa to the perfusion med¬
ium results in a large increase in dopamine into the urine, a process blocked by
carbidopa (Suzuki et al., 1984; Adam and Adams, 1985). When the L-dopa
concentration in the perfusate was in the range of the physiological plasma
concentration, urine dopamine excretion was comparable to that observed in
normal rats. However, a dopamine level comparable to the in vivo state
produced very little dopamine in urine (Suzuki et al., 1984). Similarly, in rats
studied in vivo, the administration of L-dopa produced a large increase in urin¬
ary dopamine excretion (Sato et al., 1987). Ball et al. (1982) measured the
arteriovenous difference for dopamine and L-dopa across the kidney in
anaesthetised dogs. Whereas dopamine was added to the urinary and venous
outflow, L-dopa was extracted by the kidney. A similar situation has been
demonstrated in man. An oral load of L-dopa (250 mg) produced similar
maximal increments in plasma L-dopa and urine dopamine (98- and 93-fold
respectively). There was a high correlation in the subjects between plasma
L-dopa concentration and urine dopamine output in both the baseline state and
after the administration of L-dopa (Brown and Dollery, 1981). In six subjects
undergoing catheterisation to exclude phaeochromocytoma, the same group
measured the arteriovenous difference across the kidney for L-dopa and
dopamine (Brown and Allison, 1981). They confirmed that L-dopa is extracted
to a much higher degree than accountable for by its urinary excretion, and
estimated that circulating L-dopa could produce up to 75% of the measured
level of dopamine in urine.
The kidney is known to contain a high concentration of the enzyme dopa
decarboxylase, which is concentrated at the proximal tubule (Goldstein et al.,
1972). In histofluorescence studies, Hagege and Richet (1985), elegantly demon-
strated dopamine synthesis in proximal tubular cells of rat kidney cortex slices,
a process stimulated by L-dopa, and blocked by the dopa decarboxylase inhibit¬
or, benserazide. In a micropuncture study in rats, Baines and Chan (1980)
injected L-dopa into the proximal tubule and demonstrated active dopamine
synthesis and release into the urine. There was no difference in response when
innervated and chronically denervated kidneys were compared.
In summary, although data have been derived from widely differing
experimental models, and results are at times conflicting, a reasonable
synthesis of reported work would be that under normal circumstances, free
dopamine, excreted into urine, derives from the extraneuronal decarboxylation
of circulating L-dopa in proximal tubular cells. The putative dopaminergic
nerves require further delineation in functional and anatomical terms, but
neuronal sources do not appear to make an important contribution to levels of
dopamine in the urine.
Dopamine receptors
The identification and characterisation of dopamine receptors has
attracted great interest but also much controversy, and the subject has been
widely reviewed (Lokhandwala and Barrett, 1982; Kebabian and Calne, 1979;
Goldberg and Kohli, 1983). In 1979, Kebabian and Calne proposed the existence
of two dopamine receptors in the central nervous system, which they designat¬
ed Dj and D2. Characterisation depended on the production of a biochemical
response, namely stimulation of adenyl cyclase. Activation of the D1 receptor
(eg. in the caudate nucleus) is associated with stimulation of adenyl cyclase.
Activation of D2 receptors (eg. in the striatum or anterior pituitary) either
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produces no effect or leads to inhibition of cAMP release in brain tissue. Fur¬
ther studies on dopamine receptors in the central nervous system have been
performed using radioactive labelled ligand binding assays. Conflicting results
have been presented and the existence of up to four distinct types of dopamine
receptors (or binding recognition sites), postulated to account for findings
(Stoof and Kebabian, 1984).
There is still no definite evidence that dopamine functions as a neuro¬
transmitter in the periphery. However, studies with infused dopamine and
agonists have defined specific receptors which can be pharmacologically manip¬
ulated. The basis for characterising peripheral dopamine receptors has classic¬
ally been by producing agonist and antagonist potency profiles with regard to a
physiological response. Goldberg and Kohli (1983) produced a classification
which divided peripheral receptors into DA1 and DA2 subtypes. It must be
noted that this classification has been derived by different criteria to that for
receptors in the central nervous system and direct comparisons are not straight
forward. The DA.^ receptor is situated on vascular smooth muscle and is known
as the musculotropic or post-synaptic receptor. A number of models have been
developed for analysis of the DA^ receptor, both in vivo (eg. the dog mesent¬
eric and renal vascular beds) where stimulation results in vasodilation, and in
vitro (eg. the rabbit isolated splenic artery) where vascular relaxation is the
functional response (Brodde, 1982; Shepperson et al., 1982). There is now sub¬
stantial evidence that DA^ receptors are present on coronary, cerebral, hepat¬
ic and femoral, as well as renal and mesenteric vascular beds (Lokhandwala
and Barrett, 1982). The DA2 receptor is situated pre-junctionally on sympath¬
etic nerve terminals, and it is also known as the presynaptic neuronal or
neurotropic receptor. Activation results in inhibition of stimulus-evoked norad¬
renaline release. Again, both in vivo and in vitro models have been utilised to
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characterise the DA2 receptor (reviewed by Hilditch and Drew, 1987). Lokhand-
wala and Buckley (1977) measured the effect of dopamine on vasoconstrictor
responses to sympathetic nerve stimulation and provided evidence for DA2
receptors on renal sympathetic nerves.
Dopamine receptors have also been identified on sympathetic ganglia,
activation of which results in hyperpolarisation and inhibition of ganglionic
transmission. The receptor type has not yet been fully determined (Lokhand-
wala and Barrett, 1982). Evidence for the presence and subtype of dopamine
receptors on cells of the renal tubule, juxtaglomerular apparatus and adrenal
cortex will be discussed in the next section. Dopamine itself has activity on
both DAj and DA2 receptors and in addition stimulates a and l?> adrenergic
receptors (Goldberg, 1972). The models developed have allowed analysis of the
structural and stereospecific requirements for agonists at the dopamine recept¬
ors. From such work, a number of compounds have been synthesised which have
relative specificity at each receptor, at the same time possessing little affinity
for other receptors, and potency series have been defined.
The benzazepine derivative, fenoldopam, appears to be the most specific
agonist at the DA^ receptor, whereas the partial ergoline, LY 171555 is a
selective DA2 agonist (Harvey et al., 1986; Cavero et al., 1987).
The first dopamine receptor antagonists, active in the central nervous
system, were the major tranquillisers of the phenothiazine, butyrophenone and
thioxanthine groups. They also have action on peripheral receptors, but most of
the compounds antagonise both DA^ and DA2 receptors. More recently, a
number of specific compounds have been developed which have greatly facilit¬
ated study of receptor mechanisms. Thus domperidone and the benzazepine,
SCH 23390, are highly selective antagonists at DA2 and DA^ receptors,
respectively (Glock et al., 1982; Goldberg et al., 1984). The (+) enantiomer of
sulpiride is the most selective DA^ antagonist available for use in man, where¬
as the (-) enantiomer is more than 100 times more active than the (+) form at
the DA2 receptor (Goldberg and Kohli, 1983).
The development of highly selective agonists and antagonists has allowed
comparisons to be made between central and peripheral dopamine receptors in
terms of potency series. In addition, binding assays and cyclic AMP responses
have been determined in various models of peripheral receptors (Brodde, 1982).
Goldberg and Kohli (1981) have reviewed the evidence for similarities between
the receptor systems and also pointed to the discrepancies that remain. The
latter may reflect differences in experimental design or indicate that the
central and peripheral receptors are chemically distinct.
The functional significance of dopamine receptors on the systemic
circulation is unclear. In view of the very low plasma concentration, it seems
unlikely that circulating dopamine influences vascular receptors under normal
conditions. In addition, receptor antagonists have not been reported to increase
systemic resistance or blood pressure which might suggest that dopamine is
exerting a relaxant influence on the vasculature. The mechanism by which
endogenous dopamine activates neurotropic receptors is unknown. Mannelli and
Pupilli (1988) have reviewed evidence for the concurrent release of dopamine
and noradrenaline from sympathetic nerves, and suggest that the quantity of
dopamine released may be locally sufficient to activate DA2 receptors. How¬
ever, in most models tested, receptor antagonists do not enhance noradrenaline
release, and a physiological role for the peripheral DA2 receptor cannot yet be
defined (Berkowitz, 1983; Mannelli and Pupilli, 1988). Evidence for the role of
dopamine receptors in the kidney will be reveiwed in the next section.
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Pharmacological and physiological effects of dopamine
When McDonald and co-workers (1964) infused dopamine into man, it was
evident that it was exerting unique effects in the circulation, with increased
renal blood flow and natriuresis, and a rise in cardiac index without change in
blood pressure or pulse. Such actions were distinct from those produced by
other catecholamines. Meyer et al. (1967) demonstrated that the augmentation
of renal function was not secondary to systemic haemodynamic changes, as
administration of dopamine into one renal artery produced marked ipsilateral
effects with little change at the other kidney. Renal vasodilatation has now
been demonstrated in man and animals by various techniques including electro¬
magnetic flow meter, clearance of para-aminohippuric acid (PAH), indicator
dye dilution and renal angiography (reviewed by Goldberg, 1972). The optimal
dose in man is around 5 pg/kg/min (D'Orio et al., 1984). Above this dose, a and
(?> adrenergic receptors are increasingly stimulated and most observers utilise
blocking agents on these receptors to characterise the dopamine response
(Goldberg, 1972, Goldberg and Weder, 1980). In the rat, dopamine normally
produces vasoconstriction at all doses, and a-blockade is required to unmask
specific dopaminergic actions (Chapman et al., 1980). The concept that dopa¬
mine causes renal vasodilation by action on a specific receptor was strengthen¬
ed by the discovery of specific dopamine blocking agents. Thus renal vasodilat¬
ation was attenuated by haloperidol (Yeh et al., 1969), ehlorpromazine (Brotzu,
1970) and sulpiride (Chapman et al., 1980), but not by adrenergic, cholinergic
or antihistamine antagonists (Goldberg, 1972).
The action on GFR is not consistent. Although the study of McDonald et
al. (1964) showed a 25% increase, many studies have not demonstrated signific¬
ant rises in GFR (Levinson et al., 1985; Frederickson et al., 1985). This lack of
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consistent effect (nay be explained in part by the study of Edwards (1985) who
indicated that dopamine relaxes both pre- and post-glomerular arterioles, so
that glomerular hydrostatic pressure may remain unaltered.
There has been much interest in the mechanism of natriuresis following
dopamine. Haemodynamic changes alone could partly account for the effect. A
reduction in filtration fraction, by altering peritubular physical forces, will
result in reduced proximal tubular sodium reabsorption. In addition, Hardaker
and Wechsler (1973) demonstrated in dogs that dopamine causes a redistribution
of blood flow from outer to inner cortex, and reduction in extraction of PAH
suggests shunting from cortical to medullary areas (Goldberg, 1972). Such
change may result in relative 'washout' of the medullary interstitium and
reduced sodium reabsorption at the ascending limb of the loop of Henle. How¬
ever, various workers have indicated, both with dopamine and agonists, that
natriuresis can occur in the absence of renal haemodynamic changes (McGiff
and Burns, 1967; Carey and Hughes, 1987), and direct tubular actions have
been invoked. In an early micropuncture study, Seely and Dirks (1967) pointed
to a proximal tubular site of action, though around the same time, Davis et al.
(1968) provided evidence for a distal effect without alteration in GFR. More
recently, the question has been addressed by in vitro tubular preparation
techniques. Dopamine receptors have been identified in the proximal tubule of
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the rabbit by [ Hlhaloperidol binding (Felder et al., 1984). Bello-Reus et al.
(1982) have shown that dopamine inhibits fluid reabsorption across rabbit
proximal tubules. The cellular mechanism of action at the proximal tubule is
not yet clear, but in rat proximal tubule segments, dopamine has been shown
to inhibit Na+/K+-ATPase (Aperia et al., 1987). It appears therefore, that the
natriuresis consequent upon dopamine administration has both a haemodynamic
and a direct tubular component.
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Most studies on the dopamine renal vascular receptor have focused on
models in which physiological measurements of changes in blood flow or vascul¬
ar relaxation have been made. In the brain, receptors have been characterised
by determination of a biochemical response, namely adenyl cyclase activity and
radioactive ligand binding. More recently, groups have attempted to determine
cAMP responses in the kidney after stimulation by dopamine and dopamine
agonists. Nakajima and colleagues (1977) defined a dopamine-sensitive adenyl
cyclase in a rat kidney particulate preparation, and dopamine stimulates cAMP
release in the canine renal artery (Murthy et al., 1976; Sabouni et al., 1987).
Kotake et al. (1981) identified a dopamine-sensitive adenyl cyclase in rat glom¬
eruli and found a similar order of potency in ability to stimulate cAMP, in a
series of dopamine agonists, to that in striatal homogenates. Schwartz's group
(1982) used the dog isolated kidney and found a high correlation in a group of
dopaminominetics, between renal vasodilation and stimulation of dopamine-sens¬
itive adenyl cyclase. The studies described suggest firstly that central and
renal DA^ receptors may be similar, and secondly that vasodilation of the
renal vasculature is mediated through DA^ receptors. In the study reported by
Felder et al. (1984), both dopamine and the DA^ agonist fenoldopam stimulat¬
ed cAMP release in the proximal tubule. Thus both the renal vasodilator and
natriuretic capacity of dopamine appears to be dependant on DA^ receptor
activation. This is confirmed in dogs in which the renal effects of dopamine
were abolished by pretreatment with SCH 23390, the most specific DA^ recept¬
or antagonist available, whereas the DA2 antagonist domperidone was without
significant effect (Frederickson et al., 1985). Whether cAMP mediates the
action of dopamine after DA.^ receptor stimulation is unknown. However in
dogs, infusion of dibutyryl cAMP produced a natriuresis (Gill et al., 1971) and
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in rabbit kidney brush border membranes cAMP inhibited the Na /H antiporter
(Weinman et al., 1987).
The kidney is abundantly supplied with DA2 receptor-containing adrener¬
gic nerves. Most studies in animals, as indicated, involve the use of a and (?>
blockers to characterise dopaminergic responses, which would be expected to
prevent the expression of DA2 receptor-mediated inhibition of noradrenaline
release from the renal sympathetic nerves. Thus Seri et al. (1987) showed in
the rat that the DA2 agonist lisuride reduced renal vascular resistance, and in
the presence of the DA2 antagonist S-sulpiride, dopamine did not significantly
influence renal blood flow.
Although from the evidence reviewed, dopamine exerts potent pharmaco¬
logical effects on renal haemodynamics and salt excretion, by activating specif¬
ic receptors, less work has been directed towards identifying physiological act¬
ions for the catecholamine in the kidney. Some studies involving the use of
dopamine receptor antagonists or inhibitors of dopamine synthesis suggest that
it may play a role in normal renal function. In a study already referred to
(Chapman et al., 1980), sulpiride produced vasconstriction in the rat renal
cortex as assessed by the H2 washout technique. The authors suggested that
endogenous dopamine normally regulates cortical blood flow by maintaining
vasodilatation. In two studies in man, dopa decarboxylase inhibition with carbi-
dopa was demonstrated to inhibit dopamine excretion, with both acute, and
chronic dosing over 3 days. In both cases, sodium output was significantly
reduced, compared to controls (Williams et al., 1986; Ball and Lee, 1977a),
implying that under normal conditions dopamine has a tonic influence on renal
salt handling. Another approach has been to determine the natriuretic response
to volume expansion consequent upon acute intravenous salt loading. In rats
undergoing saline-induced diuresis, both haloperidol, an unselective dopamine
antagonist, and the DA^ receptor antagonist SCH 23390, reduced the natriuret-
ic response by 25.2% and 30.3% respectively (Schnermann et al., 1986). In dogs,
carbidopa attenuated maximal salt excretion by around 40% after intravenous
saline (McClanahan et al., 1985).
It must be appreciated however, that not all studies demonstrate an
effect of dopamine in the physiological state and the subject will be discussed
in greater detail in the light of results to be presented.
The effect of dopamine on renin release from the juxtaglomerular cells
has been studied in animals and man, both in vivo and in vitro. In rat kidney
slices and the isolated rat kidney, dopamine stimulated renin release. The
effect was blocked by propranolol, leading both groups (Henry et al., 1977;
Quesada et al., 1979) to suggest that the stimulation was (?>-receptor mediated.
However, Williams et al. (1983) showed, using isolated renal cortical cells,
that sulpiride attenuated the renin response to dopamine, suggesting the
presence of specific dopamine receptors. Ayers et al. (1969) and Otsuka et al.
(1970) infused dopamine into dogs and showed stimulation of renin at high dose
levels (12 pg/kg/min), again suggesting that the response was mediated through
the l?> receptor. However, Imbs et al. (1975) and Dzau et al. (1978) used lower
doses (6 pg/kg/min and 0.28 to 3.0 pg/kg/min respectively) and produced
increased renin release. Under these circumstances the increase was prevented
by the dopamine antagonist haloperidol, but not by propranolol. More recently,
the renin response to low dose intrarenal dopamine infusion in conscious dogs
was inhibited by sulpiride, but not by propranolol (Mizoguchi et al., 1983).
Results have similarly been inconclusive in man. Wilcox et al. (1974)
showed that dopamine, in doses causing a pressor response, elevated plasma
renin activity. However, Levinson et al. (1985) infusing dopamine at between
0.03 and 3 pg/kg/min did not report any change in renin activity.
The known influences on renin release have been reviewed. Dopamine
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can interact with these in a number of ways. It may directly activate (?> and
putative dopaminergic receptors on the juxtaglomerular cells, and may inhibit
sympathetic nerve activity by its DA2 effects. In addition it affects both the
barareceptor and macula densa mechanisms by producing renal vasodilation and
natriuresis. The overall effect must therefore represent a balance of competing
influences and in the studies performed, the varying dosage, species, state of
anaesthesia, and systemic effects of blood pressure changes may account for
the discrepancies in the results.
In addition, it must be questioned whether circulating dopamine forms
the physiological moiety for controlling renin release. L-dopa, as the precursor
for dopamine, has been shown actually to inhibit plasma renin activity (Worth,
1986) and the question will be discussed in some detail in the light of the
results to be presented with the renal dopamine prodrug, y-L-glutamyl-L-dopa.
In addition to the well described stimuli to the secretion of aldosterone,
namely potassium, adrenocorticotrophic hormone and angiotensin II, studies in
whole animals and man, and in vitro, have suggested that dopamine provides a
further inhibitory input to the adrenal cortex (reviewed by Ganguly, 1984;
Sowers 1984; Fraser, 1987). Neither the infusion of dopamine, nor the admini¬
stration of bromocriptine affects aldosterone in the baseline state (Carey et
al., 1980; Noth et al., 1980). However, the dopamine antagonist metoclopramide
actively stimulates aldosterone release (Norbiato et al., 1977) and dopamine
inhibits this response in a dose dependant manner (Carey et al., 1980; Noth et
al., 1980). In addition, dopamine inhibits the angiotensin II-induced rise in
aldosterone in man during sodium restriction (Drake et al., 1984). These
findings have led to the hypothesis that in sodium replete subjects, aldosterone
is under maximal tonic dopaminergic inhibition, which can be blunted either by
metoclopramide or by salt restriction.
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In vitro, McKenna et al. (1979) reported that dopamine inhibits aldoster¬
one biosynthesis induced by angiotensin II. Dopamine levels achieved during in
vitro studies are extremely high and it is relevant to the interpretation of such
studies, that, in rat zona glomerulosa tissue, dopamine occurs at concentrations
up to 10,000 times plasma levels (Inglis et al., 1987). The source for such large
concentrations of dopamine is unknown. There is at present no evidence for
dopaminergic innervation to the adrenal cortex. Whether the uptake and local
decarboxylation of circulating L-dopa, in an analagous manner to events in the
kidney, provides the source of dopamine, awaits further study.
Bevilacqua et al. (1982) presented evidence for DA.^ receptors on calf
adrenal cells. Stern et al. (1986) used a bovine zona glomerulosa cell model and
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H-spiperone ligand binding to characterise dopamine receptors. The greater
potency of the DA2 agonist LY 171555 relative to the DA.^ agonist fenoldopam,
and lack of cAMP response to dopamine points to the importance of the DA2
receptor in mediating the effects of dopamine. However, many questions
remain. Most studies on antagonists have been performed with the relatively
non-specific agent, metoclopramide, and it is of note that the specific DA2
antagonist, domperidone, does not influence aldosterone release (Sowers et al.,
1982).
During conditions of high sodium intake, inhibition of the aldosterone
response to angiotensin II would complement the renal vascular and direct
tubular action of dopamine, in promoting natriuresis. Although such a synthesis
is attractive, the action of dopamine on the adrenal cortex under physiological
conditions is not yet fully defined.
A number of groups have shown that the infusion of dopamine into the
dog and man does not alter plasma vasopressin levels, arguing against a role
for circulating dopamine in the control of vasopressin release or destruction
(Ball et al., 1981; Morton et al., 1985; Os et al., 1987a). In an early study,
Deis and Alonso (1970) infused dopamine into the rat and postulated that the
diuresis produced was due to an inhibition of the action of vasopressin. How¬
ever, neither sodium output nor vasopressin levels were measured. In dogs,
dopamine produced a diuresis and reduction in urine osmolality but the renal
effects of concurrently infused vasopressin were unaltered by dopamine
(Cadnapaphornchai et al., 1977). More recently, Koyama et al. (1985) have
suggested in the rat that dopamine exerts a dose-dependant inhibitory effect
on the renal action of vasopressin. As exogenous dopamine does not penetrate
the blood-brain barrier (Bertler et al., 1966), a central effect of locally
synthesised dopamine on vasopressin release is a possibility. Studies in man
utilising centrally acting dopamine antagonists have not produced a consensus.
Fluphenazine and chlorpromazine have been reported to increase vasopressin
levels in plasma (De Rivera, 1975; Shah et al., 1973) but metoclopramide and
haloperidol were without effect (Os et al., 1987b; Kendler et al., 1978).
Lightman and Forsling (1980) demonstrated, in man, that infused L-dopa
suppressed resting levels of vasopressin and inhibited the rise produced by
head-up tilt. Interestingly, the response was blocked by carbidopa and they
suggested that inhibition of vasopressin must occur at a site outwith the blood
brain barrier, either at the pituitary level or at the median eminence of the
hypothalamus. This was partially confirmed by Reid et al. (1986) who reported
a marked inhibition of vasopressin after L-dopa administration to dogs, but in
this model carbidopa did not prevent the inhibition. Various groups have
attempted to study dopaminergic control of vasopressin by direct injection of
dopamine into animal brains, but results have been contradictory (reviewed by
Forsling and Williams, 1984).
Cuche et al. (1976) have suggested that dopamine can influence the
renal clearance of phosphate. Under conditions in which parathyroid hormone,
and other catecholamines were controlled, the infusion of dopamine or L-dopa
into the renal artery of the dog resulted in an increase in urinary phosphate
excretion, a response that was dissociated from the increase in renal blood
flow and natriuresis. The physiological importance of this observation is un¬
clear as inhibition of dopamine synthesis by carbidopa was without effect
under basal conditions. Kaneda and Bello-Reus (1983) have demonstrated in
isolated rabbit nephron segments, that dopamine inhibited the flux of phosphate
across the proximal tubule.
The effect of dopamine on other hormones in the kidney, and renal
hormonal interactions between dopamine and the prostaglandins and kinin-kalli-
krein system, and atrial natriuretic peptide, have been studied by a number of
workers without a consensus emerging. These topics will be discussed in great¬
er detail in relation to results presented in the present studies.
Factors influencing the renal synthesis and urinary excretion of dopamine
Alexander and colleagues (1974) first demonstrated that dietary manipul¬
ation could alter the urinary output of free dopamine in man. Increasing sodium
intake from 9 to above 200 mmol per day resulted in a 40% elevation of urin¬
ary dopamine excretion. Carey et al. (1981) showed conversely that dietary
sodium restriction suppressed dopamine release in man. In addition, a postive
and significant correlation exists between urinary sodium and dopamine excret¬
ion under normal conditions (Cuche et al., 1972; Casson, 1984). Oates et al.
(1979) further analysed the dopamine response to salt loading in man. A signif¬
icant increase in dopamine excretion preceded the rise in the natriuresis
following NaCl supplementation of the diet and the authors suggested that
renal dopamine synthesis (nay have a role in the control of salt excretion.
This effect of inorganic ions has been studied in some detail by Lee's
group in the rat. Addition of excess NaCl to the diet produced a marked
expected rise in urine dopamine. However, both KC1 and NH4C1 also produced
significant increases, highlighting the possible importance of the chloride ion
(Ball et al., 1978a). It was notable that NaHCO^ supplementation was without
effect. Dopamine is a weak base with pK 10.6 so that its excretion into urine
may be pH dependent. The chloride compounds tended to acidify the urine
which would limit back diffusion of dopamine from tubular fluid and increase
urinary excretion. Addition of NaHCOg increased the pH of urine. In a further
study, the effect of inorganic salts on renal tissue dopamine levels was deter¬
mined (Ball et al., 1978b). Again, whereas NaCl, KC1 and NH4C1 increased
renal tissue dopamine, there was no change in the group receiving NaHCO^,
implying that the lack of urine dopamine reponse to the latter compound
cannot be explained purely in terms of a partitioning phenomenon at the
tubule. Tissue pH may therefore determine the rate of dopamine synthesis in
the kidney. It is also conceivable however, that the lack of response to
NaHCOg is spurious, as dopamine is known to be unstable in alkaline media.
Alexander et al. (1974) had also demonstrated, in women, that intraven¬
ous salt loading produced an acute rise in urine dopamine excretion. Concurr¬
ently, urine noradrenaline declined and the dopaminemoradrenaline ratio signif¬
icantly increased. Thus the activity of the two catecholamines appeared to be
inversely related. Such a reciprocal relationship was also noted in response to
the upright posture (Cuche et al., 1972) and muscular activity (Christensen et
al., 1976), reduced urine dopamine excretion occuring in the setting of increas¬
ed sympathetic nerve activity and urinary noradrenaline release.
Two groups have used the dog to define further the dopamine response
to intravenous volume expansion. In the first study, in spite of comparable
volume expansion, isotonic saline was associated with an acute dopamine
response, whereas salt-free albumin did not alter the output of dopamine
(Faucheux et al., 1977). It was of note in this model, that the rise in dopamine
was delayed and followed the onset of natriuresis (c.f. response to oral salt
loading). In the second study, dogs were infused with hypo-, iso-, and hyper¬
tonic saline. All produced similar increases in fractional sodium excretion, but
hypotonic saline did not produce a dopamine response (Cuche et al., 1983).
From these studies, it is apparent that volume expansion per se is not directly
related to a dopamine response in urine, but in some way, dopamine synthesis
is intimately associated with the sodium and/or chloride ion. The possible flow
dependent nature of renal hormone release has already been mentioned, and
the question is relevant to dopamine. In man, Casson (1984) analysed 24 hour
urine sample on normal diet, and whereas a significant correlation was present
between sodium and dopamine, there was no such correlation between dopamine
excretion and urine flow. However, in the rat, water loading was associated
with an increase in urine dopamine output (Akpaffiong et al., 1980). The
authors noted that urine dopamine concentration declined, and suggested that
'washout' of performed tubular luminal dopamine was responsible for the
apparent rise.
Where groups have studied the effects of salt intake on dopamine
release, a low salt standard diet is normally given, supplemented with NaCl as
necessary, to exclude the effect of other dietary constituents. Some studies
however, have specifically sought to analyse the effect of dietary intake
(especially of protein) and fasting on catecholamine excretion. In the rat, diet¬
ary protein restriction produced a diminution of urine dopamine output whereas
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protein supplementation of a laboratory "chow" diet stimulated release (Young
et al., 1985; Kaufman et al., 1985). In a recent study in man, a protein meal
stimulated urine dopamine output (Williams et al., 1986). Interestingly the
natriuresis and increase in creatinine clearance in response to protein was
attenuated by the presence of carbidopa leading to the suggestion that extra-
neuronal decarboxylation of dopa in the kidney contibutes to acute protein-
induced changes in renal function. The source of the observed elevation of
plasma L-dopa levels was not determined, though the L-dopa content of the
meal was known to be low. Two possibilities are, an increased absorption of
dietary L-tyrosine with conversion to L-dopa in the body, or endogenous
release of L-dopa from an unknown site in response to protein-stimulation
(discussed by Williams et al., 1986). The factors controlling plasma L-dopa con¬
centrations may be of importance in other circumstances, but they are as yet
unknown. Brown and Dollery (1981) had demonstrated a strong, positive correl¬
ation between plasma L-dopa and urine dopamine both under normal conditions
and after administration of L-dopa. They therefore postulated that regulation
of dopamine synthesis was secondary to influences controlling plasma L-dopa.
In this regard, L-dopa administration to rats was associated with increased
activity of renal dopa decarboxylase (Sato et al., 1987).
The tubular uptake of filtered L-dopa at the proximal tubule, is an
active process with marked structural specificity (Chan, 1976). The transport
of amino-acids at the proximal tubule has been shown to be sodium-dependent,
active reabsorption declining in kidney cortex slices as the sodium concentrat¬
ion was lowered (Fox et al., 1964; Ullrich et al., 1974). This may represent a
physiological mechanism of control which links L-dopa uptake into the proximal
tubular cell, and dopamine synthesis in situ, to the filtered load of sodium. It
should be noted however that L-dopa actively generated dopamine in the non-
filtering isolated perfused rat kidney, suggesting that L-dopa can also be taken
up into the proximal tubular cell from the basal aspect without the necessity
for glomerular filtration (Suzuki et al., 1984). Chan (1976) also demonstrated
that the uptake of L-dopa was not inhibited in the presence of a dopa
decarboxylase inhibitor or by large changes in pH of the perfusate.
In addition to control being exerted at the level of L-dopa uptake, it is
conceivable that synthetic and degradative enzyme activity may be modulated
by alterations in salt status. In rat renal tissue there was no detectable change
in the activities of monoamine oxidase or dopa decarboxylase in response to
salt loading (Ball and Lee, 1977b). Intravenous salt loading in women decreased
plasma dopamine & hydroxylase, concurrent with the rise in urine dopamine and
fall in urine noradrenaline (Alexander et al., 1974). One interpretation is that
the enzyme may have a regulatory role in catecholamine synthesis, salt loading
reducing the activity, thereby producing a block in the synthesis of noradrenal¬
ine in adrenergic nerves, which allows increased dopamine release. However, as
already discussed, there is little evidence that free dopamine in urine derives
from neuronal tissue, and it is more likely that plasma dopamine l?> hydroxylase
levels reflect adrenergic nerve activity.
In man, the loop diuretic, frusemide, has been demonstrated to stimulate
urine dopamine excretion (Kuchel et al., 1979). Similarly, in the rat, frusemide,
the benzothiadiazine, hydrochlorothiazide, and the potassium-sparing agent,
triamterene, all evoked significant increases in dopamine output (Akpaffiong et
al., 1980). The mechanism of release is unknown. However, the study of
pharmacological natriuretic agents, with actions upon different segments of the
nephron, may lead to greater understanding of the factors influencing dopamine
synthesis, and in particular the relationship to salt handling by the kidney.
3) DOPAMINE IN RENAL PATHOPHYSIOLOGY
Essential hypertension is a multifactorial disorder, and many hypotheses
have been forwarded to account for its pathophysiological basis. Dahl's work
on the rat provided evidence for a genetic component in the blood pressure
response to dietary salt intake. Strains breeding true to type were produced
that were either resistant to, or sensitive to, increases in salt ingestion (Dahl
et al., 1962). Cross-transplantation experiments indicated that the basis for
differential responses lay in the kidney (Tobian et al., 1966).
In man, essential hypertension is believed to have a genetic component,
with a polygenic mode of transmission, in which environmental influences act
upon an inherited background susceptibility.
Hall (1987) has drawn attention to the importance of renal excretory
capacity in the long-term regulation of arterial pressure: any impairment will
result in an increase in blood pressure to maintain sodium and water balance.
De Wardener and MacGregor (1982) have proposed that a primary defect in
renal salt excretion exists in essential hypertension, sodium retention leading
to the compensatory release of a natriuretic factor, the Na+/K+- ATPase
inhibitor from the hypothalamus. The nature of the renal defect remains
unknown.
The relationship between dietary salt intake and the prevalence of
essential hypertension in man is a subject of great controversy (reviewed by
Houston, 1986). Part of the explanation for conflicting results, derived from
cross-cultural comparisons on the one hand, and controlled intervention studies
on the other, may lie in the heterogenous nature of the disease. By means of
either chronic elevation of dietary salt intake, or acute intravenous salt load¬
ing, subgroups of individuals have been identified who either show a pressor
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response to salt, 'salt-sensitive' subjects, or who are able to tolerate large
increases in salt intake with apparent impunity, salt-resistant subjects (Fujita
et al., 1980; Weinberger et al., 1986).
Dopamine is both natriuretic and renal vasodilator on administration, and
may have a physiological role in renal salt handling. There has therefore, been
interest in assessing endogenous dopamine in essential hypertension. Dopamine
excretion into urine was shown to be reduced in a group of essential hyperten¬
sives, and the acute dopamine response to frusemide was impaired (Kuchel et
al., 1979). Harvey et al. (1984) studied a group of essential hypertensives with
no evidence of renal damage. Contrary to the expected result, they displayed a
paradoxical and inappropriate decline in dopamine excretion in the face of a
salt load. This work has been followed up by Shikuma et al. (1986). A group of
patients with essential hypertension were defined as salt-sensitive or salt-
resistant in terms of a pressor response to salt loading. They demonstrated
that the salt sensitive group did not mobilise dopamine whereas the salt-resist¬
ant group produced the expected response. This defect appears to have a
genetic basis and antedates the development of hypertension: the normal
correlation between dopamine and sodium excretion was lost in a Japanese
population of normotensive first-degree relatives of patients with essential
hypertension (Saito et al., 1986). Patients with essential hypertension, in
addition, have increased renal responsiveness to low dose dopamine infusion,
which is manifest in an exaggerated rise in RBF and natriuresis and an enhanc¬
ed hypotensive effect in comparison to normal controls (Andrejak and Hary,
1986). One interpretation of such results is that a relative deficiency of
dopamine leads to upregulation of dopamine receptors in the kidney, and a
greater response to exogenous dopamine. Evidence to date therefore suggests
that some individuals are prone to the hypertensive effect of excess dietary
salt intake, and an inherited inability to mobilise dopamine in the kidney may,
at least partially, account for the underlying renal defect. It should be apprec¬
iated that other factors have been advocated, including kallikrein and the
renal prostaglandins (Weber et al., 1979; Warren and O'Connor, 1980).
The potential evolutionary advantage for effective sodium retention
mechanisms has been alluded to. Black populations in urban societies have a
greater prevalence of essential hypertension. In addition, essential hypertension
with renin suppression is more common, suggesting primary volume overload
(Warren and O'Connor, 1980). Negroes exhibit a greater pressor response to
increases in dietary salt and excrete sodium less effectively after intravenous
loading (Luft et al., 1977; 1979). Critchley et al. (1987) has studied a group of
normotensive Ghanaians living in Edinburgh. As opposed to a Caucasian control
group, they did not display the normal correlation between urinary sodium and
dopamine, and did not produce a dopamine response to salt loading. It would
appear that blacks are less able to deal with the large salt intakes of western¬
ised society. It may be that renal mobilisation of dopamine is poorly developed
as a natriuretic mechanism in blacks, and that the balance of forces is weight¬
ed towards salt retention commensurate with their original hot and humid
environments.
As chronic renal failure advances with progressive nephron loss, the
absolute ability of the kidney to excrete sodium declines. Hypertension is an
inevitable consequence of sodium retention and increase in total body sodium
and water content (Brennan et al., 1980; Koomans et al., 1981). Itskovitz and
Gilberg (1981) showed that with increasing renal failure, urinary dopamine
diminished and almost disappeared when plasma creatinine concentration was
greater than 530 pmol/1. In a group of patients with chronic glomerulonephritis
and mean plasma creatinine of 240 pmol/1, urine dopamine excretion was
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reduced by more than 50%, and there was no dopamine response to elevation of
dietary salt intake (Casson et al., 1983). The authors speculated that the loss
of normal control of dopamine synthesis may be a factor in the abnormal
retention of salt and water.
There is no information as to whether impairment of endogenous dopa¬
mine release has a pathophysiological role in the development or maintenance
of acute renal failure. Although it is a heterogenous condition, which can be
initiated by diverse insults, studies in animals have pointed to the early
importance of vasoconstriction in the kidney (reviewed by Paller and Anderson,
1983). Low dose dopamine infusion is widely used in the setting of incipient
renal failure where promotion of renal vasodilatation and natriuresis may
prevent the onset of acute tubular necrosis. In addition, one or two studies
have suggested that the combination of dopamine and frusemide may be of
benefit in established acute renal failure. Conversion to non-oliguric failure
was demonstrated in a proportion of patients and in some this was associated
with functional recovery (Henderson et al., 1980; Lindner, 1983).
4) Y-l-glutamyl-l-dopa as a renal prodrug
The potential of dopamine as a therapeutic agent was first suggested by
the study of McDonald and colleagues in 1964. In a group of patients with con¬
gestive cardiac failure, infusion at low dose resulted in renal vasodilation and
natriuresis, and an increase in the cardiac index. Since that time, it has be¬
come widely used in the intensive care setting, particularly in cardiogenic
shock and incipient acute renal failure. Dopamine is not specific for dopamin¬
ergic receptors, but activates both a and I?, adrenergic receptors depending on
the dose infused. Between 1 and 4 pg/kg/min its action is primarily on dopa¬
minergic receptors, producing systemic and renal vasodilation and a small, vari¬
able reduction in blood pressure. I?> receptors are stimulated maximally between
5 and 10 pg/kg/min, accounting for the drug's inotropic and chronotropic
effects. Above this dose, a effects predominate with systemic vasoconstriction
(Goldberg, 1972). Thus the dose range for dopaminergic actions is narrow, and
pedal gangrene resulting from intense vasoconstriction has been reported with
its use (Alexander et al., 1975). In addition, individuals may show abnormal
sensitivity to the drug: a patient developed gangrene during the prolonged
infusion of only 1.5 pg/kg/min (Greene and Smith, 1976).
There has therefore, been interest in the evaluation of agents producing
the beneficial effects of dopamine receptor stimulation, whilst avoiding the
potentially damaging consequences of activation of a and l?> receptors. One
approach has been the development of agonist drugs with relative specificity
for dopamine receptors.
DAj^ receptors are widely distributed in the vasculature, activation
resulting in systemic and renal vasodilatation, and reduction in blood pressure.
DA2 receptor agonists have a similar action, inhibition of noradrenaline release
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allowing passive vascular relaxation. Both DA^ and DA2 agonists are currently
being assessed for efficacy in essential hypertension and congestive cardiac
failure (Goldberg, 1984; Harvey et al., 1986; Clark, 1987). There are, however,
disadvantages with both groups. The action of DA^ agonists, like other vasodil¬
ators, leads to secondary activation of the sympathetic nervous system with
tachycardia and offsetting of drug action. DA2 agonists do not increase the
pulse rate, but their use is associated with nausea due to stimulation of the
chemoreceptor trigger zone at the area postrema. In addition, those passing
the blood-brain barrier such as lisuride, may produce a dose-dependant
psychosis (Critchley et al., 1986).
Another approach has been to focus on the renal actions of dopamine,
namely vasodilatation and natriuresis, and to develop drugs with effects
targeted at, and limited to, the kidney. As discussed, the basic defect in at
least a proportion of those with essential hypertension, may reside at the
kidney, with a relative inability to excrete salt. Targeting dopaminergic drug
action at the kidney may allow a smooth and sustained reduction in blood
pressure concurrent with the natriuresis. Similarly, in congestive heart failure
and incipient renal failure, promotion of natriuresis is desirable without acute
and marked fluctuations in systemic blood pressure.
The physiological precursor of dopamine is L-dopa, and its administration
in man results in an increase in renal blood flow and sodium excretion. How¬
ever, it also produces changes in systemic haemodynamics, and its use is
associated with undesirable side-effects, partly resulting from its propensity to
cross the blood-brain barrier (Finlay et al., 1971; Rajfer et al., 1984).
Goldberg's group first developed the concept of the renal prodrug (Biel
et al., 1973). They demonstrated that the aminoacyl derivative of dopamine
(N-L-isoleucyl-dopamine) produced a selective increase in renal blood flow with
only minimal systemic haemodynamic effects in the anaesthetised monkey. The
basis of the relative specificity was due to conversion to dopamine by the
enzyme aminoacylarylamidase which is abundant in the kidney.
The work of Orlowski and Wilk (1976, 1978) indicated that the kidney is
active in the uptake and metabolism of Y-glutamyl derivatives of amino-acids
and peptides. The activity is related to the presence in the kidney of the
enzyme Y-glutamyl transferase, shown by histochemical techniques to be highly
concentrated in the brush border of proximal tubular cells in rats (Albert et
al., 1961; Glenner et al., 1962) and in man (Abbs and Kenny, 1983). The
enzyme has also been demonstrated at the antiluminal surface in association
with the mirovasculature, and the high concentration of enzyme at the proxim¬
al tubule suggests an important physiological role in amino-acid handling,
glutathione transport and metabolism, and renal ammoniagenesis (Welbourne and
Dass, 1982). In the human, if activity in the kidney is taken as 100, relative
activities in other tissues are; pancreas - 8.3, liver - 3.9, spleen - 1.5, intest¬
ine - 0.95, brain - 0.5, lung - 0.31, skeletal muscle - 0.067, and heart - 0.045
(Orlowski and Szewczuk, 1961).
Wilk and colleagues (1978) administered y-glutamyl-L-dopa to rats and
mice by intraperitoneal injection and noted marked concentration of dopamine
in renal tissue, considerably higher than in other tissues. For example, the
ratio in kidney to that in heart was 25.8. After administration of L-dopa at an
equimolar dose, a much more uniform distribution pertained, and the ratio was
4.3. It had previously been reported in guinea pigs that the kidney/heart ratio
after intravenous dopamine was just 2.5 (Halushka and Hoffman, 1968).
The differential effect of dopamine accumulation was also reflected in
renal blood flow. Gludopa produced renal vasodilation whereas an equimolar
dose of L-dopa was without effect. Another index of specificity was the relat-
ive increase in dosage required to elevate systemic blood pressure above that
for renal vasodilation. A ten-fold increase in dopamine elevated both systolic
and diastolic pressure, whereas a 20-fold increase was required for gludopa,
the rise being principally in the systolic component. The same group have also
evaluated another derivative, y-glutamyl dopamine. It proved more renally
selective than dopamine, but less potent than gludopa.
The presence of yGT on both luminal and antiluminal membranes suggests
that the uptake of gludopa will be very efficient and occur both after filtrat¬
ion, from tubular lumen, and from the renal circulation. It is likely that the
enzyme functions both as carrier and hydrolytic unit so that free L-dopa is
liberated into the proximal tubular cells. L-dopa will then be available for
conversion to dopamine under the action of dopa decarboxylase, which as
discussed, is present in high concentration in proximal tubular cells (Figure 2).
The renal specificity of gludopa thus depends on the consecutive action of two
enzymes, both concentrated in the kidney. Since the generation of dopamine
from y-glutamyl dopamine requires the action of only one enzyme, it would be
expected to be less renally specific than gludopa.
Worth and colleagues (1985a, 1986) first infused gludopa into man, and
established its natriuretic potency at 12.5 and 100 pg/kg/min. In normal
volunteers, it produced renal vasodilation with a small increase in glomerular
filtration rate and reduction in filtration fraction. At the lowest dose it was
devoid of effects on systemic haemodynamics, although at 100 pg/kg/min there
was a small reduction in diastolic blood pressure and a small increase in pulse
rate. Its effectiveness as a renal prodrug with relative renal specificity was
demonstrated by the 280-fold and 2500-fold increases in urine dopamine
excretion at low and high doses, whereas plasma dopamine levels rose to only 4
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FIG. 2- The conversion of gludopa to dopamine by sequential
removal of the glutamyl and carboxyl radicals.
The agent has at present been used in two pathological states. Casson
(1984) administered glycerol which induces an ischaemic model of acute renal
failure in the rat. When gludopa was administered concurrently by subcutan¬
eous route, the pathological and clinical sequelae were significantly alleviated.
Gludopa has also been infused into human patients with essential hypertension
(Worth et al., 1985b). In comparison with controls, there was an exaggerated




1) VOLUNTEER SELECTION AND GENERAL PROTOCOL OF THE STUDIES
Volunteers were healthy normotensive males aged 19 - 40 years. A
health screen was performed including general examination, supine blood press¬
ure, routine biochemistry and full blood count, urinalysis and electrocardio¬
gram. Subjects were excluded on the basis of previous drug reaction, allergy,
or requirement for drug therapy. Women were not included in view of the poss¬
ibility of first trimester pregnancy, and the known effects of the oral contra¬
ceptive pill on salt and water balance. All volunteers gave informed consent
and the studies were subject to approval by the Medicine and Clinical
Oncology, Ethics of Medical Research Subcommittee, Lothian Health Board.
To reduce the variability of responses, subjects were given advice to
avoid excessive dietary salt, by avoiding salty and highly processed foods and
not adding salt to food over the 36 hours prior to a study. Alcohol was forbid¬
den for 36 hours prior to the study and caffeine containing drinks (tea, coffee,
coke, chocolate) and smoking were not allowed from 2200 hours on the evening
before. Subjects avoided all proprietary medicines including aspirin for at least
one week before investigation. On the morning of study, 500 mis of tap water
and a light breakfast were taken at 0800 hours before arrival at the investig¬
ation suite by 0900 hours. Subjects remained supine throughout, except for
bladder emptying. Intravenous Venflon cannulae were placed in either or both
antecubital fossae for blood sampling and drug administration. Water (200
ml/hr) was given frequently by mouth to ensure adequate urine flow rates and
to facilitate complete bladder emptying. In all studies, a run-in or baseline
period was followed by drug administration, either orally, or by intravenous
bolus or infusion, and the study then continued for a variable period with a
recovery phase as indicated. All drug infusions were given with an Imed 960
Volumetric pump. Sampling was performed at timed intervals such that, at the
end of a collection period, supine pulse and blood pressure measurement, and
blood sampling, were followed by standing and voiding. Blood pressure and
pulse were measured in duplicate by automatic inflating cuff (Critikon
Dinamap).
Studies were separated by at least 7 days to allow washout of drugs and
re-equilibration of salt balance and renal responses. Unless otherwise spec¬
ified, the studies were carried out in a random-ordered, single-blind fashion.




y-L-glutamyl-L-dopa (gludopa) was obtained from UCB Bioproducts
(Brussels). The preparation used in these studies contained 92% dipeptide, the
balance being acetic acid carried over from freeze-drying. It was prepared for
use in sterile ampoules containing 100 mg of gludopa in 5 ml of 0.9% sodium
chloride solution with 0.5% human albumin. Before use, the required amount
was added to 50 mis of 0.9% sodium chloride to give 25 pg/kg/min on intraven¬
ous infusion over the specified period.
Y-L-glutamyl-L-tyrosine (glutyrosine) was obtained from Sigma. It was
prepared in the same manner as for gludopa.





Up to 80% of urine dopamine may be in conjugated form, principally the
sulphocon jugate (Kuchel et al., 1979). As discussed in the introduction, the
physiological moiety is likely to be free dopamine. In the present assay, urine
samples were initially extracted with alumina, the rationale being that only
free dopamine binds to alumina, which can then be eluted. The extraction
phase is based on the method of Anton and Sayre (1964). Thereafter, free
dopamine was measured by high performance liquid chromatography (HPLC) and
electrochemical detection, using epinine (N-methyl dopamine) as an internal
standard.
Collection of urine samples
Timed urine samples were collected into 25 ml Universal Containers with
0.4 ml of 5M HC1. This was sufficient to lower the pH of the samples to below
3, which prevents oxidation of free dopamine. Aliquots were stored at -40°C
before assay.
Reagents
Dopamine HC1 was obtained from Sigma. A stock solution was prepared
by adding 50 mg to 50 ml M HC1 (1 mg/ml). The working standard was prepared
by diluting the standard 1:100 with distilled water and further diluting 1:50
with 0.01 M HC1 to produce a concentration of 200 ng/ml.
Epinine was obtained from Sigma. The stock solution was prepared by
adding 50 mg to 50 ml of M HC1. It was stored in aliquots at -40°C. The work¬
ing internal standard was prepared by diluting the stock 1:10 with distilled
water and further diluting 1:50 with 0.01 of M HC1 to produce a concentration
of 2 pg/ml.
The solvent used for HPLC contained citric acid monohydrate (5.75g),
sodium acetate trihydrate (6.80g), sodium hydroxide (2.40g), 1-octane sulphonic
acid, sodium salt (0.10g), acetic acid (1.05ml), di-sodium EDTA (0.10g) made up
to one litre of deionised water. The pH was 5.2. Solvent was filtered through a
0.22 pm membrane (Millipore), and methanol 10% (v/v) added prior to use.
Dissolved oxygen was removed by bubbling helium through the solvent.
Aluminium oxide (Brockman grade 1, B.D.H.) was pre-activated by heat¬
ing at 200°C for 2 hours and stored at 100°C. Activated alumina was washed
with 0.5M EDTA before use.
Chemical reagents used were obtained from standard suppliers.
Extraction of dopamine from urine samples and standards
The volume of urine used depended upon the likely concentration expect¬
ed. For example, in studies involving the administration of gludopa, consider¬
able dilution such as 1:200 with distilled water was necessary.
To 0.5 g of washed activated alumina, were added 5 ml of the test urine
sample and 0.5 ml of the working internal standard. The pH was adjusted to 8.3
with 0.5 M Tris. The mixture was rollamixed for 40 mins at 37°C and centri-
fuged at 1000 rpm for 2 mins at 4°C, before syphoning off the supernatant.
The deposit was washed three times with distilled water, each time syphoning
off the supernatant after centrifugation. Dopamine was eluted by addition of 2
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ml, 0.2 M acetic acid. Tubes were shaken for 10 minutes at 37°C and centri-
fuged at 4°C. The supernatant was removed by means of a Porex filter, and
stored at -40°C. All samples were processed and analysed in duplicate.
Dopamine standards were prepared in two ranges, 20 - 200 ng/ml, or 5 to
50 ng/ml depending upon expected sample levels. 0.5 ml of internal standard, 2
gg/ml or 0.5 pg/ml, was added to 5 ml of each standard concentration. All
standards were extracted following the same procedure as that for test
samples, and frozen at -40°C. Sufficient standards were prepared for one
months use.
The recovery of dopamine from the extraction process was 69.7 _+ 0.5%
S.D. as compared against unextracted standards.
Analytical System
Each assay consisted of test samples in duplicate standards, run at the
beginning and end of each batch, and two quality control samples. 5 pi were
injected automatically by a Waters Intellegent Sample Processor, into a solvent
stream delivered at 1 ml/min by a Beckman/Alter M410 solvent metering pump.
Solvent thereafter passed to a Waters 4 gm, Novapak C18 HPLC column under
radial compression and the column effluent stream to a Waters 460 electro¬
chemical detector, set at a potential of 0.4 volts, in oxidative mode, with back¬
ground current approximately 0.5 mA. Signals were analysed by a Shimadzu
CR3A integrator which measured the area under the curves of peaks of
interest.
Expression of results
The integrated area of all standard peaks was divided by the area of its
own internal standard. The duplicate standard ratios were measured and a
standard curve plotted against known concentrations, the plot providing a
straight line relationship. Test sample ratios were read from the curve and
urine dopamine expressed in nmol/1.
Intra- and inter-assay co-efficients of variation were 4% and 6%
respectively. The sensitivity of the assay was 5 ng/ml.
PLASMA RENIN ACTIVITY
Introduction
Renin, a proteolytic enzyme of the aspartyl protease class, has as its
natural substrate angiotensinogen - an macroglobulin, synthesised in the
liver and released into the circulation. It cleaves off a decapeptide, angioten¬
sin I which is rapidly converted in vivo into angiotensin II, under the action of
a dipeptidylcarboxypeptidase, angiotensin converting enzyme. Angiotensin II is
biologically active with a half-life of 2-3 minutes in vivo, and is reduced to
small peptides by angiotensinases. Incubation of plasma in the presence of
powerful inhibitors of angiotensinases and converting enzyme activity and
assay of generated angiotensin I by radio-immunoassay allows measurement of
plasma renin activity. The method used is based on that developed by Haber et
al. (1969).
Plasma renin activity is influenced by posture and stress; therefore,
sampling was performed after subjects had been quietly supine for at least 20
minutes. In addition, inactive renin, currently termed pro-renin, can be activat¬
ed by exposure to cold (-5°C to +4°C); therefore samples were stored at -40°C
and assayed on ice (4°C).
Reagents
Antibody to angiotensin I was raised in the rabbit and kindly provided by
Dr. Frank Goodwin (London Hospital). It was prepared for use as a 1:20 000
dilution in 0.1 M Tris-acetate buffer (pH 7.4) containing 0.25% bovine serum
albumin (BSA) to give 50% binding to labelled angiotensin I.
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Iodine - labelled angiotensin I was obtained from CIS(UK). Sufficient
crystals were dissolved in Tris-acetate buffer with 0.25% BSA (pH 7.4) to give
between 1500 and 2000 cpm/200 pi.
Standard angiotensin I was obtained from the National Institute of
Biological Standards and Control. The working standard was 180 pg/100 pi,
double diluted using 500 pi of Tris-acetate buffer with 0.25% BSA (pH 7.4) to
give a range of 180, 90, 45, 22, 11, 5 pg/100 pi for construction of standard
curves.
The inhibitor mix consisted of phenyl-methyl-sulphonyl fluoride 5% in
ethanol (2 parts), dimercaprol, 1.06 M solution in ethanol (one part) and
8-hydroxyquinoline, saturated solution in ethanol (one part).
The chemical reagents used were obtained from standard suppliers.
Method
Venous blood (5 ml) was collected into pre-cooled tubes containing 100
pi of a 5% sodium EDTA solution and kept on ice until centrifugation at 4°C,
separation and storage of plasma at -40°C.
40 pi of phosphate buffer (pH 5.3) and 10 pi of inhibitor mix were added
to duplicate 200 pi aliquots of plasma samples. One set was incubated for one
hour at 37°C in a water bath during the generation phase, the other set
remained at 4°C to allow measurement of any angiotensin I generated during
collection, together with any substances cross-reacting with the antibody. The
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reaction was terminated by the addition of one ml of cold water.
To 100 ill aliquots of the duplicate samples, were added 400 pi Tris-
acetate buffer containing 0.5% BSA and 0.1% lysozyme chloride, 200 pi of
antibody and 200 pi of angiotensin I label. Standards were prepared in duplic¬
ate in the same manner. In addition, tubes were prepared containing antibody
and label only to check binding and provide the zero point on the standard
curve, and two extra tubes contained only buffer and label as a background
check for how much non-angiotensin antibody was present. All samples were
left for 20-24 hours at 4°C.
The principle of charcoal separation is that free angiotensin I binds to
dextran-coated charcoal whereas the angiotensin-antibody complex does not.
The efficiency of separation is highly time and temperature dependant and
requires precise control. 0.9 g charcoal and 0.1 g dextran (mol.wt. 81000) were
dissolved in 50 mis Tris-acetate buffer with 0.25% BSA and mixed on ice for
45 minutes. Over a timed period of 9 minutes, 500 pi was added to each tube,
except total count tubes, mixed and left on ice. Batches were then spun at
3000 rpm for 10 minutes at 4°C. The decanted supernatant was counted for 10
minutes using a LKB-Wallace 1275 Mini Gamma gammacounter. The "bound
counts" were expressed as a percentage of total counts, and by plotting a
standard curve for the known angiotensin I concentrations, the sample values
could be read directly from the curve. The 4°C incubation value was subtract¬
ed from each sample, the result multiplied by a dilution factor of 0.0625 and
plasma renin activity expressed as ng angiotensin I/ml/hr. Intra-assay and
inter-assay co-efficients of variation were 4% and 6% respectively.
ATRIAL NATRIURETIC PEPTIDE
Introduction
Many peptide fragments with natriuretic activity have been identified
from atrial extracts in animals and humans. It would appear that a 126-amino-
acid prohormone, stored in granules in perinuclear atrial cardiocytes under¬
goes selective enzymotic cleavage on secretion, releasing the 28-amino-acid
carboxy-terminal fragment now called a-hANP. This peptide is believed to be
the normal circulating form of the hormone in man.
ANP was measured in plasma samples in the present studies by a radio¬
immunoassay, after an extraction phase, using rabbit antiserum raised to
synthetic a-hANP.
Posture is known to affect plasma ANP levels: therefore subjects
remained supine for at least 20 minutes before sampling. Lipid-laden plasma
samples interfere with the extraction procedure and subjects either fasted
before sampling or took only a light breakfast, depending on the study in
question.
Materials
a-hANP antibody was raised in this department. 1-28 a-hANP (Peninsula
0.5 mg in 1 ml sterile 0.15 M NaCl) was added to a sterile mixture of bovine
thyroglobulin (5 mg) and carbodiimide (3 mg in 3 ml sterile 0.15 M NaCl). The
solution was left overnight at 4°C before a further 3 mg of carbodiimide was
added. It was stirred at room temperature for 3 hours and dialysed in & inch
Visking tubing against 5 1 of 0.15 M NaCl at 4°C overnight. Thereafter, the
solution was made up to 5 ml with sterile 0.15 M NaCl. One ml of the conjug¬
ate was mixed with 1 ml complete Freunds adjuvant, and injected intra-
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muscularly into a New Zealand white rabbit, 0.5 ml at each of four different
sites. At four 3 weekly intervals, the remaining conjugate was administered
subcutaneously, 0.5 ml at two sites, on each occasion. The rabbit was bled
from the ear artery from the 6th week onwards, at weekly intervals, and bled
out when the antibody titre showed 50% binding at a 1:11000 dilution. The
serum was stored at 1:500 at -40°C and diluted to give a working concentrat¬
ion of 1:11000.
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Iodine - a-hANP label was obtained from Amersham International. It
was stored at -40°C as aliquots containing 500 pg in 500 pi and diluted for use
to 4 pg/100 pi.
Standard a-hANP was obtained from Bachem. It was stored at -40°C as
aliquots containing 200 pg/100 pi. A range of 5 - 200 pg/100 pi was produced
by double dilution.
Filtered phosphate buffer 0.1 M, pH 7.4 containing 0.25% egg albumin,
was used for all dilutions.
The chemical reagents used were obtained from standard suppliers.
Method
Venous blood (10 mis) was collected into pre-cooled plastic tubes con¬
taining 5% disodium EDTA and Trasylol (20 KlU/ml) to prevent destruction of
ANP by proteases, and kept on ice until centrifugation at 4°C, separation and
storage of plasma at -40°C.
Extraction of samples was performed using a SEP-PAK C^g cartridge
pack (Waters Associates) and vacuum source to pull solvents through. Each
column was wetted with 4 ml methanol and washed twice with 4 ml of 4%
acetic acid. Four ml of plasma was applied to the column and washed with 4
ml of 4% acetic acid. The ANP was eluted from the column using 2.5 ml of
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ethanol solvent (ethanol 80%, acetic acid 4%). The eluate was dried under a
stream of N2 at 37°C and the residue reconstituted in 400 pi of buffer and
stored at -40°C.
During the assay procedure, 100 pi of sample was added to 600 pi of
buffer and 100 pi of antibody. The mixture was incubated at 4°C for 24 hours.
Thereafter, 100 pi of ANP label was added and the mixture incubated for a
further 20 hours at 4°C. Standards were prepared in a similar manner, and
extra tubes set up for non-specific binding. Dextran coated charcoal was pre¬
pared by adding 0.08 g dextran (mol at 81000) and 0.8 g charcoal to 50 ml
buffer and mixing on ice for 45 minutes before use. 500 pi was added to all
samples, standards and controls (except total count tubes), the procedure being
performed in batches of 40 tubes over 10 minutes. Tubes were then spun for 15
minutes at 2500 rpm, decanted and the supernatant counted over 10 minutes
using a LKB-Wallace 1275 MiniGamma gammacounter. In the same way as for
the PRA assay, "bound counts" were expressed as a fraction of total counts,
and values read off a standard curve. Values are expressed as pg/ml after
correction for extraction and dilution during the assay. Recovery from the
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SEP-PAK cartridge of I - a-hANP was 89.5% _+ 0.58% S.D. Intra-assay and
inter-assay coefficients of variation were 4.0% and 8.4% respectively.
URINE KALLIKREIN
Introduction
Glandular kallikrein, produced by the kidney and excreted in urine, is a
serine protease, identical to that found in salivary and sweat glands, pancreas
and gastro-intestinal tract of the same species, but distinct from plasma kalli-
ti
krein. It acts on acidic glycoproteins, kininogens, to release lysylbradykinin
which has potent actions in the kidney.
Urine kallikrein was measured in the present studies by the method of
Amundsen et al (1979). Kallikrein in urine hydrolyses the chromogenic substrate
H-D-valine-leucine-arginine-p-nitroaniline: the rate of p-nitroaniline released
inceases linearity with increasing concentration of kallikrein and can be
measured spectrophotometrically. In view of the highly diluted urine produced
by water loading and diuretic administration, urine samples were initially con¬
centrated by ultrafiltration.
Reagents
Substrate S-2266 (H-D-Val-Leu-Arg-pNA 2HC1) was obtained from Kabi
Diagnostica, Stockholm. A 1.5 mmol/1 solution in distilled water was stored at
4°C.
Tris buffer, 0.2 mol/1, pH 8.2, was used for all dilutions.
Standard porcine kallikrein (Sigma) was stored as 1 Eu/100 pi aliquots in
0.9% NaCl. A working range of 0.01 to 0.04 Eu/ml was prepared with distilled
wat er.
The chemical reagents used were obtained from standard suppliers.
Method
Urine samples were stored at -20°C. Samples were concentrated before
assay by a factor of 5-20, by means of vacuum-operated Immersible-CK Ultra-
filters (Millipore) containing 10,000 molecular weight cut-off membranes. The
concentrated urine was then brought back to 5 ml with distilled water used to
rinse the membrane.
For the assay, 400 pi of concentrated urine was added to 500 pi of
buffer and kept for 5 minutes at 37°C, before addition of 100 pi of S-2266
solution. The mixture was incubated for 30 minutes at 37°C. Thereafter tubes
were transferred to ice and 100 pi of 50% acetic acid added. Standard samples
were treated in the same manner. In addition, a parallel line of urine samples
were analysed using buffer containing Trasylol (lyophilised aprotinin 20
KlU/ml), a potent inhibitor of glandular kallikrein. In such sample blank tubes,
protease activities not inhibited by aprotinin as well as the colour of the urine
itself could be estimated. The absorbance of standards, samples and blanks
were read at 405 nm by spectrophotometer (Pye/Unicam SP 1750). The sample
blank values were subtracted from those of the sample tests and the concen¬
tration of kallikrein in samples read from the constructed standard curve. The
original urine kallikrein concentrations in EU/ml were calculated after correct¬
ion for a variable concentration factor. Recovery during the concentration
procedure was 95.4 +_ 8.5% S.D. The intra- and inter-assay co-efficients of
variation were 3.7% and 5.1% respectively.
Urine cyclic AMP
Urinary cAMP was kindly measured by Dr. P.W.H. Rae, Department of
Clinical Chemistry, The Royal Infirmary, Edinburgh. The method was a radio¬
immunoassay with a rabbit anti-BSA-linked cyclic AMP antibody. Separation
was achieved using a donkey anti-rabbit serum attached to Sepharose. The
sensitivity of the assay was 2.6 nmol/1 and the intra- and inter-assay co-effic¬
ient of variation were 6% and 10% respectively (O'Reilly et al., 1986).
Plasma and urine sodium and potassium were measured by a Corning 435 flame
photometer with Corning 800 diluter.
Plasma and urine creatinine were measured by multichannel analyser (Gemstar,
Electro-nucleonics Inc.) utilising the Jaffe reaction. Briefly, when a sample is
added to an alkalinised picric acid solution, the colour change read spectro-
photometrically at 500 nm, against a reagent blank, is linearly related to
creatinine concentration.
Urine phosphate and urate were measured by continuous flow multichannel
analyser (Technicon SMA-2).
Serum and urine lithium were measured by Jenway PFP7 digital flame photo¬
meter with lithium specific filter.
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4) CALCULATIONS AND STATISTICS
Creatinine clearance (C^) as an approximate measure of glomerular
filtration rate, is defined as:
C^, (mls/min) = UCr x V
Cr p r
Cr
where U^r is urine creatinine concentration (gmol/1), V is urine volume over a
timed collection period (t) in minutes, and is plasma creatinine concentrat¬
ion (gmol/1).
Lithium and sodium clearances can be similarly calculated. Clearance
periods were between 45 and 60 minutes. Plasma creatinine, sodium and
lithium were measured at the start and end of the period and the mean value
taken for estimations.
Fractional lithium clearance is the fraction of the filtered lithium which
is excreted in the urine and can be calculated as:
Fractional CLj = C^ x 100%
CCr
Of the sodium leaving the proximal tubule, that proportion which escapes
reabsorption at the "distal tubule" (loop of Henle, distal convoluted tubule and
collecting ducts) can be represented by the following formula:
Fractional "distal tubular" clearance = CXT x 100%Na
CLi
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Absolute reabsorption of sodium by the "distal tubule" can be calculated
as:
Absolute distal reabsorption (mmol/min) = (CL- - CNa)pNa
Results are expressed as means +_ SEM. Data was analysed by repeated
measures analysis of variance (Genstat, Rothampsted Experimental Station).
Most analyses compared responses at time points after some intervention, with
results for a control period, and Dunnett's correction for multiple comparisons
was used (1955). Where single comparisons were made, student's t-test for
paired samples was employed. The values for PRA were log-transformed before
analysis in order to normalise the data. All tests were two-tailed and results
of p < 0.05 were taken as statistically significant.
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CHAPTER THREE
STUDIES WITH y-L-GLUTAMYL-L-DOPA (GLUDOPA) IN NORMAL MAN
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INTRODUCTION
The work from Wilk's group (1978) in the rat had suggested that gludopa
was a promising dopamine prodrug with relative renal specificity. Worth (1986)
followed up these findings by infusing the dipeptide in man, and showed it to
be active in terms of natriuresis and renin suppression when infused at 25 and
100 pg/kg/min. At the higher dose however, there were systemic effects with
slight reduction in blood pressure, elevation of the pulse rate, and nausea in
some subjects.
The three studies in this chapter were devised to extend this work and
further characterise the action of gludopa in the kidney. In addition to a
potential role as a therapeutic agent, a renally specific drug such as gludopa
provides a useful tool to investigate natriuretic mechanisms without the con¬
founding effects of changes in the cardiovascular system, and may allow
actions and interactions of dopamine in the kidney, under physiological
conditions, to be inferred. An infusion rate of 25 pg/kg/min was chosen with
the aim of optimising renal effects of gludopa without producing appreciable
changes in the systemic parameters, blood pressure and pulse.
The uptake of L-tyrosine is an active process, and the formation of
L-dopa, catalysed by the enzyme tyrosine hydroxylase, is the rate limiting step
in catecholamine synthesis in peripheral adrenergic nerves (Nagatsu, 1973).
Dopamine synthesis has been demonstrated extraneuronally in the proximal
tubule in the kidney (Hagege and Richet, 1985) and evidence reviewed suggests
that, under normal conditions, renal dopamine is formed from the uptake and
decarboxylation of circulating L-dopa (Lee, 1986). The first study compared
the urine dopamine synthesis and renal actions following infusion of the dipept-
ides y-L-glutamyl-L-dopa and y-L-glutamyl-L-tyrosine. With the known abund-
so
ance of Y-glutamyl-transferase in the kidney (Albert et al., 1961), the release
of large amounts of free L-dopa and L-tyrosine would be expected. The aim of
the study was therefore to compare the relative effectiveness of L-tyrosine
and L-dopa as substrates for dopamine synthesis in the kidney.
The second study was composed of two parts. The effect of the periph¬
eral dopa decarboxylase inhibitor, carbidopa, on the renal response to gludopa,
was assessed to characterise the enzyme requirement for its action. Indometh-
acin, a cyclooxygenase inhibitor was administered to investigate interactions of
dopamine, formed after infusion of gludopa, with the prostaglandin and kalli-
krein-kinin hormonal systems in the kidney.
Lithium is reabsorbed with sodium at the proximal tubule and its renal
clearance has been proposed as a quantitative marker for sodium reabsorption
at this segment of the nephron (Thomsen, 1984). The lithium clearance method
provides an attractive in vivo technique for the assessment of a direct proxim¬
al tubular effect of dopamine, after the infusion of gludopa. However, lithium
has itself been demonstrated to alter renal electrolyte handling (Singer, 1981)
and during preliminary studies it was suspected that lithium was interfering
with the natriuretic capacity of gludopa. The third study was undertaken to
further characterise any interaction between lithium and dopamine in the
kidney.
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1(a) A COMPARISON OF THE RENAL ACTIONS OF y-L-GLUTAMYL-L-DOPA
AND Y-L-GLUTAMYL-L-TYROSINE
Protocol
Six volunteers were each studied on two occasions. Each day consisted
of three 2 hour periods (-2-0, 0-2, 2-4). During the first (run-in) and third
(recovery) periods, 50 mis N saline was infused. During the second, either glu-
dopa (25 pg/kg/min) or glutyrosine (25 pg/kg/min) was administered in 50 mis N
saline in random order. Blood sampling was performed before subjects stood to
void, at hourly intervals, except for two 30 min samples after the onset of
dipeptide infusion. Pulse and blood pressure were measured, in duplicate, at
each sampling point. For analysis, the control results were those for the
second hour of the run-in period.
Results
No side-effects were reported during the infusion of either dipeptide.
There were no significant differences in control values between the two days
of study. During the infusion of gludopa, urine dopamine excretion increased
from a control value of 0.95 _+ 0.08 nmol/min to a maximum of 776.7 _+ 35.0
nmol/min in the second hour of infusion (Figure la-1). Conversion to dopamine
was still continuing at high levels at the end of the recovery period (2 hours
after the infusion of gludopa had finished). Over the 4 hour period following
the commencement of the infusion, conversion to urine dopamine was 18% of
the dipeptide given (on a molar basis). By contrast, there was no appreciable
conversion of glutyrosine to dopamine, and the levels of dopamine were not
significantly elevated above baseline (Figure la-1).
Sodium output almost doubled in the first hour of gludopa infusion, rising
from 0.14 +_ 0.03 to 0.26 +_ 0.04 mmol/min (p < 0.01, Figure la-2). Output
continued to rise and peaked in the hour after the gludopa infusion stopped.
The natriuresis was accompanied by a diuresis, urine flow rising from 4.6 +_ 1.1
to 7.6 +_ 0.8 mls/min (p < 0.05) in the first hour of infusion. Urine potassium
output also showed a small non-significant increase during the first hour
(Figure la-3). Glutyrosine did not produce any change in sodium, potassium or
volume output. Plasma renin activity fell from 1.61 +_ 0.22 ng angiotensin
I/ml/hr at control to 0.94 +_ 0.18 ng angiotensin I/ml/hr after 30 minutes of
infusion of gludopa (p < 0.01). PRA fell further after this point and remained
depressed throughout the study. With glutyrosine, there was a non-significant
rise in renin (1.04 +_ 0.2 to 1.32 +_ 0.50 ng angiotensin I/ml/hr at one hour
(Figure la-4). Gludopa caused a short-lived significant rise in urine kallikrein
at 30 minutes (0.50 +_ 0.06 to 0.81 _+ 0.17 Eu/hr, p < 0.05), but the levels had
returned to the baseline by one hour. With glutyrosine, there was a small
insignificant rise (Figure la-5).
There were no significant changes in blood pressure or pulse rate during
infusion of either dipeptide when compared to control values, though at 2






Mean arterial 81.7 80.8 76.7t 78.8 79.0
pressure (mm 1%) +_ 4.3 +_ 3.6 +_ 3.4 +_ 3.2 + 2.8
Mean pulse rate 64.0 62.0 62.0 61.0 64.0
(beats/min) + 4.0 + 4.0 + 4.0 + 4.0 + 5.0
Glutyrosine
Mean arterial 83.5 83.7 83.Of 80.5 81.0
pressure (mm 1%) +_ 1.4 +_ 3.0 +_ 2.9 +_ 3.6 + 2.8
Mean pulse rate 61.0 58.0 61.0 60.0 61.0
(beats/min) + 3.0 + 3.0 + 3.0 + 3.0 + 3.0
Table 1A-1 Mean blood pressures and pulse rates in six subjects in response
to gludopa (25 pg/kg/min) and glutyrosine (25 pg/kg/min) infused
during hours 1 and 2. Values are means +_ SEM, t p < 0.05 for
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Figure I a -1. Urine dopamine excretion in six subjects receiving either
gludopa (25/.tg/kg/min, □ ) or glutyrosine (25^tg/kg/min,□).
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Figure la-2. Urine sodium excretion in six subjects receiving either
gludopa (25^ig/kg/min) or glutyrosine (25/^g/kg/min).













































Figure la-3. Urine potassium excretion and flow in six subjects receiving either
gludopa (25/xg/kg/min) or glutyrosine (25yug/kg/min).














Time (hours) Time (hours)
Figure I a-4. Plasma renin activity in six subjects receiving either
gludopa (25/ig/kg/min) or glutyrosine (25/xg/kg/min).
Values are means ± SEM; ** p<0*0l for comparison
with control.
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Figure la-5. Urine kallikrein excretion in six subjects receiving either gludopa
(25 /xg/kg/min, o) or glutyrosine (25/xg/kg/min, •).
Values are means ± SEM; *p<0.05 for comparison with control
to
1(b) THE EFFECT OF CARBIDOPA AND INDOMETHACIN ON THE RENAL
RESPONSE TO Y~L-GLUTAMYL-L-DOPA
Protocol
Seven volunteers took part, five completing 3 days and two completing 2
days of study. Comparisons were thus made for the effect of placebo against
carbidopa, and placebo against indomethacin, on the responses to gludopa. Five
subjects also took part in study la and the results from the day of gludopa
infusion were used in the present study. As in la, gludopa (25 p/kg/min) was
infused in 50 mis N saline during the middle 2 hour period of a 6 hour study.
Placebo, indomethacin (100 mg) or carbidopa (100 mg) were given by mouth
after the first hour of the run-in period. Blood pressure and pulse were
measured and blood and urine samples collected in an identical manner to study
la. For analysis, the control results were those for the second hour of the run-
in period.
Results
No side-effects were reported during any part of the study.
Effect of carbidopa on responses to gludopa
There were no significant differences in the control results between the
two days. Table lb-1 shows the urine dopamine response to gludopa. Excretion
increased on average nearly 900-fold by the second hour of infusion with out¬
put continuing at high levels two hours after the end of the infusion. Over 4
hours mean total dopamine excretion was 18.7% of the gludopa administered on
a molar basis. However, in the presence of carbidopa, urine dopamine increased
only 24-fold on average, representing a reduction in the conversion of gludopa
9o
to dopamine by 97%. Over the four hour period, the percentage conversion to
dopamine was only 0.7% of the dipeptide infused. Sodium output (Figure lb-1)
increased from 0.12 +_ 0.02 to 0.34 +_ 0.04 mmol/min (p < 0.01) during the
second hour of gludopa infusion and excretion was still elevated above baseline
at the end of the study period. PRA fell sharply after the onset of gludopa
from 1.3 +_ 0.24 to 0.82 +_ 0.19 ng angiotensin I/ml/hr at 30 min (p < 0.01) and
levels remained suppressed after the infusion (Figure lb-2). Gludopa caused a
short-lived, though significant increase in urine kallikrein but levels had
returned to baseline by 1 hour (Figure lb-3). Table lb-3 shows that blood
pressure tended to fall insignificantly with gludopa, although at 2 hours the
mean value was significantly lower than that in the presence of carbidopa.
By contrast, in the presence of carbidopa, the effects of gludopa were
abolished. Sodium excretion and kallikrein output did not increase above base¬
line, and a small fall in PRA occured but was not significant. There were no
significant changes in pulse and mean blood pressure, compared to the control
period.
Effect of indomethacin on responses to gludopa
There were no significant differences in the control results between the
two days.
As in the first study, gludopa significantly increased sodium excretion
and lowered plasma renin activity (figures lb-4,5). Indomethacin did not alter
the conversion of gludopa to dopamine (Table lb-2) and the total output in the
4 hours after gludopa was similar to that following gludopa alone. The natriur-
esis was not significantly altered by prior administration of indomethacin and
the total sodium outputs were similar (61.2 +_ 13.0 vs 76.4 +_ 13.6 mmol, N.S.).
PRA sharply declined after indomethacin, a known effect, and levels continued
to fall during and after gludopa (Figure lb-5). In the presence of indomethacin,
urine kallikrein output did not change throughout the study (Figure lb-6). Mean
blood pressure tended to be higher one hour after indomethacin and remained
so throughout the study such that values were significantly elevated at two
hours compared to those with gludopa alone. In the presence of indomethacin,
the mean pulse rate tended to be lower during the control period and declined




























Table 1B-1 Urine dopamine output (nmol/min) in six subjects in response to
gludopa (25 pg/kg/min), infused during hours 1 and 2, with or




1.04 496.6 886.3 596.2 212.8
Gludopa +0.08 +42.7 +48.2 +43.0 +14.7
Gludopa and 1.31 507.4 984.1 593.6 194.4
Indomethacin + 0.13 + 28.5 + 69.7 + 47.7 + 11.2
Table 1B-2 Urine dopamine output (nmol/min) in six subjects in response to
gludopa (25 pg/kg/min) with or without pretreatment with





Mean arterial 86.8 85.2 81.Ot 83.2 83.4
pressure (mm Hg) +_ 4.8 +_ 3.8 +_ 3.5 +_ 4.1 4.8
Mean pulse rate 67.0 66.0 67.0 66.0 68.0
(beats/min) + 3.0 + 2.0 + 3.0 + 3.0 + 3.0
Gludopa and
Carbidopa
Mean arterial 88.8 91.3 91.0t 91.2 94.8
pressure (mm Hg) +_ 3.8 +_ 2.8 +_ 2.6 + 3.3 + 3.9
Mean pulse rate 64.0 65.0 62.0 62.0 68.0
(beats/min) + 2.0 + 2.0 + 2.0 + 2.0 + 2.0
Table 1B-3 Systemic responses to gludopa (25 pg/kg/min) infused during
hours 1 and 2 in six subjects, with or without pretreatment with
carbidopa (100 mg). Values are means +_ SEM, T p < 0.05 for
comparison between gludopa alone and gludopa with carbidopa.
Time (hours)
C 1 2 3 4
Gludopa
Mean arterial 84.8 83.5 80.Ot 81.5 81.6
pressure (mm Hg) + 3.4 + 2.8 + 2.8 + 2.8 + 3.4
Mean pulse rate 67.0 66.0 67.0 65.0 70.0
(beats/min) + 3.0 + 2.0 + 3.0 + 3.0 + 3.0
Gludopa and
Indomethacin
Mean arterial 90.5 90.5 89.0t 89.5 92.0
pressure (mm Hg) _+ 3.5 +_ 2.3 +_ 3.3 +_ 2.1 +_ 2.2
Mean pulse rate 62.0 58.0 59.0 61.0 62.0
(beats/min) + 4.0 + 2.0 + 3.0 + 3.0 + 3.0
Table 1B-4 Systemic responses to gludopa (25 pg/kg/min) infused during
hours 1 and 2, in six subjects, with or without pretreatment
with indomethacin (100 mg). Values are means +_ SEM, t p < 0.05
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Figure lb-1. Urine sodium excretion in six subjects receiving gludopa
(25/xg/kg/min) with (□) or without (□) pretreatment
with carbidopa (100 mg). Values are means ±SEM; **
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Response of plasma renin activity to gludopa
(25/ng/kg/min) in six subjects with ( • ) or without ( o )
pretreatment with carbidopa (lOOmg). Values are means






























Figure lb-3. Urine kallikrein excretion in six subjects receiving
gludopa (25jng/kg/min) with ( • ) or without ( o )
pretreatment with carbidopa (100 mg). Values are
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Figure Ib-4. Urine sodium excretion in six subjects receiving gludopa
(25jug/kg/min) with (□) or without (□) pretreatment with
indomethacin (I OOmg). Values are means ± SEM, ** p < 0-01, * p < 0-05
































Figure lb-5. Response of plasma renin activity to gludopa
(25/xg/kg/min) in six subjects with ( • ) or without ( o
pretreatment with indomethacin (lOOmg). Values ar
means ±SEM; *p<0.05,























Figure lb-6. Urine kallikrein excretion in six subjects receiving
gludopa (25/xg/kg/min) with ( • ) or without ( o )
pretreatment with indomethacin (100 mg). Values are
means ±SEM; * p<0*05 for comparison with control.
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1(c) THE EFFECT OF LITHIUM ON THE RENAL RESPONSE TO Y~L~
GLUTAMYL-L-DOPA
Protocol
Seven volunteers were each studied on two occasions. Each day consist¬
ed of three 90 minute periods. During the first (run-in) and third (recovery), 50
mis N saline were infused. Gludopa (25 pg/kg/min) was infused during the
second in 50 mis N saline. On one occasion, lithium carbonate (750 mg,
Camcolit) was taken at 2200 hours on the preceding evening so that subjects
were studied 11 hours after administration. Blood pressure and pulse measure¬
ment, and blood and urine samples were taken at 45 minute intervals. For
analysis, control results represent the calculated mean values for the two 45
minutes collections obtained during the run-in period.
Results
No subject complained of any side-effects after lithium administration or
during infusion of gludopa.
Gludopa alone increased sodium output from 0.18 _+ 0.03 mmol/min during
the control period to 0.44 +_ 0.08 mmol/min during the second 45 minutes of the
infusion (p < 0.01, Table lc-1). Excretion remained elevated above control at
the end of the study. PRA was acutely suppressed by gludopa from 1.40 +_ 0.37
to 0.85 +_ 0.18 ng angiotensin I/ml/hr (p <0.01) and levels remained suppressed
after the infusion (Figure lc-1).
Serum lithium concentration was 0.29 _+ 0.09 mmol/1 at the start of the
study falling to 0.24 +_ 0.09 mmol/1 at the end (Figure lc-2). As shown in
Figure lc-3, examination of sodium outputs during the control periods on the
two days demonstrates that lithium alone was natriuretic (0.27 +_ 0.04 vs 0.18 _+
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0.03 mmol/min, p < 0.01). In the presence of lithium, however, gludopa did not
produce a significant natriuresis (Table lc-1) and the marked attenuation of
response both during and after gludopa is shown in Figure lc-4. Cumulative
natriuresis above control values, during the three hours after the start of
infusion, was significantly reduced (41.8 _+ 9.5 to 14.5 _+ 8.0 mmol, p < 0.01,
Figure lc-5). Pretreatment with lithium resulted in an increase in PRA during
the control period (2.38 +_ 0.37 vs 1.40 +_ 0.37 ng angiotensin I/ml/hr, p < 0.05,
Figure lc-1). On infusion of gludopa however, there was a significant suppress¬
ion of PRA (p < 0.01) of similar magnitude to that for gludopa alone (around
40%) and the curves are almost parallel. Lithium did not affect urine flow
either in the control period or during infusion of gludopa (Table lc-1).
Gludopa produced an 800-fold increase in urine dopamine excretion. It is
evident from Table lc-1 that lithium did not influence dopamine output either
during the control period or after gludopa stimulation. Gludopa was both
phosphaturic and uricosuric (Table lc-1). The rise in urate excretion occured
during the infusion but levels thereafter returned to baseline. However, phos¬
phate excretion continued to increase both during and after the infusion and
levels were more than doubled at the end of the study. In the presence of
lithium, a significant increase in urate excretion was not seen, although a
small rise was apparent. The increase in phosphate excretion was similar in
magnitude with or without lithium and there were no significant differences
between the responses at any point. Blood pressure tended to fall during and
after the infusion of gludopa and the reduction was significant at 1 and 3
hours, compared to control. The presence of lithium did not influence blood
pressure and pulse rate (Table lc-2). Table lc-3 shows the results of the clear¬
ance estimations. There were no significant changes in creatinine clearance
on the two days, and although lithium clearance and fractional lithium clear-
lol
ance tended to increase, the change was small and not significant. The urinary
excretion of cAMP was not altered by pretreatment with lithium, and the
infusion of gludopa did not significantly alter output in comparison to the
control period (Figure lc-6). Plasma ANP was 43.4 +_ 6.2 pg/ml during the
control period and 44.4 +_ 5.4 pg/ml after gludopa. The respective figures after
lithium pretreatment were 37.0 +_ 4.1 and 34.8 _+ 6.2 pg/ml. None of the
changes reached significance.
Time (45 min period)
C 1 2 3 4
Without Lithium
Sodium excretion 0.18 0.31* 0.44** 0.38** 0.30*
(mmol/min) + 0.03 + 0.05 + 0.08 + 0.06 + 0.04
Urine flow 8.9 8.4 9.6 4.3 5.3
(mis/min) + 1.0 + 0.6 + 0.8 + 0.4 + 0.6
Dopamine excretion 1.12 407 854 512 285
(nmol/min) + 0.06 + 30 + 52 + 53 + 49
Urate excretion 3.46 3.61 4.16** 3.70 3.43
(pmol/min) + 0.44 + 0.31 + 0.32 + 0.24 + 0.26
Phosphate excretion 9.2 12.5 17.8** 19.0** 23.0**
(pmol/min) + 2.2 + 2.7 + 2.7 + 2.0 + 2.4
With Lithium
Sodium excretion 0.27 0.36 0.37 0.34 0.26
(mmol/min) + 0.04 + 0.07 + 0.05 + 0.05 + 0.04
Urine flow 10.0 9.2 8.8 4.5 6.0
(mls/mi n) + 0.6 + 1.3 + 0.6 + 0.6 + 0.7
Dopamine excretion 1.18 435 889 574 238
(nmol/min) + 0.11 + 36 + 68 + 37 + 21
Urate excretion 3.57 3.79 3.92 3.69 3.39
(pmol/min) + 0.40 + 0.41 + 0.27 + 0.35 + 0.32
Phosphate excretion 9.8 12.2 15.5** 17.0** 19.9**
(pmol/min) + 1.2 + 1.9 + 2.4 + 2.1 + 2.3
Table 1C-1 Responses to gludopa (25 pg/kg/min), infused during the 1st and 2nd
45 min collections, in seven subjects with or without lithium
carbonate (750 mg) pretreatment. Values are means + SEM; * p <
0.05, ** p < 0.01 compared to control.
Time (45 min period)
C 1 2 3 4
Without Lithium
Mean arterial 87.7 81.5* 84.5 81.7* 84.5
pressure (mm Hg) + 2.3 + 2.2 + 2.9 + 3.1 + 4.6
Mean pulse rate 65.0 62.0 68.0 64.0 67.0
(beats/min) + 2.0 + 2.0 + 2.0 + 2.0 + 2.0
With Lithium
Mean arterial 86.2 85.0 83.3 81.3 85.0
pressure (mm Hg) + 3.5 + 3.4 + 2.3 + 3.1 + 4.0
Mean pulse rate 67.0 66.0 66.0 67.0 69.0
(beats/min) + 4.0 + 3.0 + 2.0 + 3.0 + 3.0
Table 1C-2 Mean blood pressure and pulse rates in seven subjects in response to
gludopa (25 pg/kg/min) infused during the 1st and 2nd 45 min
collections, with or without lithium carbonate (750 mg) pretreatment.




Creatinine clearance (mls/min) 154.5 159.1 156.0
+ 7.4 + 8.8 + 8.1
With Lithium
Creatinine clearance (mls/min) 150.4 155.6 152.2
+ 9.0 + 9.4 + 12.4
Lithium clearance (mls/min) 28.4 30.7 32.7
+ 4.9 + 4.5 + 6.0
Fractional lithium clearance (%) 18.9 19.7 21.5
Table 1C-3 Effect of gludopa (25 jig/kg/min) on clearance values with or
without lithium carbonate (750 mg) pretreatment in seven
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Figure Ic-1. Response of plasma renin activity to gludopa
(25/xg/kg/min) in seven subjects with ( • ) or without ( o )
pretreatmentwith lithium carbonate (750mg). Values are
means ± SEM; ** p<0*0l, * p<0*05 for comparison with control.
(08
Figure lc-2. Decline of serum lithium concentration over time of
study. Values are means ± SEM; n=7.
Figure lc-3. Sodium excretion during control periods with or without
pretreatment with lithium carbonate (750mg). Individual





























Time (45 min periods)
Figure lc-4. Absolute increment of sodium excretion above control
at each period during and after infusion of gludopa
(25/ug/kg/min), with (□) or without (□) pretreatment
with lithium carbonate (750mg). Values are means ±SEM;




























Figure lc-5. Cumulative sodium excretion above control during and
after infusion of gludopa (25/xg/kg/min), with or without
pretreatment with lithium carbonate (750mg). Individual
values are plotted with means ±SEM; ** p<0-0l •
■gludopa
I 2 3
Time (45 min periods)
—i
4
Figure lc-6. Cyclic AMP response to gludopa (25/xg/kg/min) with ( • )
or without ( o ) pretreatment with lithium carbonate
(750mg) in seven subjects. Values are means ± SEM.
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DISCUSSION
Dopamine synthesis after gludopa
The studies in normal volunteers with infusion of gludopa at 25
gg/kg/min demonstrate it to be a potent renal dopamine prodrug. Urinary dopa¬
mine output increased up to 900-fold during infusion and continued appreciably
after the infusion. The results are comparable to those reported by Worth and
colleagues (1985a) who infused gludopa at 12.5 and 100 gg/kg/min and noted
increases in urine dopamine of 280- and 2500-fold respectively. By comparison,
infusion of dopamine within the 'renal range' at 3 gg/kg/min produced only a
60-fold increase in urine output (Levinson et al., 1985).
During the infusion of gludopa, and the recovery period (3-4 hours in
total depending on study), the excretion of dopamine accounted for around 20%
of the gludopa infused, on a molar basis. As described, the relative renal spec¬
ificity relies on the transformation of gludopa to dopamine under the sequent¬
ial actions of y-glutamyl transferase and dopa decarboxylase, both enzymes
concentrated at the proximal tubule (Albert et al., 1961; Goldstein et al.,
1972). Gludopa, with a molecular weight of 344 will be freely filtered and be
available for uptake and hydrolysis by y-glutamyl transferase at the brush
border (Abbs and Kenny, 1983). In addition, enzyme on the microvasculature, in
close association with the antiluminal surface of the proximal tubular cells will
be exposed to large amounts of circulating substrate, the degree depending on
the filtration fraction (Welbourne and Dass, 1982). The proximal tubule evid¬
ently has enormous capacity to decarboxylate L-dopa formed after degluta-
mation of gludopa, suggesting that dopa decarboxylase activity is not the rate
limiting step in dopamine synthesis under normal conditions.
The fate of the major part of the infused gludopa cannot be entirely
UV
answered from these studies. The fraction converted to dopamine is likely to
be underestimated. In the study reported by Worth et al. (1985a) urine collect¬
ions were extended and appreciable dopamine excretion was occurring at 12
hours after the infusion of gludopa. Dopamine formed in the kidney will be
metabolised along a number of pathways. Some may be taken up by sympathetic
nerves and form substrate for dopamine & hydroxylase, believed to be principal¬
ly an intraneuronal enzyme (Nagatsu et al., 1969). Levinson and colleagues
(1985) showed however, that the infusion of dopamine at 3 pg/kg/min resulted
in only a doubling of urinary noradrenaline excretion. Monoamine oxidase and
catechol-O-methyl transferase are abundant within the kidney (Nagatsu et al.,
1969), and the former at least is concentrated at the proximal tubule (Denney
et al., 1983). The metabolic products of these enzymes, 3-hydroxytyramine,
homovanillic acid and 3,4, dihydroxyphenylacetic acid (DOPAC) are likely to
form an unknown proportion of the total dopamine synthesised. Under normal
conditions, some 80% of urine dopamine is in the conjugated form principally
the 3-0-sulphate and glucuronide (Kuchel et al., 1979). After the infusion of
gludopa, work from this department (unpublished) has indicated a 20-fold
increase in conjugate excretion. The preponderance of dopamine conjugates in
the baseline state was reversed so that the free:conjugate dopamine ratio was
44:1. It is of note that the peak in conjugate excretion was later than that for
free dopamine and this in itself provides an argument against the hypothesis
that free dopamine in urine is derived from the deconjugation of circulating
conjugated dopamine (Unger et al., 1978).
It is possible that organs other than the kidney metabolised gludopa
appreciably. From the work of Wilk and colleagues, this seems unlikely. In the
rat, activity of y-glutamyl transferase in other tissues is minor compared to
the kidney (Orlowski and Szewczuk, 1961), and after the administration of
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gludopa, dopamine was not appreciably accummulated by other tissues (Wilk et
al., 1978). Plasma dopamine was not measured in these experiments, but the
infusion of gludopa at 12.5 and 100 pg/kg/min (Worth el al., 1985a) elevated
levels only 4- and 25-fold, such results also suggesting that dopamine synthesis
is not occurring to a high degree elsewhere in the body.
Previous studies have indicated that the peripheral cardiovascular
effects of L-dopa are attenuated in the presence of an inhibitor of dopa
decarboxylase (Watanabe et al., 1971) and this knowledge has been utilised in
the treatment of Parkinson's disease, where the concurrent administration of a
peripheral decarboxylase inhibitor prevents postural hypotension produced by
L-dopa (Pinder et al., 1976). The present work with carbidopa (MK-486,
a-methyl-L-dopa-hydrazine) demonstrates that gludopa is itself inactive and
requires decarboxylation to dopamine for renal effects to be exerted. Carbi¬
dopa reduced the dopamine response to gludopa by around 97% and rendered
gludopa inactive in terms of natriuresis and effect on plasma renin activity.
The decarboxylase enzyme is not specific for L-dopa and catalyses the
conversion of 5-hydroxytryptophan to serotonin (Hagage and Richet, 1985).
However, substrate specificity is many times greater for L-dopa than
5-hydroxytryptophan in various tissue models (Sourkes, 1966; Srinivasan and
Awapara, 1978). The enzyme is properly called aromatic L-amino acid
decarboxylase, though such terminology has been questioned as it has little
activity against other L-amino acids (Sourkes, 1966; Srinivasan and Awapara,
1978). Serotonin can, in various experimental models, be demonstrated to exert
diverse pharmacological effects in the cardiovascular system. However,
whether it has a physiological role in renal function is unknown. An effect on
the renal synthesis and excretion of noradrenaline and adrenaline by carbidopa
is disputed and has been referred to earlier. A significant reduction of these
catecholamines in the kidney would have produced opposing effects on sodium
excretion and plasma renin activity to those observed. These points cannot be
definitely answered, but it is clear that blockade of the renal effects of
gludopa occurred simultaneously with the inhibition of dopamine synthesis and
the evidence suggests that the two events are causally linked.
Peripheral nerves actively take up tyrosine, and the formation of
L-dopa, under the action of tyrosine hydroxylase, is the rate limiting step in
neuronal catecholamine synthesis (Nagatsu, 1973; Weiner, 1979). Nagatsu and
colleagues (1969) demonstrated in the denervated dog kidney that tyrosine
hydroxylase is an exclusively intraneuronal enzyme, whereas denervation did
not significantly alter the activity of dopa decarboxylase. The completeness of
renal denervation was confirmed by the disappearance of renal tissue noradren¬
aline. Baines and Chan (1980) have utilised a micropuncture technique in rats
to determine requirements for renal dopamine synthesis. Injection of L-dopa
into proximal tubules of denervated kidneys resulted in active dopamine form¬
ation: the similar injection of L-tyrosine did not produce a measureable
response. Again, in the isolated perfused rat kidney preparation, whereas the
infusion of L-dopa resulted in a large increase in dopamine output, L-tyrosine
was without effect (Adam and Adams, 1985). It is known that tyrosine is activ¬
ely and efficiently reabsorbed in the proximal tubule after filtration (Chan,
1976) so that in both studies, tyrosine would have been available in tubular
cells for onward synthesis of dopamine: the lack of conversion must reflect the
absence of tyrosine hydroxylase in proximal tubular cells, supporting the work
of Nagatsu's group. The present studies further confirm these reported find¬
ings. Glutyrosine, infused at pharmacological doses, would, in an analogous
manner to gludopa, have produced large amounts of free amino-acid at the
proximal tubule. However, urine dopamine excretion did not rise above baseline
values throughout the study, and the dipeptide did not exert effects on
measured indices of renal function. Under normal conditions, L-tyrosine levels
in plasma are at least 100 times those of L-dopa (Hilton, 1982; Shum et al.,
1982). Thus in spite of a ready supply in the physiological state and massive
input under the conditions of the present study, the kidney seems unable to
utilise L-tyrosine as a source for urine dopamine. The results support the evid¬
ence that circulating L-dopa is the main physiological source for the generat¬
ion of urine dopamine. The putative renal dopaminergic nerves, whilst not
materially contributing to urine dopamine, may, through local action, modulate
intrarenal blood flow and sodium excretion. The present study does not provide
direct evidence for or against this hypothesis. However, with the availability in
the kidney of large amounts of released tyrosine after infusion of glutyrosine,
active uptake and increased renal dopaminergic nerve activity might have been
expected. Renal blood flow was not measured, but the lack of change in
sodium excretion and renin activity militates against a significant role for the
dopaminergic nerves.
Dopamine, infused at doses between 1 and 4 pg/kg/min may, by producing
systemic and renal vasodilation, result in a small decrease in blood pressure
(Goldberg and Murphy, 1987), though such a finding is by no means universal
(McDonald et al., 1964; Connell et al., 1983; Levinson et al., 1985). In the
present work, there was a tendancy for blood pressure to decline during the
infusion of gludopa. It is not easy to explain such findings. Worth et al. (1985a)
demonstrated that gludopa, infused at 12.5 and 100 pg/kg/min elevated plasma
levels of dopamine by 4 and 25-fold respectively. The increase in plasma dopa¬
mine produced by the infusion of dopamine at between 1 and 4 pg/kg/min
varies from 300-1900 fold (Connell et al., 1983; Holland et al., 1983; Levinson
et al., 1985). To achieve levels comparable to those produced by gludopa,
requires the infusion of just 0.1 pg/kg/min of dopamine, a dose that is without
renal or systemic effects. Explanation of this seeming discrepancy requires
speculation on a number of possibilities. It may be that renal vasodilation per
se accounts for sufficient reduction in total systemic resistance to lower blood
pressure, as 20% of the cardiac output is normally to the kidneys. It is possible
that venous levels of dopamine do not reflect those achieved at the level of
resistance vessels due to metabolism. In this regard, there is no information as
to whether dopamine can be locally generated from gludopa at the level of the
vascular walls, given the ubiquitous distribution of y-glutamyl transferase and
dopa decarboxylase, albeit in small amounts. Finally, as will be discussed, renin
was acutely suppressed by gludopa: reduction of circulating angiotensin II could
therefore have accounted for the reduction in blood pressure through systemic
vasodilation. In the present work, a placebo control day was not included, and
it is conceivable that blood pressure and pulse changes represented a response
to prolonged rest or diurnal rhythm. However, readings were compared to
baseline values after subjects had already been supine for li to 2 hours, and
the steadiness of systemic parameters during infusion of glutyrosine, which
appears inactive, and on into the recovery period, argues against those factors
accounting for the effects seen.
Similar arguments apply to the use of L-dopa, hypotension being a
common adverse effect in patients treated for Parkinson's Disease (Pinder et
al., 1976). Goldberg and Murphy (1987) have stated that L-dopa, after oral
administration of 1-1.5 grams, produces positive inotropic effects and
increments in renal blood flow equivalent to the infusion of dopamine at 2 - 4
pg/kg/min. Rajfer et al. (1984) gave L-dopa (1.5 - 2.0 g) to heart failure
patients and reported an increase in cardiac output and decline in systemic
vascular resistance. However, plasma dopamine levels increased only 17-fold.
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L-dopa freely crosses the blood brain barrier and central mechanisms have
been postulated for its cardiovascular effects. This is unlikely to apply in the
present studies as systemic dopamine does not readily enter the brain and the
studies of Wilk and colleagues (1978) suggest that accumulation in the brain
after gludopa is minimal.
The effects of gludopa on blood pressure and pulse are important to
define. If a pro-drug such as gludopa is to attain a therapeutic role, an optim¬
al dose must balance effective natriuresis and renin suppression against a tend-
ancy to induce systemic effects. The present dose of gludopa, 25 pg/kg/min,
may be reaching the upper limit of the renally-selective range.
Natriuresis and proximal tubular function
The possible mechanisms by which dopamine enhances sodium excretion
have been referred to, including the limitations of knowledge at the present
time.
Gludopa, infused at 25 gg/kg/min, was actively natriuretic in the present
studies, with sodium output increasing between 200 and 300% above control
levels. The increase in excretion paralleled that of dopamine output in the
urine, both persisting beyond the termination of the infusion.
Renal haemodynamics were not measured, but recent work in this depart¬
ment has indicated that gludopa, infused at the same dose, results in signific¬
ant increases in renal blood flow, with lesser increases in glomerular filtration
rate and a reduction in filtration fraction (MacDonald et al., 1987). Such
changes alone would be expected to reduce proximal tubular sodium reabsorpt-
ion by effect on peritubular physical forces. The rise in circulating dopamine
after gludopa is too small to account for the effect on the renal vasculature,
and a local effect must be postulated. Dopamine can be reabsorbed from the
distal tubule (Baines et al., 1979) and it is conceivable, though speculative,
that dopamine, produced in the proximal tubule and released into the lumen,
gains access to afferent and efferent arterioles after uptake in the region of
the macula densa. Another contributing factor may be the inhibition of resting
tone, particularly at the efferent arteriole, consequent to inhibition of renin
release and suppression of angiotensin II (vide infra).
A possible direct proximal tubular effect of dopamine has been investig¬
ated by a number of workers and the evidence reviewed. In the present
studies, further evidence was sought by analysing the renal excretion of phos¬
phate and urate in response to gludopa. Phosphate is actively reabsorbed at
the proximal tubule and Puschett et al. (1972) have shown that reabsorption is
linked to that of sodium under various experimental conditions including iso¬
tonic saline diuresis and aortic constriction. Urate is freely filtered and bi¬
directional transport occurs in the proximal tubule, though overall over 90% is
reabsorbed at this site. In both human and rat, volume expansion enhances the
fractional excretion of urate (Diamond and Meisel, 1975). The observation that
gludopa increased the urinary excretion of both anions, provides suggestive
evidence for a proximal tubular site of action for dopamine. The results for
phosphate excretion confirm those reported by Cuche et al. (1976), who differ¬
entiated the natriuretic and phosphaturic effects of dopamine and L-dopa,
infused into the canine renal artery. In these studies, phosphate excretion was
still increasing at the end of the recovery period, at a time when the natriur¬
etic response was declining. The explanation is unknown but may reflect separ¬
ate transport mechanisms at the proximal tubule.
Studies involving the infusion of dopamine into man and animals are in
general agreement that the natriuresis and renal vasodilation are mediated
through stimulation of DA^ receptors. Such receptors have been defined both
on the renal vasculature and on proximal tubular cells. Thus in dogs, the highly
specific DA^ antagonist, SCH 23390, blocked the renal effects of dopamine
(Frederickson et al., 1985). Confirmatory evidence is also available after the
infusion of gludopa in man. In this department, MacDonald et al. (1987) have
shown that the natriuretic and renal vasodilator actions of gludopa are mark¬
edly attenuated by (+)-sulpiride, the most specific DA.^ antagonist available for
use in man. However, similar actions of gludopa were unaltered by the periph¬
eral DA2 antagonist, domperidone (Worth et al., 1986).
Vlachoyannis et al. (1976) demonstrated an increase in urinary cAMP
excretion after the infusion of dopamine into man. In the present studies, an
increase in cAMP in response to gludopa was not demonstrated. The interpret¬
ation of measured cAMP levels in urine is complicated. About 60% of the urine
output represents that filtered from circulating plasma (Sutherland, 1970). Of
the nephrogenous component, parathyroid hormone is believed to be the
principle determinant of normal levels (Broadus, 1981). Thus, that proportion of
the total under the influence of dopamine may be small, and changes induced
by dopamine may be masked by background levels. In addition, it is not clear
to what extent levels in the urine represent local cellular events. cAMP may
leave the cell preferentially across the basolateral membrane rather than into
tubular lumen, and the degree of phosphodiesterase activity cannot be determ¬
ined in whole animal clearance studies. Thus, although it is generally accepted
that the actions of vasopressin on the distal tubule are mediated through
cAMP, infusion of vasopressin does not result in an increase in the urinary
excretion of the nucleotide (Sutherland, 1970). Also in a recent study, infusion
of L-dopa into rats did not elevate urine cAMP excretion, but renal tissue
cAMP content showed a 300% increase (Sato et al., 1987).
The renal responses to gludopa in the presence of carbidopa are of
particular interest. Carbidopa reduced the dopamine response by 97% and
abolished the natriuresis. However, this still represented, on average, a 24-fold
increase in urine dopamine output. It is difficult to explain why such a rise
was not associated with a natriuresis. A reduction in proximal reabsorption of
sodium would have been expected by direct tubular effect. However, the distal
tubule has a large capacity to maintain glomerulotubular balance and will tend
to minimise the effect of increases in sodium delivery from the proximal
tubule. It may be that after gludopa alone, the delivery is of such a degree as
to overcome distal compensation. In an early micropuncture study, Davis et al.
(1968) postulated a distal tubular action for dopamine. A possible mechanism is
a redistribution of renal blood flow to the inner cortex as described by
Hardaker and Wechsler (1973). By increasing flow to inner portions of the
kidney, dilution of the interstitium, by a "wash-out" phenomenon, would reduce
passive sodium reabsorption in the ascending limb of the loop of Henle, and
disrupt distal compensatory reabsorption. It may be that the moderate increase
in dopamine levels produced in the presence of carbidopa was too small to
influence renal blood flow thus allowing effective distal compensation to
occur.
There was an early rise in potassium excretion after gludopa, with levels
thereafter returning towards control. Some studies involving the infusion of
dopamine have demonstrated a kaliuresis (Vlachoyannis et al., 1976), but this is
by no means a universal finding (McDonald et al., 1964; Levinson et al., 1985),
and few workers have specifically addressed the issue. Proximally acting
agents such as osmotic diuretics, produce increased potassium excretion both
by reducing proximal reabsorption with sodium, and by increasing secretion in
exchange for sodium at the distal tubule (Koushanpour and Kriz, 1986). A
similar sequence would be expected with dopamine. In the present studies with
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gludopa, inhibition of the renin-angiotensin system and hence removal of the
principle stimulus to aldosterone, would tend to promote potassium retention,
and offset an early direct kaliuretic response of dopamine. An analagous
situation has been postulated for atrial natriuretic peptide, the infusion of
which does not consistently increase potassium excretion (Needleman and
Greenwald, 1986).
Under conditions of experimentally produced maximal water diuresis,
urine flow is directly proportional to the proximal tubular natriuretic response
induced by an agent. In the present studies, water was given to maintain
reasonable flow rates with the principle aim of ensuring complete voiding at
collection points, but no attempt was made to fully suppress vasopressin
activity. Gludopa produced an early significant rise in urine flow in the first
study but the rise was not sustained and did not parallel natriuresis. Evidence
that dopamine may interact with vasopressin at the collecting ducts further
complicates the picture and further studies will be required with protocols
specifically designed to address this problem.
Renin release
The controversy as to the effect of dopamine on renin release has
already been referred to. What is clear from the present studies is that PRA is
consistently inhibited by gludopa at an infusion rate of 25 pg/kg/min. The
results are also notable for the demonstration that inhibition occurs early,
within 30 minutes of the start of infusion and levels continue to be suppressed
beyond the infusion in spite of appreciable cumulative net sodium deficit. The
results are in agreement with the work of Worth et al. (1985a, 1986) who
demonstrated a fall in plasma renin activity with gludopa infused at 12.5 and
100 pg/kg/min.
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What is unclear, is the mechanism of inhibition of renin release, given
the multiple potential inputs to the juxtaglomerular cells. Renal vasodilation at
relatively constant perfusion pressure would be expected to inhibit renin
release, through the renal baroreceptor, as would the natriuresis per se, acting
through the macula densa mechanism. However, these stimuli are unlikely to be
of over-riding importance. For instance, dopamine infusion produces a marked
natriuretic response and renal vasodilation, but most studies have pointed to
either no effect, or stimulation of renin release (Otsuka et al., 1970; Levinson
et al., 1985). In addition, in man, in the presence of domperidone, gludopa fail¬
ed to influence renin in spite of renal vasodilation and natriuresis (Worth et
al., 1986, vide infra).
In vitro and in vivo studies in animals (Imbs et al., 1975; Dzau et al.,
1978; Williams et al., 1986) have provided evidence for direct dopaminergic
input to the juxtaglomerular cells. Being modified myoepithelial cells of the
afferent arteriole it seems likely that the juxtaglomerular cells will possess
DA^ receptors, the subtype known to be characteristic of the renal vasculat¬
ure. The effects of stimulation of DAj receptors are believed to be mediated
via adenylase cyclase and the formation of cAMP as second messenger. In a
study in dogs, dibutyryl cyclic AMP was a potent stimulus to renin release
(Vikse et al., 1985). Further evidence for a stimulatory affect of DA.^ receptor
activation on renin release comes from work with the selective DA.^ agonist,
fenoldopam. Administration in man is associated with an early and marked rise
in plasma renin activity (Harvey et al., 1986). It has been suggested that the
rise is a secondary response to reflex sympathetic drive, consequent upon a
reduction in blood pressure (Brennan et al., 1983). However, Montier and
colleagues (1987) have demonstrated in the dog that the renin response to
fenoldopam was unchanged by propranolol but completely blocked by the
US
specific DAj^ antagonist SCH 23390.
Most studies indicate that administration of L-dopa results in suppression
of renin (reviewed by Sowers, 1984). L-dopa is able to cross the blood-brain
barrier, and Blair et al. (1977) have postulated a central role for dopamine in
inhibition of renin, through reduction in sympathetic outflow. They administ¬
ered L-dopa to anaesthetised dogs and produced an increase in renin activity.
This was reversed by addition of a peripheral decarboxylase inhibitor, in the
presence of which L-dopa suppressed renin, and the response was abolished by
renal denervation. However, not all evidence is in agreement with this, and in
rats, L-dopa increases renal noradrenaline content (Sato et al, 1987). Gludopa
penetrates the brain poorly and in the present studies, the effect of carbidopa,
a peripheral dopa decarboxylase inhibitor, points to inhibition of renin being a
peripheral, renal event. This is supported by the study of Worth et al. (1986)
who demonstrated in man that the peripheral DA2 receptor antagonist,
domperidone, blocked the renin inhibition produced by gludopa. That the DA2
receptor mediates the inhibition of renin is supported by the study of Cavero
et al. (1987), in which the DA2 agonist quinpirole reduced PRA after infusion
into intact rats.
In discussing the effect of gludopa and L-dopa on renin release, it is
relevant to consider the physiological manner by which dopamine is presented
to the juxtaglomerular cells. Infusion of dopamine and administration of a drug
such as fenoldopam will result in very large concentrations of agonist directly
to the juxtaglomerular cells. Ball et al. (1981) investigated renin release in the
conscious beagle dog. Infusion of dopamine at 1.6 nmol/kg/min more than
doubled plasma dopamine but produced no change in plasma renin activity. A
ten-fold increase produced only a small increase in renin, and an infusion rate
of 160 nmol/kg/min was required to double plasma renin levels. It is therefore
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evident that circulating levels of dopamine within the physiological range, are
unlikely to modulate renin release under normal conditions. Gludopa infusion
results in large increases in urinary dopamine, with modest amounts entering
the circulation and mimics the physiological mode of synthesis. Thus endogen¬
ous dopamine, produced in the proximal tubular cells and released into the
tubular lumen, gains access to the juxtaglomerular cells by an unknown mechan¬
ism which may involve uptake by the macula densa into the microenvironment
around the juxtaglomerular cells. The DA2 receptors on presynaptic neurones
are perhaps 1000 times more sensitive to dopamine than are DA^ receptors
(Kebabian and Calne, 1979). It may be therefore that relatively small amounts
of dopamine, gaining access to juxtaglomerular cells after gludopa infusion,
preferentially stimulate DA2 receptors on the noradrenergic nerve endings in
contact with the renin-producing cells. The result will be to inhibit noradrenal¬
ine release and hence remove a tonic stimulus to renin synthesis. The renin
response following gludopa is therefore a balance between the stimulatory
effect of DA^ receptors and inhibitory effect of presynaptic DA2 receptors. It
seems clear that at doses between 12.5 and 100 pg/kg/min, inhibitory
influences predominate.
One can speculate upon the dopamine-lithium interaction in the kidney
with regard to renin-release. Lithium abolished the natriuresis produced by
gludopa, without affecting glomerular filtration rate, a response possibly
attributable to DA.^ receptor blockade at the proximal tubule. However, the
reduction in plasma renin activity following gludopa was comparable in the
presence or absence of lithium, suggesting that lithium is not active upon pre¬
synaptic DA2 receptors.
The capacity of a renal dopamine prodrug to suppress renin confers
great therapeutic potential. Most natriuretic and vasodilator substances, have
127
the tendancy to increase renin by a reflex sympathetic mechanism, the effect
of which is to offset drug action. An agent that is able to inhibit renin, or at
least prevent reflex increases, may have a prolonged natriuretic and vasodilat-
ory action and avoid the propensity for tachyphylaxis (false tolerance).
Interactions with other hormones
Dopamine and vasodilatory prostaglandins exert similar vasodepressor
effects in the circulation, and more particularly produce renal vasodilation and
natriuresis after pharmacological administration. The prostaglandins, PGE2 and
PGI2 may mediate, at least in part, the renal action of kinins, and many
influences in the kidney are known to modulate prostaglandin synthesis and
release. It has therefore been questioned whether dopamine stimulates the
local formation of various prostanoids in the kidney, and through this mechan¬
ism, exerts its known effects on renal function.
Previous work is scanty on the question as to whether prostaglandins are
stimulated by dopamine. A recent study in man (Nadler et al., 1986) reported
increased urinary prostaglandin release in response to dopamine infusion (1
pg/kg/min) but in the anaesthetised dog, intrarenal arterial dopamine did not
influence PGE2 excretion (Vikse et al., 1985). Giillner and colleagues (1982)
have conversely studied the effect of alterations in prostaglandin synthesis on
dopamine excretion. Chronic inhibition of prostaglandin synthesis with indo-
methacin (2 mg/kg/day) for seven days, did not alter urine dopamine excretion
in healthy women, and dopamine output was normal in a group of patients with
Bartters syndrome in which overproduction of the prostaglandins, PGE2 and
PGI2 is a characteristic feature (Gullner, 1982).
Yehati et al. (1986) have reported that infusion of indomethacin (2
mg/kg) attenuated the renal effects produced by dopamine infused at 6
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pg/kg/min into five subjects. In a study in rats, Chevillard et al. (1978) provid¬
ed evidence for a contribution of prostaglandins to the vasopressor effects of
dopamine, though renal function was not assessed. Three other studies suggest
that the prostaglandins and dopamine do not importantly interact within the
kidney. Dressier et al. (1975) infused low dose dopamine into the renal artery
of anaesthetised dogs and showed that whereas indomethacin increased the
renal vasoconstrictor response to angiotensin II, it did not affect the vasodilat-
ory response to dopamine. Similarly, Robertson et al. (1980) studied the Wistar
albino rat pretreated with phenoxybenzamine and propranolol. Neither the
reduction in mean arterial blood pressure nor renal vascular resistance
produced by dopamine was influenced by indomethacin. Pendleton and
Woodward (1976) had earlier shown in the anaesthetised dog that renal vasodil¬
ation produced by dopamine (3 pg/kg/min) was selectively inhibited by the
dopamine antagonist, bulbocapnine, and that produced by PGAp by indometh¬
acin, but there were no crossover effects between the two antagonists.
The present studies provide no evidence for hormonal interactions in the
kidney after pharmacological stimulation with gludopa. The dose of indometh¬
acin chosen has previously been shown to inhibit prostaglandin excretion by at
least 80% (Mackay et al., 1984) and the expected decline in plasma renin act¬
ivity pointed to effective prostaglandin suppression during the course of the
study. The peak responses in sodium excretion were comparable after gludopa
in the presence or absence of indomethacin, and total sodium outputs over the
study period were not significantly different. As discussed, prostaglandins in
pharmacological doses, produce renal vasodilation and may inhibit tubular
reabsorption of sodium at the distal tubule, and the system assumes greater
importance during conditions of sodium depletion or reduced renal perfusion
pressure. It is conceivable that under certain experimental or clinical condit-
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ions, indomethacin might modify the renal effects of dopamine, by inhibiting
distinct, though synergistic effects evoked by the prostaglandins at separate
sites in the nephron. The study of Yehati et al. (1986) referred to, was notable
for the age range of the subjects, quoted between 40 and 60 years. Renal
function declines steadily after the age of 40, and such a process may be
associated with greater prostaglandin-dependance of renal blood flow and
glomerular filtration rate in older age groups.
Urinary prostaglandins were not measured in the present studies. Seminal
vesicular fluid contains large amounts of prostaglandins and contamination of
urine samples in males renders interpretation of urinary prostaglandin levels
hazardous. Even after abstention from sexual intercourse for three days,
enormous variations in baseline values can be recorded (McAuslane, personal
communication). It is unknown at present, whether dopamine synthesis block¬
ade, with carbidopa for instance, affects endogenous prostaglandin excretion
which might provide evidence for an interaction under physiological conditions.
From the present work and most reported studies, it is most likely that
dopamine exerts effects on renal function by an action on specific receptors,
and that the prostaglandin system is not required as a mandatory intermediary.
Rather they form separate, parallel systems each of which, under certain
conditions, may influence or modify the respective action of the other.
The effects of gludopa on urine kallikrein excretion were inconsistent. A
small increase was apparent within 30 minutes of infusion, but levels quickly
returned to baseline at a time when sodium excretion was approaching maximal
values. A number of stimuli that produce diuresis are associated with increased
kallikrein excretion, and in the present studies, the kallikrein response may
represent a "washout" phenomenon. Mills and colleagues (1978) studied the
kallikrein response to a number of vasoactive agents and postulated a natciur-
etic hormonal cascade in the kidney in which dopamine leads kallikrein
production. From the present results, the kinin-kallikrein system did not partic¬
ipate in the natriuretic actions of gludopa, and any relationship between the
two systems does not appear to be important.
With the developing interest in ANP, various groups have suggested that
the renal effects of the peptide are mediated through dopamine receptors. This
will be described in some detail in a further section. Gludopa did not signific¬
antly affect plasma ANP levels measured after 90 minutes of infusion. This
agrees with the study reported by Shenker et al. (1987), during dopamine
induced natriuresis in man. The physiological stimulus to ANP release is
believed to be the degree of atrial stretch, itself dependant on central venous
pressure. The constancy of plasma ANP during the infusion of gludopa
therefore probably reflects the stability of the systemic parameters, blood
pressure and pulse, and presumably central venous pressure.
Lithium
A simple method for the determination of segmental tubular sodium and
water handling in the nephron, under in vivo conditions, has been widely
sought. Maximal free water clearance, enhanced fractional urine excretion
under maximal diuresis, and endogenous markers have been utilised, but the
validity of results has been questioned (reviewed by Schuster and Seldin, 1985).
Studies in water-loaded humans have shown a high degree of correlation
between urine flow during water diuresis, and the clearance of lithium
(Thomsen and Olesen, 1984). A comparable situation exists in ADH-deficient
Brattleboro rats (Thomsen, 1977). In rats, micropuncture has confirmed that
lithium is reabsorbed in the proximal tubule to the same extent as water and
sodium, but neither reabsorbed nor secreted in the distal tubule except under
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conditions of salt depletion. Thus analysis of lithium clearance in urine after
single dose administration provides an estimate of fluid delivery from the
proximal tubule, and comparison of the fractional clearances of lithium and
sodium allows analysis of proximal and distal tubular handling of sodium
(reviewed by Thomsen, 1984). The method has been used to assess the site of
action in the nephron of various natriuretic agents including calcium antagon¬
ists (Krusell et al., 1986), ANP (Brown, 1986) and diuretics (Thomsen and
Leyssac, 1986). However, many studies have demonstrated that lithium itself
alters renal electrolyte handling. Effects produced by the administration of
lithium have been variable and confusing, both sodium depletion and retention
having been described. These variable findings may relate to prevailing salt
status, the animal model, acute versus chronic lithium administration, and
whether toxicity was induced (Myers et al., 1980; Singer, 1981).
Under the conditions of this study, lithium was natriuretic at around 12
hours after ingestion. Previous studies in humans (Murphy et al., 1969; Baer et
al., 1971) have also demonstrated acute natriuresis during the first 24 hours of
lithium administration followed by sodium retention over the succeeding days.
Martinez-Maldonado et al. (1975) demonstrated in rats that lithium increased
the renal excretion of urate and phosphate, both principally reabsorbed in the
proximal tubule, and micropuncture suggests that inhibition of sodium
reabsorption affects all segments of the nephron (Hecht et al., 1978). The
mechanism of the effect is unknown. Thompson et al. (1984) infused lithium
into rats and ascribed part of the natriuresis to expansion of the extracellular
fluid volume. This cannot be a factor in the present study as the total dose
administered was only 20 mmol. Lithium can partially substitute for sodium and
potassium in the intracellular space and may affect transport mechanisms. For
instance, in the brain, lithium has been demonstrated to inhibit Na+/K+-ATPase
(Guerri et al., 1981) and the Na+/Li+ countertransport mechanism is inhibited
by lithium in red blood cells (Ehrlich et al., 1983). In addition, there is evid¬
ence that lithium can induce a relative resistance to the action of aldosterone
on the distal nephron (Singer, 1981). In a recent report, an increased require¬
ment for mineralocorticoid replacement was demonstrated in a patient with
Addison's disease requiring concurrent lithium therapy (Stewart et al., 1987).
The increased plasma renin activity produced by lithium has been report¬
ed previously in animals (Nally et al., 1980) and man (Shopsin et al., 1973). The
blood pressure was unchanged by the administration of lithium arguing against
an appreciable stimulus to the renal baroreceptor or change in sympathetic
tone. In the study reported by Murphy et al. (1969), the salt deficit over the
first 24 hours of lithium averaged 32 mmols, an amount unlikely to be import¬
ant in the present salt replete subjects. In addition, the increased sodium load
at the macula densa would be expected, if anything, to inhibit renin release. In
fact, Nally et al. (1980) have argued that the acute increase in plasma renin
activity produced by lithium in dogs represents a direct effect at the juxta¬
glomerular cells.
Paradoxically, after producing an increase in control sodium output,
lithium, at low serum concentration, markedly attenuated the natriuresis
produced by gludopa, and in fact sodium excretion did not significantly
increase. A number of possibilities exist for this effect. It seems unlikely, as
discussed above, that the small sodium deficit produced by lithium would alter
the renal responsiveness to gludopa. However, the elevated PRA levels before
and during the infusion were likely to have been accompanied by raised angio¬
tensin II levels. Angiotensin II is antinatriuretic and has a direct action at the
proximal tubule (Schuster et al., 1984a). Interactions between angiotensin II
and dopamine have not so far been reported and further studies will be
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required on this possibility, perhaps using angiotensin converting enzyme
inhibitors. The effect of lithium on the phosphaturic and uricosuric actions of
gludopa are of interest. The increase in urate excretion was blocked by lithium
in a manner analogous to that of sodium. Lithium did not significantly affect
the marked phosphaturic response, further evidence that the renal handling of
phosphate, and modulation by dopamine, is not directly linked to that of the
sodium ion.
Lithium is known to have marked effects on adenyl cyclase activity. The
cAMP responses to vasopressin, glucagon and parathyroid hormone are blocked
by lithium (Waller et al., 1983 and 1984) and it has also been demonstrated to
block dopamine induced cAMP release in the brain (Geisler and Klysner, 1985).
Lithium did not alter GFR, and it seems reasonable to postulate that lithium
attenuates the natriuretic capacity of gludopa by interfering with cAMP
release at the proximal tubule. The results presented for urine cAMP release
do not provide direct evidence for this, and the difficulties in assessing urinary
cAMP values has been discussed. It is of relevance that lithium has also been
demonstrated to interfere with the action of preformed cAMP on the renal
tubule (Forrest et al., 1974). Further studies are required on the effect of
lithium on dopamine induced cAMP release in the kidney, ideally using isolated
tubule preparations.
Much interest is being generated in the role of the phosphoinositide
system as an intracellular second messenger. The recent demonstration that
both dopamine and lithium have actions upon different parts of this system,
dopamine stimulating phospholipase C (Felder et al., 1987) and lithium inhibit¬
ing inositol di- and mono-phosphatase (Drummond, 1987), opens up a new area
of potential interaction that awaits clarification.
Gludopa did not significantly increase lithium clearance although there
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was a tendancy towards a rise. Two points however deserve mention. Firstly,
the natriuresis was small and insignificant in the presence of lithium so that
the increase in lithium clearance was within the background error of the
observations. Secondly, to use lithium as a marker presumes it to be pharmaco¬
logically inert which was patently not the case. The clearance results may
therefore be uninterpretable and the lithium clearance method not suitable for
the investigation of dopaminergic mechanisms in the kidney. It will also be of
great interest to attempt to establish whether the acute effects of lithium
seen in this study can also be observed in patients on long term lithium
therapy or whether some form of adaptation takes place.
CHAPTER FOUR
STUDIES ON THE URINE DOPAMINE RESPONSE
TO FRUSEMIDE IN NORMAL MAN
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INTRODUCTION
The loop diuretic frusemide is a powerful natriuretic agent with its prin¬
ciple action at the ascending limb of the loop of Henle. An increase in renal
blood flow and plasma renin activity are intimately associated with its action.
Kuchel et al. (1979) reported that intravenous frusemide acutely stimulated
urine dopamine excretion in man, although the mechanism was not investigated,
nor, in detail, the time course of the response. The group also demonstrated
that the dopamine and natriuretic response to frusemide was reduced in
essential hypertension. This is a finding of some interest. As discussed, a
relative dopamine deficiency in response to salt loading may identify those
with a predisposition to "salt-sensitive" hypertension: the response to frusemide
may provide a simple method to discriminate between those with impaired
dopamine regulation compared to normal subjects. However in this department,
a short preliminary study (Rutter, unpublished) suggested, in normal subjects,
that dopamine excretion actually declined after the oral administration of
frusemide.
The first aim of the present group of studies was to further characterise
the dopamine response to oral frusemide, in relation to the time course of
sodium output and urine flow. Thereafter, the response was compared in the
same subjects given the same dose of frusemide intravenously.
The dose of frusemide chosen has been demonstrated to stimulate prosta¬
glandin release from the kidney, and a number of the effects of frusemide are
believed to be mediated through the prostaglandins, although there remains
some controversy (Carmichael and Shankel, 1985). The cyclooxygenase inhibit¬
or, indomethacin, was administered in the second part to assess whether the
dopamine response to frusemide is similarly related to, and dependant on,
m
prostaglandin release.
Dopamine, in terms of its ability to produce renal vasodilation and
natriuresis, mimics certain of the effects of frusemide. In the final part, the
renal responses to frusemide were compared in the presence or absence of the
dopa decarboxylase inhibitor, carbidopa, to determine whether dopamine plays
any part in its natriuretic and hormonal effects.
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2(a) THE EFFECT OF ORAL FRUSEMIDE ON URINE DOPAMINE EXCRETION
Protocol
Nine subjects were studied on a single occasion. Frusernide (30 mg) was
given by mouth after a 2 hour run-in period. The study continued for a further
5 hours. Urine and blood samples, and blood pressure and pulse measurements
were taken at 30 minute intervals except for two 15 minute intervals in the
first 30 minutes after frusemide was given. Two subjects were unable to
consistently pass urine at required times and their results are not included.
Control results were those for the final 30 minutes of the run-in period.
Results
Figure 2a-l shows the natriuretic and urine flow response to frusemide
in seven subjects. An increase in both parameters was evident at the first
collection point at 15 minutes, though maximal responses were not, on average,
attained until 1-li hours after administration. There was however marked
variation between individuals in terms of the magnitude of, and time to, peak
responses, which is evident from the size of the error bars. Diuresis closely
paralleled the natriuresis, and in all subjects the responses were completed
within 5 hours of administration of frusemide. Plasma renin activity increased
gradually during the course of the study, and levels were significantly elevated
above control from 3i hours (Figure 2a-2). Haematocrit values however showed
a steep and early rise, reaching a maximum at 2 hours, and thereafter tending
to decline. Mean blood pressure and pulse rates were not significantly altered
from control throughout the study (Table 2a-l). Urine dopamine excretion
increased transiently though significantly at 15 minutes, the rise being of the
order of 40% and occuring in all subjects. However, levels had returned to
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baseline by 30 minutes, a point at which urine flow and sodium output were
still increasing. Dopamine excretion tended to fall thereafter and at 3i hours,
was significantly below control (Figure 2a-3).
Time (hours)
Mean arterial 81.7 82.1 83.6 86.0 85.4 85.9 82.7 81.1
pressure (mm Hg) +_ 2.3 _+ 1.5 _+ 1.9 +_ 2.1 + 3.0 _+ 1.8 +6.2 _+ 1.9
Mean pulse rate 58 57 59 59 59 59 60 60
(beats/min) +2 +2 +3 +3 +3 +1 +3 +2
Haematocrit 42.4 42.4 43.3 44.3* 44.6** 44.4** 43.9 44.5**
(96) +1.1 +1.1 +0.9 +1.0 +1.0 +0.9 +1.1 +0.8
Table 2A-1 Mean blood pressure, pulse and haematocrit values in response to
frusemide (30 mg) by mouth in seven subjects. Values are means _+
SEM; * p < 0.05, ** p < 0.01 in comparison with control.
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Figure 2a-2. Plasma renin activity in response to oral frusemide
(30mg) in seven subjects. Values are means ± SEM,
* p < 0*05 in comparison with control.
Figure 2a-3. Urine dopamine output in response to oral frusemide
(30mg) in seven subjects. Values are means ± SEM,
**
p < 0*01 * p < 0*05 in comparison with control.
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2(b) THE EFFECT OF INDOMETHACIN ON THE URINE DOPAMINE RESPONSE
TO INTRAVENOUS FRUSEMIDE
Protocol
Seven volunteers were each studied on two occasion. A 2 hour run-in
period (-2 to 0 hr) was followed by an intravenous bolus of frusemide (30 mg)
over one minute. The study then continued for a further 3 hours. At -li hrs
either placebo or indomethacin (100 mg) was given by mouth. Urine and blood
sampling, and blood pressure and pulse measurements were taken at -1, -i, 0,
3, i, 1, li, 2, 2i, and 3 hours. For statistical analysis, the results for the last
I hr before the administration of frusemide were taken as control (0 hr). After
each study, cumulative salt loss above baseline was replaced by sodium
chloride tablets. In addition, 3 volunteers undertook two further study days,
taking indomethacin (100 mg) and placebo respectively. The protocol was
identical to that above except that frusemide was not given.
Results
Baseline determinations
For each individual, total dopamine, sodium and volume output were
calculated during the 2 hour baseline-period. Correlation analysis was not
undertaken due to the small number of individuals. The mean and SEM for the
ratios of dopamineisodium and dopamineturine flow rate were calculated (6.64 +_
0.43 nmol dopamine/mmol Na vs 0.17 +_ 0.03 nmol dopamine/ml). The much
lesser variability for the former suggests that dopamine output is more closely
linked to sodium excretion than to urine flow rate. A comparison of values at
time 0 hr, before frusemide was given, indicated that urine volume, sodium
excretion and plasma renin activity, were all lower after indomethacin, but
/vs
only the results for volume reached significance (p < 0.05). Indomethacin did
not alter urine dopamine output at this point (1.00 +_ 0.16 vs 1.03 +_ 0.11
nmol/min, N.S.). The results for the three subjects studied separately without
frusemide are shown in Figure 2b-l. Statistical comparison was not undertaken
but urine volume, sodium and plasma renin activity, were consistently reduced
by indomethacin, compared with placebo. However, there was no apparent
change for dopamine over the 3 hour period.
Responses to intravenous frusemide
Table 2b-l shows the results of renal responses to intravenous frusemide.
Maximal values all occured at 15 minutes. Sodium output increased 20-fold on
average with a parallel increase in urine flow rate (Figures 2b-2, 3). Natriures-
is and diuresis were complete in 3 hours. Plasma renin activity showed a 4-fold
rise at 15 minutes. Levels thereafter declined to plateau significantly above
control until the end of the study (Figure 2b-5). Urine dopamine excretion more
than doubled within the first 15 minutes, though levels thereafter started to
decline and by li hours were not significantly above baseline.
Effects of indomethacin on responses to intravenous frusemide
Sodium excretion and urine flow rates in response to frusemide were
reduced at all times after pretreatment with indomethacin (Figures 2b-2, 3).
Comparison of total sodium outputs over the three hours after frusemide
revealed a 25% reduction overall (199.2 _+ 11.7 to 142.7 +_ 10.2 mmol, p < 0.01,
Figure 2b-4). Total volume output was similarly reduced (1376 +_ 78 to 999 +_ 92
mis, p = 0.01). The PRA response to frusemide was entirely abolished by
indomethacin (Figure 2b-5). From Figure 2b-6 it is evident that the urine
dopamine response to frusemide after indomethacin was similar to that
observed with placebo and the results are almost superimposed.
Systemic responses
Table 2b-2 shows the results for mean arterial blood pressures and pulse
rates. In the presence of indomethacin, arterial pressure was higher at all
points compared to placebo, and this was significant during the control period.
Frusemide with placebo, resulted in a significant increase in blood pressure at
15 minutes. Thereafter there was a non-significant decline. Pulse rate tended
to be lower in the presence of indomethacin, and values declined during the
study. Frusemide produced a large and early increase in haematocrit, starting
at 15 minutes and values remained elevated. In the presence of indomethacin
the initial haematocrit tended to be higher in comparison with placebo, though
the increase after frusemide was less marked.
SodiumexcretionUrinefl wPRADopamineexcret on (mmol/min)( l/min)ngofANGIhl)nmol/mi
Beforefrusemide0.15+_023 50 _+31 42. 6 15minafterfrusemide3. 7+_0 147.0084 4 _+.952 26 SignificanceP<0.0011 Table2B-1Sodiumexcretion,urinfl wndhormonval sbefo15minutter30gffruse de intravenously.V luesrexpressedm an _+SEM;=7.
i*8
Time (hours)
C 3 3 12 3
Frusemide and
placebo
Mean arterial 83.6 89.3* 86.9 86.1 83.1 82.9
pressure (mm Hg) +_ 3.2 +_ 2.8 +_ 2.9 +_ 2.2 +_ 0.9 _+ 2.0
Mean pulse rate 59 60 59t 62T 601 60
(beats/min) +3 +2 +3 +3 +3 +2
Haematocrit 40.7 43.3** 43.6** 44.3** 43.1** 43.5**
(%) + 1.8 + 1.4 + 1.6 + 1.4 + 1.7 + 1.4
Frusemide and
indomethacin
Mean arterial 89.7t 89.4 88.9 87.0 84.4 85.7
pressure (mm Hg) +_ 2.5 +_ 3.1 +_ 3.3 +_ 2.8 +_ 1.7 + 2.8
Mean pulse rate 57 55 53 52* 53 57
(beats/min) +2 +3 +2 +2 +2 +2
Haematocrit 43.0 43.9 44.7* 44.9** 44.6** 44.3
(%) + 1.1 + 1.1 + 1.1 + 1.1 + 1.0 + 1.4
Table 2B-2 Mean blood pressure, pulse and haematocrit values in seven sub¬
jects in response to intravenous frusemide (30 mg), after pretreat-
ment with either placebo or indomethacin (100 mg). Values are
means ^SEM; * p < 0.05, ** p < 0.01 for comparison with control;
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Figure 2b-1. Mean renal responses in three subjects given placebo ( o )
or indomethacin (lOOmg, • ) at time - I 'A hr.
ISO
Figure 2b-2. Urine sodium output in response to intravenous
frusemide (30mg) with ( • ) or without ( o ) pretreatment
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Figure 2b-3. Urine flow in response to intravenous frusemide (30mg)
with ( • ) orwithout ( o ) pretreatmentwith indomethacin







Figure 2b-4. Total natriuretic response in seven subjects, to 30mg
intravenous frusemide, alone (F), and after pretreatment
with lOOmg indomethacin (F+l). Individual values are

















Figure 2b-5. Plasma renin activity in response to intravenous
frusemide (30mg) with ( • ) or without ( o ) pretreatment
with indomethacin (lOOmg) in seven subjects. Values are
means ± SEM, * p < 0*05, ** p < 0*01 in comparison
with control (Ohr).
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Figure 2b-6. Urine dopamine output in response to intravenous
frusemide (30mg) with ( • ) or without ( o ) pretreatment
with indomethacin (lOOmg) in seven subjects. Values are
means ± SEM, *p<0*05, **p<0*0l in comparison with
control (0 hr).
2(c) THE EFFECT OF CARBIDQPA ON THE RENAL RESPONSE TO INTRA¬
VENOUS F RUSEMIDE
Protocol
Eight volunteers were studied on two occasions. After a 2 hour
equilibration period (-4 to -2 hr) carbidopa (100 mg) or placebo was given by
mouth. A further two hour period was then followed by an intravenous bolus of
frusemide (30 mg) (0 hr). Blood and urine samples and blood pressure and pulse
measurements were taken at -2, -1, 0, i, i, 1, 2, and 3 hours. Cumulative salt
loss was replaced at the end of the study. For statistical analysis, the results




Carbidopa reduced dopamine excretion from 1.25 +_ 0.12 nmol/min to the
lower level of detection of the assay by two hours (Figure 2c-l). It did not
produce any changes in baseline sodium excretion (Figure 2c-2), plasma renin
activity (Figure 2c-4), or urine kallikrein excretion (Figure 2c-5), compared to
placebo at time 0 hr.
Effect of carbidopa on responses to intravenous frusemide
Frusemide, with placebo, produced similar and comparable increases in
sodium and dopamine output, and plasma renin activity to those recorded in
part 2b. In addition, frusemide stimulated urine kallikrein excretion at 15
minutes (0.53 + 0.08 to 0.94 + 0.11 Eu/hr, p < 0.01), but the response was not
sustained and levels had declined to baseline at 30 minutes.
ISb
In the presence of carbidopa, dopamine excretion remained below the
limit of detection and no rise occurred after frusemide. There was a mean 16%
reduction in the total natriuretic response to frusemide. This was largely
accounted for by one subject who showed a marked decline. Three subjects
produced a greater natriuretic response, and as a result, the overall change
was not significant (182.4 + 11.8 vs 156.0 + 11.8 mmol, Figure 2c-3). The
pattern and time course of the stimulation of plasma renin activity after
frusemide was almost identical after pretreatment with either placebo or
carbidopa (Figure 2c-4). Similarly, the rise in urine kallikrein excretion was not
significantly altered by blockade of dopamine synthesis (Figure 2c-5).
Systemic responses
Frusemide produced an increase in mean blood pressure at 15 minutes
which was not quite significant, but did not alter pulse rate throughout the
study period.
In the presence of carbidopa, there was a significant increase in mean
arterial pressure, one hour after frusemide, compared to control. There were
however, no significant differences between placebo and carbidopa, on



































Mean arterial 86.1 90.4 90.0 93.0** 88.7 87.2
pressure (mm Hg) + 2.6 + 2.6 + 2.1 + 2.6 + 2.7 + 2.9
Mean pulse rate 62 58 59 64 64 63
(beats/min) +3 +3 +2 +2 +3 +3
Table 2C-1 Mean blood pressure and pulse in eight subjects in response to
intravenous frusemide (30 mg) after pretreatment with either
placebo or carbidopa (100 mg). Values are means +_ SEM; * p <
0.05, ** ; < 0.01 for comparison with control.
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Figure 2c-1. Urine dopamine output in response to intravenous
frusemide (30mg) with ( • ) or without ( o ) pretreatment
with carbidopa (lOOmg) in eight subjects. Values
are means ± SEM, * p < 0-05, ** p < 0-01 in comparison
with control (0 hr). The broken line represents the lower
limit of detection of dopamine.
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Figure 2c-2. Urine sodium output in response to intravenous
frusemide (30mg) with ( • ) or without ( O ) pretreatment
with carbidopa (lOOmg) in eight subjects. Values are
means ± SEM.
250
Figure 2c-3. Total natriuretic response, in eight subjects, to 30mg
intravenous frusemide, alone (F) and after pretreatment
with IOOmg carbidopa (F+C). Individual values are plotted
































Figure 2c-4. Plasma renin activity in response to intravenous
frusemide (30mg) with ( • ) or without ( o ) pretreatment
with carbidopa (IOOmg) in eight subjects. Values are
means ± SEM, * p<0-05, ** p<0-0l in comparison with
control (0 hr).
UZ
Figure 2c-5. Urine kailikrein output in response to intravenous
frusemide (30mg) with ( • ) or without ( o ) pretreatment
with carbidopa (lOOmg) in eight subjects. Values
are means ± SEM, ** p < 0-01 in comparison with
control (Ohr).
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DISCUSSION
The members of the sulphamoyl benzoate group of drugs, which includes
frusemide, bumetanide and piretanide, are described as loop or high ceiling
diuretics, and are the most powerful natriuretic drugs in clinical use.
Frusemide is actively secreted at the proximal tubule by the organic anion
transport system, and inhibits sodium chloride transport from the luminal
surface of the nephron. The principle site of action is at the thick ascending
portion of the loop of Henle were it blocks the activity of the Na:K:2Cl
cotransporter situated on the luminal membrane (Friedman and Hebert, 1987).
Frusemide is also a renal vasodilator, with increased flow primarily
directed towards the deeper renal segments (Data et al., 1978). Glomerular
filtration rate shows a less consistent change so that filtration fraction tends
to decline (Wilson et al., 1982; Mackay et al., 1984). The demonstration that
frusemide reduces proximal tubule fluid and phosphate reabsorption, may be at
least partly explained by such alterations in renal haemodynamics (Brenner et
al., 1969b; Haas et al., 1977).
The various stimuli to the secretion of renin have been discussed and
various groups have focused on the mechanisms by which frusemide and other
loop diuretics produce large and sustained increases in renin release. Animal
studies, in particular those utilising the non-filtering isolated perfused kidney
have shown that the early response to frusemide, that is within 15 minutes, is
mediated by intrarenal events with a contribution from both the macula densa
and baroreceptor mechanisms (Vander and Carlson, 1969; Corsini et al., 1975).
The response to frusemide appears to be biphasic, a secondary rise in renin
occuring after one hour or so. Imbs and colleagues (1977) have provided clear
evidence, in the anaesthetised dog, that the delayed rise is a function of salt
and water loss, with compensatory activation of the sympathetic nervous
system: both propranolol and replacement of urinary losses by ureterovenous
anastomosis, though not affecting the immediate rise, abolished the secondary
increase in renin release after intravenous frusemide. In agreement with this
was a study reported by Cannella et al. (1983) in man, in which significant
rises in plasma catecholamines were demonstrated from 60-90 minutes after
intravenous frusemide.
The marked natriuretic capacity of both intravenous and oral frusemide
(30 mg) was evident in the present studies. After intravenous administration,
there was a rapid onset of action with peak response normally within 15
minutes, and drug action was complete by three hours. Concurrent with the
natriuresis was a large increase in urine flow. Both inhibition of sodium chlor¬
ide reabsorption in the thick ascending limb, and an increase in medullary
blood flow will lead to reduction in the medullary longitudinal osmolar concen¬
tration gradient, impairing normal urinary concentration and leading to the
excretion of large volumes of isotonic urine.
The administration of oral frusemide produced a lesser though more pro¬
longed natriuretic and diuretic response, with marked variation between
individuals as to the timing of onset and peak responses. This is likely to
reflect variable and limited bioavailability, reported to be around 50% in
comparison to an intravenous dose (Cutler and Blair, 1979).
The mechanism of action of frusemide, by which a primary natriuretic
effect produces a 'solute-diuresis', accounts for the close correlation noted
between sodium excretion and urine flow, after both oral and intravenous
administration.
In addition to its widespread clinical uses, workers have applied frusem¬
ide as a tool to study renal electrolyte handling and in particular, to investig-
ate intrarenal hormonal interactions. Intravenous frusemide, in animals and
man, stimulates the production of arachidonic acid and hence the renal
synthesis and excretion of a range of prostaglandins including PGE2, TXB2'
PGF^ and the stable hydrolysis product of prostacyclin, 6-keto-PGFla (Weber
et al. 1977; Ciabattoni et al., 1979; Wilson et al., 1982; Mackay et al., 1984).
In addition, frusemide has been shown to inhibit the prostaglandin degradative
enzymes, 15-OH prostaglandin dehydrogenase (Paulsrud and Miller, 1974) and
PGE2~9-Keto reductase (Stone and Hart, 1976). As already discussed, prosta¬
glandins, particularly PGE2 and prostacyclin produce, on administration, renal
vasodilation and renin release, and in vitro, PGE2 inhibits sodium reabsorption
at the ascending limb of the loop of Henle. There is ample evidence from
studies utilising inhibition of cyclooxygenase, that the prostaglandins largely
mediate the renal haemodynamic changes and renin hyperexcretion following
intravenous frusemide (Patak et al., 1975; Williamson et al., 1975; Frolich et
al., 1976; Weber et al., 1977; Mackay et al., 1984). In the present studies
intravenous frusemide produced a rapid and large rise in plasma renin activity,
with levels thereafter declining but remaining significantly elevated above
baseline three hours later. The prostaglandins act as modulators to known
stimuli for renin release, but do also provide an independent separate input to
the juxtaglomerular cells. The marked prostaglandin-dependence of the renin
response following intravenous frusemide was demonstrated by the abolishment
of both the early and sustained rise in plasma renin activity after the prior
administration of indomethacin. A dose of 100 mg of indomethacin is known to
decrease the urinary excretion of PGE2 by 80% within one hour, with the
effect persisting for at least 4 hours (Mackay et al., 1984).
It is of note that the renin response was distinct following oral frusem¬
ide. There was no early rise and levels gradually increased over five hours, a
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phenomenon presumably reflecting the progressive, cumulative, salt and water
deficit.
In the present studies, indomethacin did not apparently affect baseline
sodium excretion. However the peak natriuretic response was smaller, and total
sodium excretion over 3 hours, in response to frusemide, was significantly and
appreciably attenuated by the order of 25% (p < 0.01) in the presence of
indomethacin.
There is less consensus in the literature on the importance of prosta¬
glandins in the natriuretic capacity of frusemide. Conflicting reports probably
reflect differences in protocol, animal model, and experimental technique. In
addition, chronic dosing studies are complicated on account of renal compen¬
satory adjustment that may occur. An important factor appears to be the pre¬
existing state of the renal circulation, such that under conditions of antinatri-
uresis and increased vascular tone, the prostaglandins assume an important
controlling function in modulating the effects of activated renin-angiotensin
and sympathetic nervous systems (reviewed by Dunn and Zambraki, 1980;
Patrono and Dunn, 1987). Thus Berg (1977) showed in humans with renal impair¬
ment, that acetyl salicylic acid decreased the natriuresis produced by an intra¬
venous infusion of frusemide. Similarly, in cirrhosis (Planas et al., 1983) and
the nephrotic syndrome (Tiggeler et al., 1977), both conditions characterised by
intravenous volume depletion, the natriuretic response was markedly inhibited
by cyclooxygenase inhibition.
In normal man and animals, inhibition of prostaglandin synthesis has been
demonstrated either to significantly attenuate, but never abolish, the natriur¬
etic response to frusemide (Patak et al., 1975; Frolich et al., 1976; Brater,
1979; Mackay, 1984), or produce no change (Bailie et al., 1976; Weber et al.,
1977). In a study performed in dogs, Neis et al. (1983) argued that the
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reduction in natriuresis is due to blockade of the renal haemodynamic effects:
in salt depleted dogs, indomethacin completely blocked the increment in renal
blood flow and decreased the peak sodium excretion produced by frusemide. In
contrast, in sodium replete dogs, frusemide did not increase renal blood flow,
and indomethacin had no effect on either renal haemodynamics or natriuresis.
On a rather similar vein, Brater et al. (1979) noted a reduction in the
natriuretic response to 40 mg of intravenous frusemide in man, but no
difference in fractional excretion of sodium after normalising for a small
decline in creatinine clearance, in the presence of indomethacin.
Indomethacin has been reported to have a large number of actions in
addition to prostaglandin-inhibition (Dunn and Zambraski, 1980) and the authors
caution against presuming that any physiological function is prostaglandin
mediated if it is attenuated after indomethacin. In addition, indomethacin, like
other non-steroidal anti-inflammatory drugs, is secreted through the proximal
tubule by the same organic anion transport system utilised by frusemide, thus
presenting a possible pharmacokinetic interaction, distinct from any effect on
prostaglandins. In a study in man, indomethacin did not affect the total amount
nor the time course of the urinary excretion of frusemide. However, a
pharmacodynamic interaction was evident in that the dose-response curve,
relating urinary frusemide excretion rate to sodium excretion rate, was shifted
downwards and to the right (Chennavasin et al., 1980). Further support for a
direct tubular interaction comes from an in vitro study demonstrating that
prostaglandin inhibition alters chloride uptake at the loop of Henle after
frusemide administration (Kirchner, 1985).
Whether the attenuation of natriuresis by indomethacin in the present
study was related to haemodynamic or tubular events cannot be answered.
However in a similar study in salt replete subjects, Mackay et al. (1984)
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demonstrated that indomethacin blocked the frusemide-induced increment in
renal blood flow associated with a significant reduction in sodium excretion.
By means of salt loading manoeuvres, various groups have claimed to
have identified subsets of essential hypertensives which are particularly
sensitive, in terms of blood pressure responses, to the effect of an increase in
dietary salt (Fujita et al., 1980; Weinberger et al., 1986). Harvey et al. (1984)
showed in a small group of essential hypertensives, that dopamine mobilisation
in the kidney is defective in the face of a salt load. Shikuma and colleagues
(1986) extended this work, and showed that only subjects characterised as
being 'salt-sensitive' hypertensives possessed the abnormal dopamine response.
They postulated that the lack of appropriate rise in dopamine on salt loading
might prevent normal sodium excretion, and predispose individuals to salt
retention and hypertension. The demonstration of 'salt-sensitivity', by salt
loading over a number of days, is laborious and not easily widely applicable.
Kuchel and colleagues (1979) had made the interesting observation that
intravenous frusemide, produced an acute rise in urine dopamine excretion. In
addition, both the dopamine and natriuretic response was impaired in essential
hypertension. However, the group did not clearly characterise the response in
terms of sodium and volume output, or the relationship to other hormonal
systems in the kidney, and the mechanism was not considered. It was of
interest to follow up this observation to determine whether the dopamine
response to frusemide is consistent in normal subjects. Further studies, beyond
the scope of the present work, might then assess the response in essential
hypertension, with a particular aim of identifying salt-sensitive patients. The
use of frusemide as a simple test in this way would be rather analagous to its
use in the separation of renin-responsive subsets in essential hypertension
(Padfield et al., 1975).
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In this department, a preliminary study had demonstrated an actual
decline in urine dopamine excretion after oral frusemide. The present work
therefore sought to further characterise the dopamine response after oral
administration and allow comparison with changes after intravenous frusemide
in the same subjects. After oral frusemide there was a small increase in dopa¬
mine excretion within 15 minutes of administration, occuring in all subjects.
Thereafter, levels declined back to baseline and at 4 hours a significant
decline from control was apparent. The explanation for the early increase is
not straightforward. Although sodium output and urine flow had started to
increase in all volunteers by this time, peak responses did not occur for a
further 1-2 hours, and relatively little drug would have been expected to be
absorbed at this stage. The decline in dopamine output may be a feature of the
induced salt and water depletion, but such a pattern was not seen after
intravenous frusemide in spite of greater cumulative natriuresis. Further
studies should be performed with different doses of oral frusemide to
determine dopamine responsiveness. However at 30 mg, overall changes were
small and, due to limited bioavailability and variable interval to peak
natriuresis, it seems unlikely that oral administration of frusemide will provide
a standard and reproducible method for stimulating appreciable dopamine
release.
The results confirm that intravenous frusemide produces a prompt, and
significant increase in urine dopamine excretion. The peak response at 15
minutes represented at least a doubling of dopamine output before a steady
decline and return to baseline around li hours. After intravenous frusemide,
the rise in urine dopamine excretion correlated closely with that of both
natriuresis and urine flow rate, although it was noticeable that dopamine
excretion had declined at a time when sodium output was still appreciable, and
the latter did not reach control values until 3 hours after dosing. The
excretion of both prostaglandins and kallikrein can, under certain conditions,
be demonstrated to be flow dependent. One possibility is the washout of
preformed hormone from the tubular lumen. It is conceivable that the increase
in dopamine also represents a "washout" phenomenon. However when normal
subjects undertook 24 hour urine collections, urine dopamine excretion
correlated closely with sodium output, but not with urine flow rate (Casson,
1984). Also, under the baseline condition of this study, urine dopamine
excretion appeared to have a closer relationship to sodium excretion than to
flow rate. It has also been shown in dogs, that intravenous volume loading with
saline increases dopamine output, but that similar expansion with albumin
solution does not (Faucheux et al., 1977), pointing to the importance of the
sodium (or chloride) ion in dopamine stimulation. Thus prevailing evidence
might suggest that the dopamine response after frusemide is causally related to
the natriuresis (vide infra).
Pretreatment of subjects with indomethacin did not alter the output of
dopamine in the baseline state, either in the seven subjects compared just
before frusemide was given, or in the three subjects studied over five hours. In
addition, in spite of a 25% reduction in the natriuretic response to frusemide,
indomethacin did not alter the pattern of dopamine release after frusemide,
either in magnitude or time course. The results suggest that the dopamine
response to frusemide, in contradistinction to other effects of the diuretic, is
not dependant on the availability of prostaglandins. As previously described,
the dose of indomethacin used would be expected to markedly impair prosta¬
glandin synthesis. It remains possible that residual prostaglandin synthesis,
resistant to the action of indomethacin, could have mediated the increase in
dopamine, but the completeness of inhibition of the renin response, as an
indicator of active prostaglandin synthesis, renders this unlikely. This conclus¬
ion has implications for the possible mechanisms by which frusemide stimulates
dopamine excretion. The limiting factor, under normal circumstances, for
dopamine synthesis in the proximal tubular cell may be the availability of
L-dopa, and the uptake of this compound into tubular cells appears to be
dependent on the sodium chloride concentration within the tubular lumen
(Ullrich et al., 1974). Frusemide has inconsistent effects on the filtered load of
sodium, but renal vasodilatation, by altering the peritubular physical forces,
will ensure a relatively increased sodium load at the proximal tubule. It could
then be postulated that it is the change in renal haemodynamics that modulates
dopamine synthesis. Renal haemodynamic monitoring was not carried out in this
work, but in the study already referred to (Mackay et al., 1984), indomethacin
prevented the rise in renal blood flow. As a result, a reduced dopamine
response would have been expected in the present study. This was not the case
however, and it would seem necessary to propose another mechanism for
dopamine excretion after pharmacological stimulation with frusemide. There is
at present no evidence that the dopamine synthetic process can respond to an
increase in salt load at a more distal site in the nephron, though such a
mechanism cannot be discounted. An alternative unproven possibility is that
frusemide directly stimulates dopamine production at the proximal tubule. The
drug is directly secreted through proximal tubular cells, the site of active
dopamine synthesis, and as discussed, indomethacin does not interfere
significantly with its transport into the urine. In addition, the secretion rate of
frusemide correlates closely with the natriuretic response (Cutler and Blair,
1979). This question deserves further study and might be approachable with in
vitro tubular preparations.
From the reported literature and the results of the present studies, the
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prostaglandins appear to mediate only a small proportion of the natriuretic
response to frusemide. Dopamine, when administered exogenously, produces
renal vasodilation and an increase in sodium excretion, effects similar to those
exerted by frusemide. It was therefore of interest to determine whether the
acute rise in endogenous dopamine, produced in response to frusemide, contrib¬
uted in any way to the renal effects of the diuretic. Carbidopa in a single
dose of 100 mg by mouth, markedly inhibited dopamine excretion during the
baseline period, the effect being apparent by one hour, and levels being
unrecordable within two hours. Thereafter, the rise following frusemide was
abolished and levels remained below the limit of detection for a further three
hours. Baseline natriuresis was not altered by the presence of carbidopa, and it
is clear that dopamine synthesis blockade with carbidopa did not significantly
affect the natriuretic response to frusemide, either in magnitude or time
course. Therefore, under the conditions of these studies, dopamine did not
contribute to the natriuretic action of frusemide and its enhanced excretion
must be regarded as an epiphenomenon. Whether the dopamine response to
intravenous frusemide, could provide a discriminatory test in essential
hypertension remains to be determined. The mechanism of the increase in
dopamine excretion is still unclear, and may not relate directly to salt handling
by the kidney. Whether or not this is so, a pharmacological stimulus, such as
that produced by frusemide could still provide an indication of the capacity of
an individual to mobilise dopamine, which may relate to the physiological
stimulus of salt loading.
The potential interactions of renin and dopamine in the kidney have
already been discussed in some detail. The studies with frusemide allowed
analysis of the relationship from two approaches. Firstly, prostaglandin-synth¬
etase inhibition with indomethacin tended to lower plasma renin acitivity in
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the baseline state and abolish the rise induced by frusemide, but did not affect
the output of dopamine. Secondly, almost complete inhibition of dopamine
synthesis did not alter plasma renin activity, either at baseline or after
frusemide. Therefore, dopamine is not important in the renin response to
frusemide which is markedly prostaglandin-dependant, and conversely, changes
in renin release do not appear to alter the output of dopamine.
An acute increase in urine kallikrein and kinin excretion has previously
been reported in man after intravenous frusemide (Abe et al., 1978), and this
was confirmed in this work for kallikrein output. The rise was short-lived and
levels had returned to baseline by 30 minutes after administration. It is clear,
that dopamine plays no part in the kallikrein response after such
pharmacological stimulation: the pattern of excretion after dopamine blockade
with carbidopa was almost identical to that in the presence of placebo.
Further light may be shed upon the dopamine response to frusemide by
study of other diuretics with actions on different segments of the nephron.
Although there is doubt as to whether the thiazide diuretics stimulate prosta¬
glandin release (Patak et al., 1979; Kramer et al., 1980), they do not appear to
alter renal blood flow or renin release in the acute situation (Brater, 1986;
Imbs et al., 1977). It would therefore be of interest to determine the dopamine
response to such drugs which, exert a primary natriuretic action on the distal
tubule, but do not influence renal haemodynamics.
Frusemide, after intravenous administration, produced an acute rise in
mean arterial pressure at 15 minutes, with values declining thereafter. The
diuretic is known to exert extra-renal haemodynamic effects, producing
systemic venodilatation and reduction in left ventricular filling pressure
(Dikshit et al., 1974; Johnston et al., 1983a). In addition, in humans, it
produces an early reduction in forearm blood flow with arterial
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vasoconstriction. Such effects are apparent within 15 minutes of administration
and are therefore distinct from diuresis and reduction in extracellular fluid
volume. The extrarenal effects of frusemide depend on the presence of
functioning kidneys (Bourland et al., 1977) and are abolished in the presence of
both cyclooxygenase inhibition and angiotensin converting enzyme inhibition
(Johnston et al., 1983a,b). Johnston's group has therefore proposed that renin,
released from the kidney, is the principle mediator. In the peripheral
circulation, stimulated angiotensin II produces arterial vasoconstriction,
whereas at the vein wall it promotes the release of dilatory prostaglandins.
The present results are compatible with such a hypothesis: in the presense of
indomethacin, frusemide did not increase blood pressure, presumably due to the
inhibition of renin release. Blood pressure was however elevated prior to the
administration of frusemide and remained elevated above values obtained with
placebo. That cyclooxygenase inhibition is hypertensive is widely accepted
(Carmichael and Shankel, 1985). The propensity for indomethacin to produce
sodium retention cannot explain the increase in blood pressure within li hours
of administration. It is more likely that inhibition of extrarenal
cyclooxygenase and decrease in vascular wall prostaglandin synthesis allows
vasoconstrictor influences to act unopposed, leading to increased resistance of
systemic vascular beds. In this context, there is evidence that the inhibition
of prostaglandin synthesis may increase sympathetic nerve activity (Samuelsson
and Wennmalm, 1971). The haematocrit data give further information on
systemic responses induced by frusemide. After frusemide, haematocrit
increased significantly from 15 minutes and then remained elevated throughout
the study. Such an early rise cannot be explained on the basis of extracellular
fluid loss, and the mechanism is unknown but must reflect extra-renal actions
of the drug. It may be due to increased capillary transudation resulting from
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altered arterial and venous tone, or the drug may directly alter red cell size.
This interesting observation requires further study.
Whether dopamine receptors on the systemic vasculature normally have a
modulating role in systemic vascular resistance and blood pressure seems, as
discussed, unlikely. Carbidopa did not influence blood pressure in the baseline
state, but at one point after frusemide there was an elevation, compared to
placebo, though the rise was not sustained. The significance of this isolated
result is unclear.
In summary, the renal effects of frusemide are markedly influenced by
prostaglandin-synthesis inhibition. However, the acute increase in dopamine
excretion is not mediated through the prostaglandins and no interaction bet¬
ween the hormonal systems is apparent. In addition, dopamine does not contrib¬
ute to the action of frusemide in the kidney.
CHAPTER FIVE
THE EFFECT OF CARBIDQPA AND LITHIUM ON THE SYSTEMIC AND RENAL
RESPONSE TO ACUTE INTRAVENOUS SALINE LOADING IN NORMAL MAN
Ill
INTRODUCTION
Expansion of the ECF space by intravenous saline loading provides an
effective stimulus to sodium excretion. Much work has been performed in
animals and man to elucidate the mechanisms involved. De Wardener and
colleagues (1961) demonstrated in dogs that a natriuretic response to volume
expansion persisted in the absence of changes in RBF, GFR and mineralocorti-
coid activity. This led to the search for other possible natriuretic factors. One
such factor is endogenous dopamine. Studies in animals and man have confirmed
that an acute salt load leads to an increase in urinary excretion of dopamine
(Faucheux et al., 1979; McClanahan et al., 1985; Alexander et al., 1974). With
the known natriuretic effect of exogenous dopamine, it was of interest to
determine whether dopamine is a contributory factor in the natriuretic
response. It was demonstrated in a previous chapter that the dopa decarboxyl¬
ase inhibitor, carbidopa, markedly reduced urinary dopamine output. In the
present study, therefore, the effect of carbidopa on renal and systemic
responses to saline infusion was assessed in normal subjects, to determine any
possible dopaminergic component.
Measurement of the renal clearance of lithium has been used to invest¬
igate the tubular nephron segments involved in salt excretion. Lithium carbon¬
ate was therefore administered to determine those segments contributing to
the natriuresis of intravenous saline loading. In a previous chapter, the
potential pitfalls of its use as a marker of renal function were highlighted. In
particular, it elevated sodium excretion but subsequently attenuated the
natriuresis produced by gludopa. It was important to determine whether lithium
affected the natriuretic response to the volume expansion, either through
influencing the dopaminergic, or some other mechanism. Lithium was therefore
178
given on a separate day in the presence of intravenous saline, to assess the
effect of the ion per se, and a larger dose of 1000 mg was chosen to
accentuate any possible interaction.
Protocol
Nine subjects were each studied on three occasions. After a 2 hour run-
in (0-2) period, subjects received an intravenous infusion of 0.9% isotonic
saline (20 mls/kg/hr) over 3 hours (2-5) followed by a 2 hour recovery period
(5-7). At the end of the 7th hour, a light snack was provided which contained
almost no protein and no more than 3 mmol of sodium. Thereafter, they were
allowed to rise, and urine, passed at will, was collected for a further 4 hours
(7-11). Each subject took on separate occasions, either no active drug, carbid-
opa 100 mg by mouth at 0 and 5 hours, or lithium carbonate, 1000 mg by
mouth, at 2200 hours on the evening before study. Placebo tablets were used
such that tablets were taken every dosing time. At each hour (1-7), supine
blood sampling, and blood pressure and pulse measurements were followed by
voiding and collection of urine samples. For analysis, the control baseline
results were mean values for the 2 hour run-in period.
Results
None of the subjects felt unwell during the study manoeuvres. Some how¬
ever, noted swelling of the fingers and two experienced a change in voice
quality during saline infusion.
Renal and systemic response to intravenous saline infusion
In the presence of placebo, sodium excretion rose steadily during intra¬
venous volume expansion from 0.15 _+ 0.03 mmol/min during the run-in period to
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reach a peak of 0.73 +_ 0.12 mmol/min in the hour following the infusion (p <
0.01, Figure 3a-l), representing a five-fold increase. Levels declined after this
point but remained well above control during the final four-hour urine collect¬
ion. The degree of intravenous volume expansion was evident from the sharp
drop in haematocrit (41.9 +_ 0.9 to 36.4 +_ 0.8%, p < 0.01) during the last hour
of infusion (Table 3a-l). During the entire study only about 26% of the
administered salt load was excreted. This was reflected in the persistent rise
in body weight in all subjects.
Salt loading produced a large fall in PRA, the greatest change being
evident during the first hour (2.06 _+ 0.28 to 0.92 +_ 0.16 ng angiotensin I ml 1
h \ p < 0.01, Figure 3a-2). Plasma ANP exhibited only a modest rise during
the first hour of infusion which was not significant. By the last hour of infus¬
ion, however, levels had increased to 240% of control values (42.7 +_ 6.0 to
103.0 _+ 10.2 pg/ml, p < 0.01, Figure 3a-3). ANP then tended to decline, though
it remained significantly above control two hours after the end of the infusion.
During the period of intravenous saline infusion, urine dopamine excretion did
not change from control values (Figure 3a-4). A modest but significant rise of
about 26% was apparent during the hour after the infusion (1.33 _+ 0.12 to 1.67
+_ 0.13 nmol/min, p < 0.05), and this was maintained at the end of the study.
Creatinine clearance tended to decline during saline infusion but there
were no significant changes throughout the study (Table 3a-2). The systemic
parameters, mean arterial pressure and pulse were unchanged.
The effect of carbidopa on responses to intravenous saline infusion
Carbidopa, administered orally (100 mg) at the start of the study (0 hr)
and again at 5 hours, effectively blocked dopamine excretion during the 11
hours of the study. In seven of the subjects, levels were markedly depressed
towards the limit of detection of the HPLC assay. Mean values shown in
Figure 3a-4 were elevated by values in two subjects in whom the levels fell
only modestly in response to carbidopa. By the final collection period,
dopamine excretion had started to rise, presumably reflecting recovery from
dopa decarboxylase inhibition. It is evident from the results that blockade of
dopamine synthesis did not affect renal and systemic parameters measured
during the control period. In addition, sodium excretion was comparable at all
time points during and after the infusion of saline, the response curves being
almost superimposed (Figure 3a-l). The responses of PRA (Figure 3a-2),
creatinine clearance (Table 3a-2), mean arterial pressure and pulse (Table 3a-l)
were similar in the presence of either placebo or carbidopa. Plasma ANP levels
tended to be lower after pre-treatment with carbidopa, but there were no
significant changes in comparison with placebo during volume expansion.
The effect of lithium on responses to intravenous saline infusion
Lithium carbonate, administered in a dose of 1000 mg by mouth on the
evening before the study, resulted in a mean serum lithium level of 0.40 +_ 0.03
mmol/1 11 hours later at the start of the study. Analysis of the two hour run-
in period revealed that in the presence of lithium, baseline sodium excretion
was appreciably elevated compared to values obtained on placebo (0.21 +_ 0.04
vs 0.15 + 0.03 mmol/min) though the change just failed to reach significance by
students' t-test (p < 0.08). Lithium resulted in a significant increase in PRA at
baseline (2.80 +_ 0.24 vs 2.06 _+ 0.28 ng angiotensin 1 ml 1 h \ p < 0.01).
During intravenous volume expansion, sodium excretion increased signif¬
icantly. However, after one hour, the excretion rate at each point tended to
be lower when compared with placebo, and the peak natriuretic response was
less than three times that of the control value (0.21 + 0.04 to 0.58 + 0.06
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mmol/min, Figure 3a-5) in the hour after the infusion. The absolute increment
in sodium excretion above the control values was lower at all time points and
cumulative natriuresis compared with control was reduced significantly by
lithium (106.8 + 30.1 vs 179.6 +_ 29.1 mmol) representing about a 40% reduction
(Figure 3a-6). PRA declined sharply during saline infusion to values similar to
those on placebo alone (Figure 3a-2). Plasma ANP and urine dopamine were
similar on lithium and placebo during the baseline period and exhibited compar¬
able increments during saline loading (Figures 3a-3, 4). The responses of mean
arterial pressure, pulse and creatinine clearance were not significantly changed
by lithium (Tables 3a-l, 2). Lithium clearance data are depicted in Table 3a-3.
There was a highly significant increment in lithium clearance both during the
period of saline infusion and during the succeeding two hour recovery period (p
< 0.01). Similarly, lithium clearance expressed as a fraction of creatinine
clearance increased significantly. The ratio of sodium to lithium clearance,
representing the percentage of fluid escaping reabsorption in the "distal
tubule", increased, and was significant during the recovery period (p < 0.01). In
spite of this, absolute "distal tubular" sodium reabsorption increased markedly
during both periods in comparison with control (p < 0.01).
Time (hours)
C 3 4 5 6 7
Placebo
Mean arterial pressure 85.4 86.4 88.3 88.4 86.6 88.5
(mm Hg) + 3.3 + 2.8 + 3.2 + 3.4 + 3.2 + 3.2
Mean pulse rate 57 55 56 61 59 59
(beats/min) + 2 + 2 + 3 + 3 + 3 + 3
Haematocrit (%) 41.9 38.4** — 36.4** - 36.9**
+ 0.9 + 0.5 + 0.8 + 0.8
Body weight (Kg) 79.9 82.4** - 83.3** - 82.6**
+ 6.3 + 6.8 + 6.5 + 6.4
Carbidopa
Mean arterial pressure 88.6 86.9 90.1 91.4 88.1 88.0
(mm Hg) + 3.1 + 3.3 + 3.9 + 4.6 + 3.4 + 3.5
Mean pulse rate 59 56 58 61 62 60
(beats/min) + 2 + 2 + 3 + 4 + 3 + 3
Haematocrit (%) 41.9 39.0** — 37.1** - 37.6**
+ 0.9 + 1.1 + 1.1 + 1.0
Body weight (Kg) 79.9 80.9** - 83.0** - 82.3**
+ 6.4 + 6.4 + 6.5 + 6.4
Lithium
Mean arterial pressure 87.5 86.8 87.8 91.6 91.3 93.6
(mm Hg) + 3.2 + 3.1 + 3.6 + 4.5 + 4.4 + 4.1
Mean pulse rate 58 56 59 58 56 57
(beats/min) + 2 + 3 ± 3 + 4 + 2 + 3
Haematocrit (%) 43.0 39.8** - 37.7** - 38.9**
+ 1.0 + 0.8 + 0.9 + 1.0
Body weight (Kg) 78.9 80.1** - 82.3** - 81.7**
+ 6.3 + 6.3 + 6.3 + 6.4
Table 3A-1 Effect of intravenous saline (infused during hours 3, 4 and 5)
on systemic parameters in nine subjects. Results are expressed
as means _+SEM; *p<0.05; **p<0.01 in comparison with control.
Control Saline infusion Recovery
(hours 0-2) (hours 2-5) (hours 5-7)
Placebo 131.5 123.7 145.6
+ 8.2 + 10.0 + 11.1
Carbidopa 146.2 140.9 142.3
+ 9.7 + 13.1 + 9.7
Lithium 123.5 115.4 126.9
+ 4.9 + 3.6 + 7.0
Table 3A-2 Effect of intravenous saline on creatinine clearance in nine
subjects. Results are expressed as means j^SEM.
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Control Saline Recovery
(hours 0-2) (hours 2-5) (hours 5-7)
Lithium clearance 27.0 34.5* 37.0**
(mls/min) + 2.3 + 4.3 + 5.0
Fractional lithium 22.3 30.1** 28.9*
clearance (%) + 1.7 + 3.5 + 3.0
Fractional distal tubular 5.9 8.6 11.1**
sodium clearance (%) + 1.1 + 1.2 + 0.8
Absolute distal tubular 3491 4403* 4591**
sodium reabsorption +_ 304 + 560 +_ 650
(mmol/min)
Table 3A-3 Effects of intravenous saline on tubular function in nine
subjects. Results are expressed as means +_ SEM; * p<0.05, **
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Figure 3a-1. Urine sodium excretion in response to intravenous
saline loading in nine subjects pretreated with placebo
( o ), or carbidopa ( • ). Values are means ± SEM;
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Figure 3a-2. Plasma renin activity in response to intravenous saline
loading in nine subjects pretreated with placebo ( o ),
lithium carbonate ( a ), and carbidopa ( • ). Values are
means ± SEM; ** p<0.0l for comparison with control,
tf p< 0.01 for comparison between lithium and placebo
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Figure 3a-3. Plasma ANP in response to intravenous saline loading in
nine subjects pretreated with placebo ( o ), lithium
carbonate ( a ), and carbidopa ( • ). Values are

























Figure 3a-4. Urine dopamine excretion in response to intravenous
saline loading in nine subjects pretreated with placebo
( o ), lithium carbonate ( a ), and carbidopa ( • ). Values are
means ± SEM; * p < 0.05, ** p< 0.01 for comparison with
control.
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Figure 3a-5. Urine sodium excretion in response to intravenous saline
in nine subjects pretreated with placebo ( o ), or lithium




















Figure 3a-6. Cumulative sodium excretion above control over 9 hours
in response to intravenous saline loading after
pretreatment with placebo or lithium carbonate.
Individual values and means ± SEM are plotted for nine
subjects; ** p< 0.01.
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DISCUSSION
Expansion of the circulating blood and ECF volume has been widely used
as a method to analyse mechanisms of natriuresis. The most widely used
technique is the administration of an acute intravenous load of isotonic saline.
It should be noted that such a manoeuvre is likely to provide a supra-physiol¬
ogical stimulus, but by placing a stress on the system, it allows determination
of those factors which can modulate sodium excretion. Similar expansion of the
effective circulating volume can also be achieved by water immersion and
lower body positive pressure applied by inflating cuff (Coruzzi et al., 1986;
Bennett et al., 1982).
In this study, the infusion of saline at a rate of 20 ml/kg each hour
resulted, in normal volunteers, in a total load of about 4.5 litres over 3 hours.
The effectiveness of expansion of the vascular space was evident from the
marked drop in haematocrit values. During the placebo infusion sodium excret¬
ion started to increase during the first hour, and the peak response, represent¬
ing a 5-fold rise above baseline, occurred during the first hour after the infus¬
ion. Excretion was still elevated during the final 4-hour collection period,
though levels were starting to decline. In spite of the marked natriuretic
response, only around 26% of the administered sodium was excreted in the 9
hours of study and this was reflected in the persisting increment in weight. To
encompass the total response in sodium excretion would have required a much
more prolonged study which was not feasible.
The components of the natriuretic response following saline infusion
have attracted great interest and possible factors were discussed in the intro¬
ductory chapter. Sodium excretion represents the final outcome of the balance
of opposing natriuretic and anti-natriuretic influences. Volume expansion with
192
saline is associated with reduced activity of the sympathetic nervous system,
with reduction in urinary noradrenaline excretion (Alexander et al., 1974), and
inhibition of the renin-angiotensin-aldosterone axis. A reduction of tonic
influence of these systems would be expected to promote natriuresis. Certainly
a marked and sustained reduction in PRA was evident in this study, the largest
decrement occurring during the first hour of infusion.
Other influences may also play a facilitatory role. The renal prosta¬
glandin and kallikrein-kinin systems, and the Na+/K+ ATPase inhibitor have
been advocated as important influences in the response to saline, but their role
was not determined in the present study. Although increases in systemic blood
pressure and GFR may be associated with increased salt excretion, it has been
well demonstrated that such changes are not mandatory or limiting (Krishna et
al., 1985; de Wardener et al., 1961), and these parameters were unchanged in
this study in spite of the marked response. Similarly, although inhibition of
aldosterone release produced by volume expansion removes an antinatriuretic
influence, natriuresis persists in the presence of mineralocorticoid excess (de
Wardener et al., 1961).
Micropuncture studies have highlighted the importance of physical
factors at the proximal tubule in the response to saline infusion (Reineck et
al., 1985). Reduction of the filtration fraction would thus have the effect of
inhibiting fractional sodium reabsorption. Renal blood flow was not measured in
this study. However, it has tended to remain stable during saline infusion in
other studies, although redistribution of intrarenal blood flow could not be
excluded (Alexander et al., 1974; McClanahan et al., 1985). The physical forces
can however modulate proximal tubule reabsorption after saline infusion, even
in the absence of changes in GFR and RBF. The mechanism is by alteration in
the peritubular capillary oncotic pressure and disruption of glomerular tubular
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balance, produced by haemodilution and the marked reduction in systemic
plasma oncotic pressure.
During chronic oral salt loading, Oates et al. (1979) noted in man that
the dopamine response preceded natriuresis, suggesting an effector role for
dopamine. During intravenous infusion of saline, an acute dopamine response is
demonstrable. However, in this setting, Faucheux and colleagues (1977) showed
in rats, that the rise in dopamine succeeded the peak natriuretic response. In
dogs, the urine dopamine response is appreciable and McClanahan et al. (1985)
measured nearly a 4-fold increase in dopamine output. In man, however, the
increase was only of the order of 28% in the study reported by Alexander and
colleagues (1974). In the present study, dopamine excretion gradually increased
and reached peak response one hour after the infusion, the same time as the
peak sodium response. The increase was 26% on average, comparable to that
reported, and values remained elevated at the end of the study.
To study the influence of endogenous dopamine on the natriuretic
response to saline infusion, blockade of the effects of dopamine can be
approached in two ways. Firstly, dopamine receptor antagonists can be used. It
is likely that the DA^ receptor mediates the natriuretic effects of exogenous
dopamine so that a DA^ receptor antagonist would be the suitable agent. The
second approach would be to inhibit the renal synthesis of dopamine. The dopa
decarboxylase inhibitor, carbidopa, was shown in the previous chapter to
inhibit markedly the urinary excretion of dopamine, presumably reflecting a
reduction in renal synthesis. Carbidopa was administered in two 100 mg doses
during the study. It resulted in an appreciable inhibition of dopamine excretion
and abolished the rise in response to saline. It is of note that dopamine levels
were starting to recover at the end of the study, presumably reflecting a
wearing-off of the inhibition of dopa decarboxylase.
Analysis of sodium excretion showed that the blockade of dopamine
synthesis in no way affected the natriuretic response to saline infusion. At
each time point, levels were matched and there was no significant difference
in the cumulative salt outputs on carbidopa or placebo. It is also of note that
carbidopa did not affect baseline natriuresis, suggesting that dopamine was
not exerting an influence on sodium excretion under resting conditions.
Similarly, dopa decarboxylase inhibition did not influence systemic blood
pressure and pulse, or creatinine clearance, either during the baseline or after
saline. The almost identical PRA values on carbidopa and placebo argue
against a controlling role for dopamine on renin release under the conditions
of this study.
These results need to be assessed with regard to previous studies in
animals and man which have sought to assess a dopaminergic contribution to
natriuresis. In anaesthetised rats the non-selective dopamine antagonist cis-
flupenthixol partially attenuated natriuresis induced by Ringer loading (Pelayo
et al., 1983). Similarly, racemic sulpiride inhibited saline-induced diuresis in
rats, whereas the other antipsychotic drugs haloperidol, clozapine, pimozide
and chlorpromazine were without effect (Imondi et al., 1979). In conscious
dogs, carbidopa, adminstered by nasogastric tube at 1 mg/kg 8 hourly for 24
hours before saline infusion, markedly reduced dopamine excretion and abolish¬
ed the large rise following saline in control animals. Neither saline nor carbi¬
dopa affected mean arterial pressure, GFR or RBF, but sodium excretion was
reduced from a maximal value of 855 to 449 peq/min, suggesting interference
with tubular dopaminergic mechanisms (Sowers et al., 1984). Goldberg's group
followed up this study and assessed the highly specific DA^ and DA£ receptor
antagonists, SCH 23390 and domperidone respectively, in conscious dogs. Inter¬
estingly, there was no tendancy towards attenuation of the natriuretic
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response to saline infusion with either agent (Bradley et al., 1986b).
Krishna et al. (1985) reported in normal man, that the relatively non¬
specific dopamine antagonist, metoclopramide, markedly impaired sodium
excretion in response to 2 litres of isotonic saline infused over 4 hours. In
fact, no significant natriuretic response was apparent in the presence of the
antagonist. Coruzzi et al. (1987) studied natriuresis during central hyper¬
volemia induced by water immersion. In a normotensive control group, metoclo¬
pramide significantly blunted sodium excretion and it abolished exaggerated
natriuresis demonstrated in a group of essential hypertensives. Further clouding
the picture are studies reported by Bennett et al. (1982) and Coruzzi et al.
(1986). Volume expansion was achieved in man by lower body pneumatic cuff
and water immersion respectively. In both models, the specific DA2 antagonist
domperidone blunted the increment in sodium excretion.
It is difficult to reconcile the outcome of all these reported studies. A
number of factors are likely to influence the results. Anaesthesia and pre¬
existing state of salt balance will affect the degree of activation of the
renin-angiotensin and sympathetic nervous systems. Salt balance may also
influence dopamine responsiveness: salt depletion might be expected to lead to
up-regulation of dopamine receptors. In fact in the studies referred to, and in
the present study, animals and human subjects were salt replete. Confusion
may result from studies using antagonists that are not specific for dopamine
receptors. Metoclopramide in particular, has multiple actions, including release
of noradrenaline and cholinergic properties (Kuchel et al., 1985). Where highly
specific antagonists were used, as in the study of Bradley et al. (1986), no
apparent reduction in natriuresis could be demonstrated. It could be argued
that the antagonists did not gain sufficient access to the dopamine receptors
in vivo. However, the doses used had been shown to be effective in blocking
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pharmacological effects of dopamine. Differences in animal model may be
significant. Whereas the dopamine response to volume expansion is only modest
in man, it is very much more marked in dogs, and dopamine may assume greater
importance in this species. It is possible, in spite of appreciable suppression of
output by carbidopa in the present study, that sufficient endogenous dopamine
was present to modulate sodium excretion. However, the dose used had been
previously shown to block the effects of gludopa, and a degree of attenuation
might have been expected. Chronic inhibition of dopa decarboxylase, over
three days, has been shown to result in a significant reduction in sodium
excretion in man (Ball and Lee, 1977). It is important to note, in the present
study, that dopamine excretion increased after the infusion and remained
elevated at the end of the study, at a time when more than 70% of the sodium
load remained to be excreted. It is conceivable that dopamine assumes greater
significance as an endogenous natriuretic hormone during the later stages of
the response, and it would be illuminating, though complicated in execution, to
extend such a study over a period of 24 hours or more.
As discussed, the renal DA^ receptor is believed to subserve the natriur¬
etic effects of dopamine. The DA2 receptor modulates noradrenaline release
from sympathetic nerves and may assume greater importance when sympathetic
tone is high. Volume expansion is associated with a decline in sympathetic
nerve activity and it is therefore difficult to explain the effects of the select¬
ive DA2 antagonist domperidone. Further studies will be required to elucidate
the mechanism(s) involved.
Dopamine and ANP have a rather similar spectrum of activity. Both
produce renal vasodilatation and are believed to have direct effects on the
nephron. In addition, both are associated with inhibition of aldosterone release.
A number of studies suggest that intact renal dopaminergic mechanisms are
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necessary for the renal actions of infused ANP. The evidence is most persuas¬
ive in the rat model, where various dopamine antagonists including haloperidol
and chlorpromazine (Marin-Grez et al., 1985; Pettersson et al., 1986), metoclo-
pramide (Racz et al., 1986), and SCH 23390 and R-sulpiride (Webb et al.,
1986), attenuated the natriuresis produced by atrial peptides. Most workers
have attributed the effect to activation of DA^ receptors, either directly or
indirectly. In the dog however, the DA^ antagonist SCH 23390 was without
effect (Murphy et al., 1986). In man, metoclopramide did not affect the
natriuresis and inhibition of renin release produced by infusion of h-aANP
(Jungmann et al., 1986). Of interest, in one study in man, carbidopa signific¬
antly reduced the natriuretic response to h-aANP suggesting that dopamine
synthesis and activity are mandatory for the effects of ANP (Wilkins et al.,
1986). In the most recent study reported from this department, the selective
DA^ antagonist R-sulpiride had no effect on the renal response to low dose
h-aANP infusion in man (Freestone et al., 1988).
Species differences may partly account for the discrepant results, and in
addition, the animal work has been mostly performed in the anaesthetised
state. It is not clear how dopamine and ANP would interact in the kidney.
Dopamine is believed to act through cAMP release after DA^ receptor activat¬
ion, whereas ANP appears to use cGMP as second messenger. Whereas
dopamine has its principle tubular action proximally, there is little evidence
that ANP exerts a direct proximal effect. Further studies, directed at cellular
and biochemical level will be required to solve this problem.
In the present study, intravenous salt loading produced a marked
increase in ANP that paralleled the natriuresis, showing a peak at the end of
the infusion before declining, though remaining above baseline values. As
discussed, evidence has been presented to suggest that ANP release is a
198
contributory factor in the natriuresis of volume expansion, but studies are
dogged by lack of available antagonists.
A confounding factor in the assessment of components of natriuretic
responses is that blockade of one component may be associated with compen¬
satory upgrading of other components. There is no evidence in the present
study that ANP responses were greater in the presence of dopamine blockade.
In fact the peak response with carbidopa tended to be less than that with
placebo, though this diminution was not significant. A lower response may be
compatible with data presented by Racz et al. (1986). In rats, metoclopramide
decreased both the baseline and saline-induced increase in plasma ANP,
suggesting that dopamine normally exerts a tonic influence on ANP secretion.
However, this has to be reconciled with the fact that in man, dopamine
infusion was not associated with any change in plasma ANP levels (Shenker et
al., 1987).
To analyse further the mechanisms of natri uresis and define the
importance of respective nephron segments, the lithium clearance technique
has been utilised in the setting of acute intra vascular expansion and the
ensuing natriuresis. In studies reported in man, fractional lithium clearance
increased by an order of 30% or so (Hoistein-Rathlou et al., 1985; Atherton et
al., 1987). This implies that the tubular rejection of fluid from the proximal
tubule is increased, which may result from changes in the Starling forces at
the proximal tubule, either due to alteration in the filtration fraction and/or
reduction in plasma protein and hence peritubular capillary oncotic pressure, or
due to direct hormonal effects. In the present study, fractional lithium
clearance increased by 35% during saline infusion, a change that was highly
significant. Lithium clearance represents the isotonic fluid volume leaving the
proximal tubule. The ratio of sodium and lithium clearances therefore
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represents the fraction of fluid entering the "distal tubule" (comprising the
loop of Henle, distal convoluted tubule and collecting duct), which escapes
reabsorption. In response to intravenous saline, this ratio increased. However,
absolute reabsorption by the distal tubule also markedly increased indicating
that this segment partially compensated for the increased delivery to maintain
glomerular tubular balance. Therefore the distal segment did not contribute to
the natriuretic response under the conditions of the present study. These
results are in agreement with those previously reported (Hoistein-Rathlou et
al., 1985; Nielsen et al., 1987).
However, it must be questioned whether lithium provided a suitable
marker for tubular sodium handling. A dose of 1000 mg is somewhat higher
than that usually used, but the plasma levels at the start of our study were
below usual therapeutic levels so that a toxic effect cannot be invoked.
Lithium showed a tendancy towards increasing baseline sodium excretion, and
PRA values were significantly elevated at the commencement of the study.
Thereafter, the natriuretic response to saline infusion was reduced at each
time point and cumulative sodium excretion above the control values was
significantly reduced by around 40%. It could be argued that the kidney
possesses a maximal capacity to excrete sodium after isotonic volume
expansion which was attained in the present study. The apparent reduction in
cumulative sodium excretion above control would thus be explicable purely in
terms of the elevated baseline value, and not due to any specific effect of the
lithium ion. However, this is unlikely to be the case. Absolute sodium excretion
was reduced at each time point after the first hour of infusion, and a clear
cross-over effect was apparent. More important evidence comes from the work
of Epstein and colleagues (1979), in normal man. This group demonstrated that
elevation of baseline sodium excretion by dietary supplementation markedly
exaggerated the absolute natriuretic response to volume expansion achieved by
head-out water immersion. Thus in the present study, the elevated baseline
sodium excretion induced by lithium might have been expected to increase,
rather than decrease, the natriuretic response to volume loading. The most
likely interpretation of the present results is that the lithium ion in some way
interferes with normal excretory responses in the face of an intravenous salt
load. However, the attenuation of natriuresis is unlikely to have involved
dopaminergic mechanisms. Lithium did not interfere with dopamine output
either during the baseline period or the infusion of saline. Also, as shown,
blockade of dopamine synthesis did not attenuate the natriuretic response. The
mechanism is therefore unknown, but this important interaction requires
further study in two regards. Firstly, lithium must not influence renal function
to be of use as a marker: a dose must be identified that is truly inert.
Secondly, analysis of the effects of lithium on the nephron may advance our
knowledge of receptor and transport mechanisms, and intracellular processes
involved in sodium transport and renal hormonal release.
CHAPTER SIX
FINAL DISCUSSION AND CONCLUSIONS
The diverse experimental approaches into the actions of dopamine in the
periphery have demonstrated the amine to possess various interesting features.
By activation of distinct receptors it is capable of producing systemic and
renal vasodilatation and of modulating sympatho-adrenal outflow. By a combin¬
ation of haemodynamic and direct tubular effects it is actively natriuretic, and
influences hormonal release from the kidney and adrenal cortex.
As a local regulator of sympathetic activity at the sympathetic ganglion
and the pre-synaptic DA£ receptor, it may function as a classical neurotrans¬
mitter. A different situation appears to pertain to the kidney, and conceivably
the adrenal cortex, where large amounts of dopamine are produced extraneur-
onally, and where it may act as a local hormone. Such a dichotomy of function
is not unique: there is a growing appreciation that regulatory peptides can be
produced by endocrine and neural tissue, and function, individually or in com¬
bination, as circulating hormones, local regulators and neurotransmitters (Polak
and Bloom, 1983).
Research interest into dopamine in the periphery, and especially the
kidney, has focussed on three main areas; a potential physiological role in
blood pressure regulation, hormonal interaction and renal salt balance;
involvement of dopaminergic mechanisms in pathophysiological conditions,
notably essential hypertension; and the pharmacological manipulation of
dopamine receptors in the treatment of various disease states. The work in this
thesis has touched upon some of these aspects in the kidney in normal man.
A physiological function in the kidney is strongly suggested by the prod¬
uction and excretion of large amounts of free dopamine, by the close relation¬
ship between dopamine excretion and sodium output in the urine, and by the
characterisation of a widespread distribution of dopamine receptors. Such
observations do not however, prove that endogenous dopamine has physiological
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significance and more compelling evidence accrues when an inhibitor of
dopamine can be shown to alter some parameter of normal function. Such
studies have been approached using either dopamine receptor antagonists or
dopa decarboxylase inhibitors to block dopamine synthesis, and a number of
animal models have been utilised, notably in man, dog and rat.
As yet, no firm consensus has emerged, and it must be conceded that
many studies have failed to demonstrate significant effects. Certainly, in the
present work, the effective blockade of renal dopamine synthesis with
carbidopa, did not consistently influence sodium excretion or hormonal release,
either under baseline conditions or after acute intravenous salt loading. There
are, however, a number of points which must be raised before an important
role for endogenous dopamine in renal function can be discounted.
Analytical methods for the study of renal function in vivo are crude.
The measurement of indices in blood and urine represents an "averaging-out" of
the outcome of a host of interacting physical, hormonal and neuronal
influences at the cellular micr©environment in compartmentalised regions of
the kidney. Salt balance is subject to tight and complex control mechanisms,
and physiological, as opposed to pharmacological, manipulations, may produce
subtle, but nevertheless real changes in function which are not easily
demonstrable in short term, in-vivo, studies. Work in man, on an out-patient
basis is particularly difficult in this setting as subjects are often not in true
steady state for salt balance, individual variation may be large, and various
extraneous influences unaccounted for. In addition, compensatory adjustments
in other control systems may mask the significance of changes in any
particular system. In vitro work allows characterisation of isolated stimuli, but
the very principle negates the physiological implications.
The development of highly specific and selective dopamine receptor
antagonists may clarify certain issues. Many studies should be repeated with
the newer agents, as the earlier antagonists used crossed the blood-brain
barrier and effects were likely to be complex due to their non-selective
nature. However, even here, caution is required. A particular antagonist,
active in an in vitro-model, or capable of nullifying the effects of administered
dopamine, may still not possess a suitable pharmacokinetic profile to allow
access to dopamine receptors in sufficient concentrations in vivo. If
endogenous dopamine is a physiological mediator it is important to define the
necessary conditions by which such a role can be demonstrated, and these are
not yet clear. With the known natriuretic action of the administered amine, it
might be expected that dopamine is involved in the response to excess sodium
intake. Both oral salt loading and intravenous saline volume expansion
stimulate dopamine excretion, suggesting a homeostatic function. However, the
response in man is modest. As discussed earlier from an evolutionary
standpoint, if the dopaminergic mechanism was developed to offset excessive
sodium retention, man, with principally a herbivorous pedigree, might not be
the most suitable model. The poor dopaminergic responsiveness displayed in
blacks, from limited work performed, has been alluded to. The greater
responsiveness demonstrable in dogs, with a carnivorous background, may give
credence to this theory, but direct comparisons between species have not been
undertaken.
Aldosterone secretion appears to be under tonic maximal dopaminergic
inhibition under salt replete conditions, and this inhibition can be removed by
salt depletion. Such observations also point to a physiological role in the
response to salt excess, where inhibition of aldosterone would have a permiss¬
ive action in natriuresis.
Mannelli and Pupilli (1988) have recently however produced interesting
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data in man to suggest that dopamine is important in the catecholamine
response to stress. Domperidone, the DA2 antagonist, significantly increased
catecholamine excretion during graded exercise, though having no effect at
rest. Thus endogenous dopamine appeared to be modulating sympatho-adrenal
outflow. The sympathetic nervous system is activated by salt depletion, and
exerts salt-retaining and vasoconstrictive actions. It is tempting to speculate
that under such conditions dopamine prevents excessive vasoconstriction and
renal shut-down, in a manner rather analogous to that of the renal prosta¬
glandins.
There is no evidence as yet, that dopamine functions as a circulating
hormone under normal circumstances: plasma levels of free hormone are
extremely low and it seems likely that activation of receptors results from
local synthesis at tissue level, either intra- or extra-neuronally. The infusion
of dopamine itself is unlikely to provide useful information on physiological
function for two main reasons. Firstly, infusion, even at small doses,
enormously increases plasma dopamine levels. Secondly, its ability to stimulate
a and (?> receptors makes interpretation of results difficult. The many studies
performed with infused dopamine have, in some ways, clouded our
understanding of dopaminergic mechanisms. In addition, the propensity for
systemically administered dopamine to produce peripheral vasodilatation and
reduce blood pressure complicates the renal actions in that various
compensatory mechanisms, including the renin-angiotensin and sympathetic
nervous systems, are activated by the resulting systemic changes.
Gludopa has proved a valuable agent in investigating the action of
dopamine in the kidney as divorced from those in the systemic circulation. The
large increase in urine dopamine excretion, with only modest elevation of
plasma dopamine, is paralleled by its renal actions without marked alteration in
blood pressure and pulse, reflecting the renal specificity of the pro-drug. The
levels of urine dopamine achieved by gludopa are well above the physiological
range. The important point, however, is that dopamine synthesis occurs at
tubular level, mimicking the normal pattern of production. Therefore, observ¬
ations made with gludopa may be pertinent to the physiological state. It might
be expected that such large tissue concentrations of dopamine in the kidney
would activate a and (?>, as well as dopamine receptors, and this possibility has
not been excluded. However, the pattern of action, vasodilatation and natriur-
esis, and blockade of effects by dopamine antagonists, points to dopamine
receptor activation being predominant.
It can be concluded for the present studies and from other reported
work that dopamine exerts independent action in the kidney, without the
requisite mediation of other hormonal, neural or physical factors. More likely
is a system of parallel influences, including dopamine, interacting in an array
of negative and positive feedback loops, forming a highly complex control
mechanism which maintains homeostasis and is able to respond rapidly to
changes in the local and wider environment.
The clear inhibition of PRA produced by gludopa is an observation of
theoretical and potential therapeutic significance. It is conceivable, that under
conditions of salt excess, inhibition of renin by dopamine would amplify the
direct suppression of aldosterone at the adrenal cortex, the result being to
allow effective natriuresis. However, as yet, dopamine antagonists have not
produced consistent effects on renin release and the question needs further
study.
Although the initial studies concerning dopamine in the kidney were
performed more than 25 years ago, fundamental questions remain, in particular
the relationship to prevailing salt status. By some unknown mechanism, a
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change in salt content alters dopamine synthesis and release. In vitro evidence
suggests that the uptake of L-dopa into proximal tubular cells is a sodium
dependant process. It is not known whether control of dopamine synthesis lies
at the level of cellular dopa decarboxylase, uptake and transfer of L-dopa into
the cell, or depends on the availability of L-dopa at the proximal tubule. This
last point raises questions as to the source and regulation of L-dopa in plasma,
and thence the filtered load, under conditions of altering salt status.
Little is known of other physiological or pharmacological manoeuvres
which influence dopamine synthesis and excretion. Frusemide has proved to be
an effective stimulus but it remains unclear exactly which aspect of its action
is responsible. Further studies should assess whether an increase in GFR per
se, increasing the filtered load of sodium and L-dopa, provides the stimulus or
whether alterations in renal haemodynamics and physical forces at the proximal
tubule are pre-requisite. The effects of calcium antagonists on dopamine
synthesis are unknown. In addition to producing renal vasodilatation and
natriuresis, their use may indicate whether the intracellular events that
modulate dopamine synthesis are dependant on the calcium second messenger
system.
The fortuitious discovery that lithium blocked the natriuresis induced by
gludopa should provide new insights into the mechanism of action of dopamine.
It is firstly important to determine whether renal vasodilatation produced by
dopamine is similarly attenuated by lithium - the use of gludopa will allow
renal events to be more easily distinguished. Measurement of urinary cAMP has
not been useful in studying interactions between dopamine and lithium in the
kidney in man. It may be more appropriate to use an animal model such as the
rat and measure renal tissue cAMP levels after pharmacological intervention.
Interference with cAMP production after dopamine stimulation would suggest
that the action of lithium is on the DA^ receptor. Confirmatory evidence of
this could be sought by assessing the effect of lithium on the renal actions of
specific DA^ and DA2 agonists. The action of lithium may however be rather
complex. Its attenuation of natriuresis after intravenous saline did not appear
to involve a dopaminergic mechanism. In addition, it has recently been
demonstrated in man to block the natriuretic action of ANP, widely believed to
be a cGMP-mediated phenomenon (Freestone, personal communication). These
observations suggest that it may be a general inhibitor of stimulated sodium
excretion, acting at some common pathway after receptor activation by
diverse stimuli.
In spite of the arguments concerning a physiological role for endogenous
dopamine, it clearly exerts potent pharmacological actions after administration.
Dopamine itself has drawbacks that limit its therapeutic potential, namely its
propensity to stimulate a and l?> adrenergic receptors, and its poor oral bio¬
availability, and attempts have been made to produce pharmacological agents
which overcome these problems. Thus fenoldopam and bromocriptine are orally
available agonists, active in man, at DA.^ and DA2 receptors, respectively
(Goldberg, 1988). A different approach has been to develop prodrugs which
avoid metabolism before absorption and release free dopamine into the circul¬
ation. The dopamine precursor L-dopa has already been mentioned. Recently,
the pharmacological properties of TA-8704 (N-(N-acetyl-L-methionyl)-O,
O-bis(ethoxycarbonyl) dopamine) have been evaluated. Free dopamine, released
into plasma after oral administration, correlated with the increment in RBF in
dogs, and it produced an increase in RBF and sodium excretion in human
subjects with renal impairment (Nishiyama et al., 1985; Ozawa and Mort, 1985).
Ibopamine is the diisobutyric ester of N-methyl dopamine (epinine). After oral
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ingestion it is converted by plasma esterases to epinine which is active on DA^
and to some extent a and l?>2 receptors (Goldberg, 1988). Stimulation of
dopamine receptors in the systemic circulation readily produces generalised
vasodilatation and reduction in after load, and the various agents are being
evaluated for possible therapeutic use in essential hypertension and cardiac
failure. The ideal agent would be orally active, and preferably not cross the
blood-brain barrier. A combination of DA^ and DA2 agonist activities would
seem beneficial - DA^ activity to produce direct vasodilatation and enough
DA2 activity, to avoid nausea on the one hand, but block baroreceptor -
mediated sympathetic activation and direct renin stimulation, on the other. An
alternative would be to combine a DA.^ agonist with an inhibitor of
angiotensin converting enzyme, for a possible synergistic action.
Two further novel approaches to the manipulation of dopamine receptors
have been reported, Langer et al. (1987) demonstrated in cat atria that the
mono-amine oxidase inhibitor pargyline increased endogenous levels of
dopamine, and postulated that increased pre-synaptic DA2 activity might
contribute to the antihypertensive effect of this drug group. Berkowitz and
Ohlstein (1987) have studied the dopamine l?> hydroxylase inhibitor SKF 102698.
In spontaneously hypertensive rats it produced a marked increase in vascular
dopamine/noradrenaline ratio, concurrent with a fall in blood pressure.
Whether or not the kidney has direct pathophysiological significance in
the genesis of essential hypertension, it is a major determinant of the reponse
to antihypertensive therapy. Active systemic vasoconstriction is a character¬
istic feature of the hypertensive state, and it might be expected that vasodil¬
atation would constitute an ideal treatment to reverse the abnormality.
However the classical vasodilators minoxidil, hydralazine and sodium
nitroprusside are not effective as monotherapy. The initial reduction in system-
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ic vascular resistance and blood pressure activates baroreceptor-mediated
sympathetic drive and stimulation of the renin-angiotensin system, and the
renal response is to produce sodium retention - effects that offset drug action
(Hollenberg, 1986).
Guyton et al., (1974) propounded the concept of the renal function curve
in which blood pressure is primarily dictated by renal excretory function.
According to this model, a causal approach to the treatment of hypertension
would be enhancement of the renal capacity to excrete sodium. Struyker
Boudier (1980) developed a computor simulation model which predicted that the
consequences of preferential renal vasodilatation would represent a reversal of
the autoregulatory hypothesis for essential hypertension (Guyton et al., 1974).
Thus renal vasodilatation and natriuresis lead to reduction in intravascular
blood and ECF volume, and hence cardiac output and tissue perfusion. Reduced
perfusion would be opposed by local autoregulatory mechanisms resulting in
vasodilatation and a shifting of the renal function curve to a lower blood
pressure. In this light Nievelstein (1987) has made interesting observations in
the spontaneously hypertensive rat. He compared the hydralazine-like compound
CGP 18137A with its N-acetyl-L-y-glutamated derivative CGP 22979A.
Whereas the former produced a response pattern similar to that of the
classical arteriolar vasodilators, the response for the latter was very different.
An initial natriuresis and elevation of RBF was followed by a gradual
reduction in mean arterial pressure over 5 days without elevation of heart rate
or stimulation of renin release. There are direct parallels here with gludopa.
CGP 22979A is a prodrug of the parent compound which produces high
concentrations of drug in the kidney because hydrolysis by acylase and
y-glutamyl transferase occurs at a higher rate in the kidney than elsewhere.
MacDonald et al. (1988) have recently infused gludopa into normal
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volunteers for 8 hours. Natriuresis persisted for 6 hours, there was a small
reduction in blood pressure, and compared to placebo, no increase in PRA.
Such infusions need to be performed over a number of days and in a group of
essential hypertensives. According to the computer model, blood pressure might
be expected to decline gradually without reactive increase in PRA. In compar¬
ison with CGP 22979A, gludopa may possess two further beneficial properties.
The first is its ability to directly inhibit renin release. Secondly, if it is the
case that a defect of dopamine mobilisation exists, at least in a proportion of
those with essential hypertension, the use of gludopa may reverse a specific
defect in the aetiology of the condition.
By having effects targeted at the kidney, without exerting systemic
actions or incurring compensatory negating responses, gludopa may have a
number of potential therapeutic actions. The agent should be assessed in the
setting of incipient and established acute renal failure in which dopamine itself
has been applied. It may be of benefit in cadaveric renal transplantation both
in the donor, before organ removal, and in the early post-operative period.
Particularly it would be of interest to determine whether gludopa can increase
the incidence of immediate function, and, by counteracting nephrotoxicity
produced by the standard immunosuppressive agent cyclosporin, allow maximal
effective dosage to be administered. Similarly its use may encourage renal
function after liver and cardiac transplantation. The common tendancy towards
renal impairment in acute hepatic failure may be prevented by encouraging
renal dopamine production with gludopa. The agent is at present being
evaluated in women with ovarian carcinoma under treatment with cis-platinum,
a drug whose benefits and maximal dose prescribable are limited by
nephrotoxicity (Lee, personal communication).
Parental gludopa possesses a theoretical advantage over dopamine in
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that it can safely be given through a peripheral vein, removing the need for
central access. As a prodrug, it is unlikely to produce the local
vasoconstriction and tissue sloughing, due to a-agonist activity, that is
associated with extravasation of the parent compound.
At present, the use of gludopa in chronic conditions such as essential
hypertension is limited by its requirement for parenteral administration.
Research must be directed towards producing oral cogeners which avoid
metabolism during drug absorption. It must then be assessed in those conditions
in which renal vasodilatation and the promotion of natriuresis might be
advantageous. For instance, a possible application might be to determine
whether the progressive deterioration of function in chronic renal failure can
be altered. The combination of gludopa with a systemic vasodilator or inotropic
agent may provide a beneficial spectrum of activity in the treatment of
congestive cardiac failure.
With the increasing interest in dopamine and the kidney it seems likely
that the next decade will see a focusing of the physiological and pathophysiol¬
ogical significance of endogenous dopamine, and it is quite possible that
pharmacological manipulation of dopamine receptors will have added to our
therapeutic armamentarium.
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